Drug, bio-affecting and body treating compositions inventions 01/09

20090028784 - Antibodies to il-6 and use thereof: The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also... Agent: Hunton & Williams LLP Intellectual Property Department

20090028785 - Medical devices with coatings for delivery of a therapeutic agent: Described herein are implantable coated medical devices, such as intravascular stents, for delivering therapeutic agents to the body tissue of a patient, and methods for making such medical devices. In particular, described herein are implantable coated medical devices comprising a substrate having a surface, and a coating disposed upon the... Agent: John J. Gagel C/o Fish & Richardson

20090028786 - Methods and apparatus for imaging agents for disease detection: Methods and apparatus for identifying disease status according to various aspects of the present invention include delivering one or more imaging agents to all or parts of the body for disease observation, screening and/or detection. The methods and apparatus may deliver imaging agents that include any suitable disease-associated compositions, such... Agent: The Noblitt Group, Pllc

20090028787 - Novel heteroaryl substituted benzothiazoles: The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090028788 - Compounds having rd targeting motifs: The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging agent and a targeting agent. The compounds may be used to detect, monitor... Agent: Polsinelli Shalton Flanigan Suelthaus Pc

20090028790 - Labelled adrenomedullin derivatives and their use for imaging and therapy: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is... Agent: Louis Tessier

20090028789 - Methods for detecting parenchymal plaques in vivo: Methods for detecting parenchymal plaque deposits in the brain of a living mammal are described that include administering a polyamine modified, labeled polypeptide having specific binding affinity for the extracellular deposit, to the living mammal. Isolated β-amyloid peptides that are polyamine modified and labeled with a radioisotope or contrast agent... Agent: Quarles & Brady LLP

20090028791 - Dichloroacetate analogs as imaging agents: wherein xC is selected from the group consisting of 11C, 12C, and 13C; R is selected from the group consisting of —OH, —O−R4+ wherein R4 is selected from the group consisting of Na and K, —OR3 wherein R3 is selected from the group consisting of C1-8 alkyl and C1-8 alkenyl,... Agent: Williams, Morgan & Amerson

20090028792 - Nano-particle surface modification: Oxide, oxysulfide, halide or phosphate host particles with a self-assembled organophosphonate monolayer covalently bonded thereto. Methods for coating the host particles and use of rare earth ion-doped particles in imaging methods and photodynamic therapy methods are also disclosed.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090028793 - Vascular tumor markers: The present invention relates to a method for identifying neovascular structures in mammalian tissue, wherein said neovascular structures are identified by the detection of at least one specific protein in said tissue. It also relates to a method for identifying diseases or conditions associated with neovascularization, methods for targeting and/or... Agent: The Nath Law Group

20090028795 - Nod1 as an anti-tumor agent: The invention provides compositions and methods for treating tumors that involve increasing the expression of Nod1 and/or the activity of NOD1.... Agent: Schwegman, Lundberg & Woessner, P.a.

20090028796 - Pesticidal composition comprising indole derivates: The present invention is directed to pesticidal compositions comprising indole derivatives. These indole derivatives are especially active against phytopathogenic fungi. Furthermore, the invention relates to the use of indole derivatives for the production of pesticides and the use of the compositions according to the invention as pesticides. The present invention... Agent: Connolly Bove Lodge & Hutz, LLP

20090028794 - Uses and compositions for treatment of psoriatic arthritis: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090028798 - Method for determining redox status of a tissue: Disclosed is a method for determining the redox status of a region of interest in an animal tissue. The method includes administering a nitroxyl contrast agent to the region of interest, obtaining a magnetic resonance image of the region of interest, determining the amount of reduced nitroxyl contrast agent in... Agent: Leydig, Voit & Mayer, Ltd.

20090028799 - Contrast agents: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing a hydrophilic aliphatic central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The... Agent: Ge Healthcare, Inc.

20090028797 - Novel polymeric ultrasound contrast agent and methods of making thereof: The present invention provides a novel method of manufacturing nanosized polymeric echogenic contrast agents. The method of the present invention comprises a modified salting out process which results on nanosized polymeric capsules encapsulating an aqueous core that is subsequently evacuated. The compositions of the present invention can be used as... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090028800 - Method of treating postpartum depression and aggression: The present disclosure is directed towards administering a biologically effective amount of a thiomolybdate compound to a patient who demonstrates either depressive or aggressive behavior. According to the present disclosure, thiomolybdate compounds can be administered orally, sublingually, intravascular, intraperitoneal, intradermal, intramuscular, or via any other known administrative techniques. Administration of... Agent: Lanier Ford Shaver & Payne P.c.

20090028801 - Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans,... Agent: Peters Verny , L.l.p.

20090028802 - Organoleptically acceptable indole serotonin receptor agonist oral dosage formulations and methods of using the same: Organoleptically acceptable oral dosage formulations of an indole receptor serotonin agonist, and methods of making and using the same, are provided. An aspect of the formulations is that they include an indole receptor serotonin agonist and a masking component. In certain embodiments, the masking component includes one or more of... Agent: Bozicevic, Field & Francis LLP

20090028803 - Flavorant ester salts of polycarboxylic acids and methods for immobilizing and delivering flavorants containing hydroxyl groups: Compositions are provided which contain immobilized flavorants for flavor delivery. In particular, smoking compositions are provided which contain flavorant ester salts of polycarboxylic acids.... Agent: Buchanan, Ingersoll & Rooney Pc

20090028804 - Ahr mediators: The invention relates to a method for finding and assessing agonists [and] antagonists of the aryl hydrocarbon receptor (Ah receptor; AhR), to the agonists and antagonists themselves and to uses thereof.... Agent: Connolly Bove Lodge & Hutz LLP

20090028805 - Bacterial extracts cultured in thermal waters comprising anti-redness agents: Red blotches on the skin such as those associated with environmental stresses, or red blotches associated with a skin disorder, for example those occurring during rosacea, are treated/reduced by administering to individuals afflicted therewith, thus effective amounts of at least one extract of a non-photosynthetic and non-fruiting filamentous bacterium cultured... Agent: Buchanan, Ingersoll & Rooney Pc

20090028807 - Composition comprising a polycondensate, method of treatment, polycondensate, and method of preparation: The present application relates to a cosmetic or pharmaceutical, in particular lipstick, composition comprising a polycondensate The application also relates to a method of cosmetic treatment using the composition, the polycondensate thus defined and a method of preparing the polycondensate.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090028806 - Medicine for external application containing anti-inflammatory agent and soy lecithin: Disclosed is a medicine for external application which contains an anti-inflammatory agent, an organic ultraviolet absorbent and soy lecithin. This medicine for external application enables to surely prevent photo-allergies caused by a transdermal preparation containing a photosensitive anti-inflammatory agent.... Agent: Licata & Tyrrell P.c.

20090028809 - Personal care article for sequentially dispensing compositions with variable concentrations of hydrophobic benefit materials: The present invention relates to a personal care article for providing at least two liquid personal care compositions. The personal care article comprises a single chamber package and a liquid personal care product. The package comprises a dispensing orifice, a first zone proximate, to the dispensing orifice and a second... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090028808 - Personal care article for sequentially dispensing compositions with variable concentrations of partitioned benefit or suspended benefit agents: The present invention relates to a personal care article for providing at least two liquid personal care compositions. The personal care article comprises a single chamber package and a liquid personal care product. The package comprises a dispensing orifice, a first zone proximate to the dispensing orifice and a second... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090028810 - Stabilization of biosolids using iron nanoparticles: This invention discloses a stabilized biosolids composition and a method for the stabilization of biosolids. It entails the use of a chemically and biologically reactive material, in the form of ultrafine iron particles. The nanometer-sized iron particles are capable of degrading odorous organosulfur compounds, transforming persistent and toxic organic pollutants... Agent: Ratnerprestia

20090028812 - Hydrophilic biodegradable adhesives: A moisture-curable and biodegradable adhesive that includes the reaction product of: (a) an isocyanate component having an average functionality of at least 2; (b) an active hydrogen component having an average functionality greater than 2.1; and (c) an ionic salt component having an average hydroxyl or amino functionality, or combination... Agent: Fish & Richardson P.c.

20090028811 - Personal lubricant: A personal lubricant composition comprises a mixture of a latent lubricant additive and a carrier lubricant, in which the latent lubricant additive is insoluble in the carrier lubricant but is capable of activation on contact with body fluids to realise lubricant properties. The additive may comprise a poly(ethylene oxide) polymer... Agent: Miles & Stockbridge Pc

20090028813 - Methods for treating body tissue: Methods of treating body tissue including repairing defects in body tissue as well as augmenting body tissue. Body tissue defects are repaired by injecting a polymeric adhesive composition through an injector into the region of the defect and allowing the adhesive composition to cure to repair the defect or to... Agent: Morgan, Lewis & Bockius, LLP

20090028814 - High molecular weight medicine-containing preparation in powder form for administration through mucosa: By adding a cationic polymer (in particular, a copolymer of aminoalkylmethacrylate or polyvinyl acetal diethylaminoacetate) or a cationic polymer plus a viscous polymer to a medicine of high molecular weight for producing a preparation in powder form, it is possible to achieve effective absorption of the medicine of high molecular... Agent: Foley And Lardner LLP Suite 500

20090028819 - Compositions and methods for healthy pregnancy: Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of... Agent: Morris Manning Martin LLP

20090028817 - Compositions and methods for soft tissue augmentation: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090028815 - Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.... Agent: Connolly Bove Lodge & Hutz LLP

20090028818 - Heterocyclic antiviral compounds: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3 and R4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives... Agent: Roche Palo Alto Llc Patent Law Dept. M/s A2-250

20090028816 - Treatment of depression, psychosis, and anxiety: The use of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) for treating affective disorders, such as depression, psychosis, or anxiety, is described.... Agent: Robins & Pasternak LLP

20090028820 - Antiviral agent: An antiviral agent consisting of hepatocyte growth factor (HGF) or an agonist of the HGF receptor, and a medicament for prophylactic and/or therapeutic treatment of a disease caused by hepatitis C virus comprising using said agent simultaneously or separately with other anti-viral agent.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20090028821 - Prodrugs of cc-a1065 analogs: The present invention provides prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group containing a sulfonic acid containing phenyl carbamate, in which the protecting group confers enhanced water solubility upon the prodrug, and in which the prodrug also has a moiety, such as a sulfide or... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090028822 - Glycopegylated interferon alpha: The present invention provides IFN-α conjugates including IFN-α peptides and modifying groups such as PEG moieties. The IFN-α peptide and modifying group are linked via an intact glycosyl linking group interposed between and covalently attached to the IFN-α peptide and the modifying group. The IFN-α conjugates are formed from glycosylated... Agent: Morgan, Lewis & Bockius LLP (sf)

20090028824 - Systems and methods for delivering drugs: A patch pump device generally includes at least one fluid source, a fluid communicator, and an electrochemical actuator. The fluid communicator is in fluid communication with the fluid source. The electrochemical actuator is operative to cause fluid to be delivered from the fluid source into the fluid communicator.... Agent: Sutherland Asbill & Brennan LLP

20090028823 - Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases: In one embodiment, a therapeutic composition containing a pentavalent antimonial is provided. The pentavalent antimonial can be sodium stibogluconate, levamisole, ketoconazole, and pentamidine and biological equivalents of said compounds. Additionally, pentavalent antimonials that can be used in accordance with the present invention may be any such compounds which are anti-leishmaniasis... Agent: Morgan Lewis & Bockius LLP

20090028825 - Compositions and methods for studying and treating inflammatory diseases and disorders: Disclosed are compositions and methods that can be used in the treatment of diseases and disorders caused, exacerbated or otherwise affected by inflammation.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090028838 - Hematopoietic cell culture nutrient supplement: The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.... Agent: Invitrogen Corporation C/o Intellevate

20090028835 - Human transcriptome corresponding to human oocytes and use of said genes or the corresponding polypeptides to trans-differentiate somatic cells: Also, a core group of 66 transcripts was identified by intersecting significantly up-regulated genes of the human oocyte with those from the mouse oocyte and from human and mouse embryonic stem cells. Within the up-regulated probe sets, the top overrepresented categories were related to RNA and protein metabolism, followed by... Agent: Hunton & Williams LLP Intellectual Property Department

20090028837 - Methods for altering the reactivity of plant cell walls: Methods and means are provided for the modification of the reactivity of plant cell walls, particularly as they can be found in natural fibers of fiber producing plants by inclusion of positively charged oligosaccharides or polysaccharides into the cell wall. This can be conveniently achieved by expressing a chimeric gene... Agent: Hunton & Williams LLP Intellectual Property Department

20090028836 - Stem and progenitor cell expansion by evi, evi-like genes and setbp1: A method of increasing cell proliferation by modulating levels of EVI and related genes. Activation of EVI-1, PRDM16, or SETBP1 can increase the proliferation rate, self renewal and/or in vitro and/or in vivo survival and/or engraftment of human cells, either in vitro or in vivo. The gene modulation can be... Agent: Knobbe Martens Olson & Bear LLP

20090028826 - Bacterial extracts cultured in thermal waters for reducing bags and/or dark circles around the eyes: Bags and/or dark circles around the eyes of individuals afflicted therewith are reduced by administering to such individuals thus effective amounts of at least one extract of a non-photosynthetic and non-fruiting filamentous bacterium cultured in a medium which includes at least one non-sulfurous mineral and/or thermal water, e.g., an extract... Agent: Buchanan, Ingersoll & Rooney Pc

20090028839 - Compositions and methods for the prophylaxis and treatment of vaginal infections: Applicants have discovered that a particular bacteriocin from the vaginal strain of Lactobacillus rhamnosus, lactocin (160), possesses a particularly advantageous activity against microorganisms associated with vaginal infections, and more specifically those associated with Bacterial Vaginosis (BV). Specifically, this compound is an effective and non-cytotoxic antibacterial agent that provides the basis... Agent: Christopher G Izzo Rutgers University - Ocltt

20090028840 - Compositions for preventing or treating arthritis comprising lactic acid bacteria and collangen as active ingredients: The present invention relates to a composition for preventing or treating arthritis, which comprises a lactic acid bacterium and collagen as major active ingredients. The present composition shows excellent prevention or treatment efficacies on arthritis of animal models. In addition, since the active ingredients used in the composition of this... Agent: Sughrue Mion, Pllc

20090028827 - Method for preventing and treating influenza: The present invention provides a method for preventing and/or treating influenza in a mammal. The method includes orally administering a composition comprising sporoderm-broken germination activated Ganoderma lucidum spore (GLS) to a mammal susceptible to or suffering from influenza. The present invention also provides a method for stimulating the host immune... Agent: Andrews Kurth LLP

20090028828 - Rotavirus vaccine inducing heterotypic cross protection: The invention provides a method of inducing an immune response against rotavirus strain, the method comprising administering to a subject a composition comprising an attenuated rotavirus strain of a GxPy type, said composition generating an immune response against a rotavirus strain which is neither a Gx nor a Py type.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090028832 - Compositions and methods for targeted tumor therapy: The present invention relates to a method of treating a human patient having one or more tumor cells. In one embodiment, the method comprises the step of implanting at or around the site of one or more tumor cells in the patient a cell population comprising one or more prostate... Agent: Morris Manning Martin LLP

20090028829 - Fusion proteins for the treatment of cns: This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as... Agent: Pepper Hamilton LLP

20090028834 - Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof: Compositions and methods are provided for stimulating cell proliferation and differentiation with substance P or a substance P analog. In one embodiment, the methods provide for stimulating or promoting stem cell differentiation by contacting a stem cell with substance P or a substance P analog. In another embodiment, the methods... Agent: K&l Gates LLP

20090028830 - Preparation of multipotent stem cells and the use thereof: The invention relates to a method for the enriched induction of multipotent stem cells, named P-stem cells, from CD14+ peripheral monocytic cells. P-stem cells are capable of differentiating into osteoblasts, chondrocytes, neuron cells, etc. Also disclosed relates to a method for tissue repairing by in vivo implanting P-stem cells into... Agent: Troxell Law Office Pllc Suite 1404

20090028833 - Proliferative primary human sertoli cell cultures and their applications: Technology for the isolation and propagation of primary human Sertoli cells from normal testes tissue, including cultures of proliferative primary human Sertoli cells for research and clinical applications, and a pharmaceutical composition for cell therapy, ex vivo gene therapy, and for the reduction of autoimmune, allograft, and xenograft immune reactions.... Agent: Faegre & Benson LLP Patent Docketing

20090028831 - Stem cell regulator, compositions and methods of use: The disclosure provides methods and compositions comprising Slit2 agonists and antagonists useful for modulating hematopoietic stem cell (HSC) proliferation and growth. In some aspects, the disclosure provides methods and compositions for stimulating HSC proliferation in vivo, ex vivo, or in vitro. In other aspects, the disclosure provides methods and compositions... Agent: Crowell & Moring LLP Intellectual Property Group

20090028841 - Oxygen scavenging composition, coating composition and package containing free fatty acid: An oxygen scavenging composition being an oxidizable ascorbic acid derivative, a multi-copper oxidase enzyme, and a free fatty acid wherein the enzyme is disposed upon the surface of the oxidizable ascorbic acid derivative, and wherein the free fatty acid is intermixed with the oxidizable ascorbic acid derivative. The invention extends... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090028842 - Dekkera/brettanomyces cytosine deaminases and their use: The present invention relates to cytosine deaminase protein and cDNA from various species of the yeast genus Dekkera/Brettanomyces. Compared to yeast cytosine deaminase the novel cytosine deaminases are more efficient and have a higher stability. The invention also relates to the field of suicide gene therapy based on activation of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090028849 - Agents and methods for inhibition of airway hyperresponsiveness: The present invention provides methods and compositions for inhibition of Airway Hyperresponsiveness (“AHR”) by deleting, inactivating or inhibiting a subset of innate γδ T cells, alone or in conjunction with the inhibition of Natural Killer T (“NKT”) cells. The methods comprise selective leukophoresis to remove the γδ T cells from... Agent: Sheridan Ross Pc

20090028844 - Galnts as modifiers of the igfr pathway and methods of use: Human MIGFR genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of MIGFR are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090028843 - Iga allelic variants: The invention relates to a method for determining susceptibility to an IgA-related disorder in an animal, the method comprising: a) identifying the or each IgA allelic variant present in a sample from the animal; and b) thereby determining whether the animal is susceptible to an IgA-related disorder.... Agent: Melissa W. Acosta Fulbright & Jaworski L.l.p.

20090028846 - Immunoglobulin fractions: The present invention relates to novel pharmaceutical compositions comprising fractions of human immunoglobulin preparations, novel applications of these compositions and a method for manufacturing the compositions.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090028845 - Molecular diagnostic method and treatment in dementia with lewy bodies: The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of... Agent: Trask Britt

20090028847 - Multiple myeloma and al amyloid immunotherapy targeting immunoglobulin light chains and uses thereof: The present invention relates generally to the prevention and treatment of disease states, and more particularly to the treatment and prevention of plasma cell disorders and plasma cell dyscrasias and other malignancies, amyloidosis and amyloid-associated diseases. In particular, the present invention relates to methods and compositions comprising immunogenic peptides for... Agent: Ronald I. Eisenstein

20090028848 - Sequence based engineering and optimization of single chain antibodies: The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of single chain antibodies (scFvs), including stability, solubility, and antigen binding affinity. These methods and strategies can be used individually or in combination. The methods of the present invention... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090028856 - Anti-cd79b antibodies and immunoconjugates and methods of use: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20090028855 - Inhibitors of akt/pkb with anti-tumor activity: The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090028851 - Novel antibodies directed to the mammalian eag1 ion channel protein: The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain or the mammalian EAG1 ion channel and to nucleic acid molecules encoding the same and to vectors comprising said nucleic acid... Agent: Ropes & Gray LLP

20090028857 - Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.... Agent: Jones Day

20090028850 - Prolongation of survival of an allograft by inhibiting complement activity: Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allotransplant recipient an inhibitor of complement activity together with one or more immunosuppressants. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing... Agent: Ropes & Gray LLP

20090028852 - Roles for dual endothelin-1/angiotensin ii receptor (dear) in hypertension and angiogenesis: The present application is directed to the identification of mutations and/or polymorphisms in the Dual Endothelin-1/Angiotensin II Receptor (Dear) that indicate susceptibility to, or show current affliction with, hypertension. Additionally, the present invention discloses methods for the modulation of angiogenesis via the regulation of Dear.... Agent: Ronald I. Eisenstein

20090028854 - Sc(fv)2 site-directed mutant: To solve the above-mentioned problems, the present inventors introduced site-specific mutations into sc(Fv)2 and examined the stabilizing effects on sc(Fv)2. As a result, they succeeded for the first time in significantly increasing the Tm value of sc(Fv)2 by amino acid substitutions. Furthermore, they discovered that sc(Fv)2 is stabilized by introducing... Agent: Fish & Richardson Pc

20090028858 - Substituted quinoline derivatives: The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:... Agent: Novartis Vaccines And Diagnostics Inc.

20090028853 - Treatment and prevention of chronic asthma using antagonists of integrin alphavbeta6: The present invention relates to methods of asthma treatment and prevention using αvβ6 antagonists, such as αvβ6-binding antibodies. In particular, the invention relates to the discovery of a correlation between reduced expression of αvβ6 and the protection from the increase in airway sensitivity seen in chronic allergen-challenged mice. This protection... Agent: Fci Usa Inc Intellectual Property Law Department

20090028859 - Bispecific antibodies that bind to vegf receptors: The present invention is directed to production of antigen-binding proteins that bind specifically to an extracellular domains of two different VEGF receptors. The bispecific antigen-binding proteins block activation of the VEGF receptors and are used to reduce or inhibit VEGF-induced cellular functions such as mitogenesis of vascular endothelial cells and... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090028860 - Use of il-17 expression to predict skin inflammation; methods of treatment: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17 and/or IL-23.... Agent: Dnax Research Inc. Legal Department

20090028861 - Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to... Agent: Seed Intellectual Property Law Group Pllc

20090028862 - Emmprin antagonists and uses thereof: EMMPRIN (Extracellular Matrix Metalloproteinase Inducer) antagonists, such as antibodies, including specified portions or variants, siRNA, shRNA, antisense and DNAzymes, can be used to treat pathological processes associated with proliferative diseases, such as cancer, by specifically preventing or inhibiting the ability of proliferating tissue to develop a blood supply.... Agent: Philip S. Johnson Johnson & Johnson

20090028863 - Markers for diagnosis of cancer and its use: Disclosed herein are diagnostic markers CTHRC1, CANP and KIAA0101, which are overexpressed specifically in breast or colorectal cancer. A method for diagnosing the cancer by-detecting the markers, and a method for preventing or treating by inhibiting the expression and activity of the markers are also disclosed.... Agent: Cantor Colburn, LLP

20090028864 - L-amino acid oxidase with cytotoxic activity from aplysia functata: The present invention relates to a cytotoxic polypeptide which is an L-amino acid oxidase isolated from the ink of the sea hare Aplysia punctata.... Agent: Millen, White, Zelano & Branigan, P.c.

20090028865 - Method of treating hepatocellular carcinoma: Materials and Methods for treating hepatocellular carcinoma in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and... Agent: Zymogenetics, Inc. Intellectual Property Department

20090028867 - Antagonists specific for denatured collagen and methods of using same: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations... Agent: Hogan & Hartson L.l.p.

20090028868 - Anti-cancer pharmaceutical compositions and methods for treating patients with cancer: and (ii) an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and pharmaceutical compositions for use in said method. A method for treating gastric cancer, colon cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma... Agent: Frishauf, Holtz, Goodman & Chick, Pc

20090028866 - Use of ccr9, ccl25/teck, and nitegrin alpha4 in diagnosis and treatment of melanoma metastasis in the small intestine: The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin α4 gene. Also disclosed are methods for treating subjects so identified.... Agent: Hogan & Hartson L.l.p.

20090028869 - Diagnosis and treatment of alzheimer's and other neurodementing diseases: Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in... Agent: Foley And Lardner LLP Suite 500

20090028870 - Treatment of hematologic disorders: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example,... Agent: Choate, Hall & Stewart LLP

20090028871 - Novel use of ligands specific to fex-2 polypeptide: The present invention relates to novel use of a ligand specific to a FEX-2 polypeptide. More specifically, the present invention relates to methods for modulating the secretion of an inflammation-associated cytokine and for treating or preventing an inflammatory disease using the FEX-2-specific ligand. The ligand specific to the FEX-2 polypeptide... Agent: Buchanan, Ingersoll & Rooney Pc

20090028872 - Human monoclonal antibodies to cd70: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions... Agent: Baker Botts L.l.p.

20090028873 - Substituted cyclohexanols: Disclosed herein are substituted cyclohexanol opioid receptor modulators and/or neurotransmitter reuptake modulators of Formula I or Formula II, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20090028876 - Methods of modifying cd11c+ dendritic cell development to form osteoclasts functional in the bone environment: An ex vivo method of producing osteoclasts is described that includes providing isolated CD 11 C+ dendritic cells and culturing the CD 11 C+ dendritic cells in culture medium under conditions effective to produce osteoclasts. Also disclosed are methods of up-regulating or down-regulating bone resorption by manipulating the osteoclastogenesis of... Agent: Nixon Peabody LLP - Patent Group

20090028874 - Synthetic protein as tumor-specific vaccine: The invention provides a GMP compatible method to chemically synthesize proteins which may be advantageously used in compositions for vaccination that are free of biological contaminants. The method uses conventional synthesis of peptides and linking these to yield synthetic proteins that preferably comprise all T cell epitopes for an antigen.... Agent: The Webb Law Firm, P.c.

20090028875 - Use of gilz protein expressed in dendritic cells to modulate an antigen-specific immune response: The invention concerns the use of at least one: a) a GILZ protein, a functional fragment of at least 5 consecutive amino acids of said protein, a GILZ modulator, or a recombinant vector expressing same, isolated or expressed in modified dendritic cells, and b) an antigen of interest and/or a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090028877 - Antibody composition specifically binding to ganglioside gm: An anti-ganglioside GM2 antibody composition having enhanced effector function which is useful as a medicament has been desired. The present invention provides an antibody composition comprising an antibody molecule which specifically binds to ganglioside GM2 and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type... Agent: Sughrue-265550

20090028878 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20090028879 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20090028881 - Conjugate of an antibody against ccr5 and an antifusogenic peptide: The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of... Agent: Roche Palo Alto Llc Patent Law Dept. M/s A2-250

20090028882 - Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof: e

20090028883 - Novel p-selectin ligand protein: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the... Agent: Wyeth/finnegan Henderson, LLP

20090028884 - Oligomeric receptor ligand pair member complexes: This invention concerns an oligomeric receptor-ligand pair member complex which includes (i) an oligomeric core, said core comprising at least two chimeric proteins, said chimeric proteins comprising a first section including at least one domain forming part of a first member of a complementary binding pair and a second section... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090028880 - Serum albumin binding proteins: The present invention relates to amino acid sequences that are capable of binding to serum albumin, which sequences do not significantly reduce or inhibit the binding of serum albumin to FcRn or significantly reduce the half-life of serum albumin. It further relates to proteins and polypeptides comprising or essentially consisting... Agent: Wolf Greenfield & Sacks, P.c.

20090028888 - Cancer antigen mage-a9 and uses thereof: The present invention relates to the detection of MAGE-A9 in a biological sample and to the diagnosis, prevention and treatment of MAGE-A9-associated aberrant cell growth, through the targeting of the MAGE-A9 polypeptide and/or polynucleotide. Diagnosis is accomplished by examining or monitoring cells for perturbations in MAGE-A9 expression. Prevention and treatment... Agent: Ogilvy Renault LLP

20090028886 - Carrier conjugates of gnrh-peptides: The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of GnRH-related diseases and conditions and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090028885 - Citrulline peptides derived from fibrin and recognized by rheumatoid arthritis specific autoantibodies, and the use thereof: The invention relates to novel citrulline peptides derived from fibrin α and β chains which are recognisable by specific citrulline antiprotein autoantibodies (AAPC) of a rheumatoid arthritis (PR) and to the use thereof for detecting the presence of said specific PR AAPC in a biological sample.... Agent: Alston & Bird LLP

20090028887 - Compounds and methods for treatment and diagnosis of chlamydial infection: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with... Agent: Seed Intellectual Property Law Group Pllc

20090028889 - Novel polypeptide ligands for toll-like receptor 2 (tlr2): The present invention provides novel polypeptide ligands for Toll-like Receptor 2 (TLR2). Preferrably, the novel polypeptide ligands modulate TLR2 signaling and thereby regulate the Innate Immune Response. The invention also provides vaccines comprising the novel polypeptide TLR2 ligands and an antigen. The invention further provides methods of modulating TLR2 signaling... Agent: Baker Botts L.l.p.

20090028890 - Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein: The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or... Agent: Williams Mullen

20090028891 - Chlamydia antigens and uses thereof: The invention provides protein and nucleic acid sequences of Chlamydia species which are particularly suitable for diagnosis, treatment and/or prevention of Chlamydia or Chlamydophila infection in mammals, particularly humans. The invention particularly provides a pharmaceutical composition and method for preventing or treating Chlamydia or Chlamydophila infection.... Agent: Proskauer Rose LLP

20090028892 - Ostertagia vaccine: The present invention relates to nucleic acid sequences encoding Ostertagia ostertagi proteins and to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof.... Agent: Intervet/schering-plough Animal Health Patent Department

20090028893 - Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides: The present invention relates to the cloning and expression of foreign protein or polypeptides in bacteria, such as Escherichia coli. In particular, this invention relates to expression tools comprising a FKBP-type peptidyl prolyl isomerase selected from the group consisting of FkpA, SlyD, and trigger factor; methods of recombinant protein expression,... Agent: Dinsmore & Shohl, LLP One Dayton Centre

20090028894 - Papilloma virus capsomere vaccine formulations and methods of use: Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.... Agent: Marshall, Gerstein & Borun LLP

20090028896 - Compositions and method for weight loss: Dietary supplements and methods for management and control of body weight comprising at least one liver protecting agent and at least one mushroom in the form of powder, extract, or combinations thereof.... Agent: Mcdermott Will & Emery LLP

20090028895 - Methods and compositions for reducing facial lines and wrinkles: A dietary supplement composition comprising a therapeutically effective amount of at least one sirt 1 activating agent, a therapeutically effective amount of at least one Qi activating agent, and a therapeutically effective amount of at least one adaptogen is disclosed. An optional herbal treatment for stress-related deep wrinkles comprises chronic... Agent: Brown Rudnick LLP

20090028897 - Cosmetic use of an active agent capable of stimulating tensin 1 expression: A cosmetic skincare process intended to prevent and/or treat at least one cutaneous sign of aging, includes the topical application to the skin of a composition containing at least one active agent capable of stimulating tensin 1 expression. The cosmetic use of an active agent capable of stimulating tensin 1... Agent: Young & Thompson

20090028898 - Instant additive solution for the filter of cigarette, its production method and use: The present invention relates to the field of tobacco science and smoking, providing an instant additive solution for the filter of cigarette which can efficiently reduce the tar and a great number of toxicants in main-stream smoke and simultaneously lower the temperature of main-stream smoke when flowing through the respiratory... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20090028899 - Method of producing seaweed paste and seaweed paste obtained by such a method: A method of producing seaweed paste including the steps of: placing seaweed, a chelating agent and water in a tank; and stirring the resulting composition at 0-20° C. to cut the seaweed, wherein the interior of the tank is in a vacuum state. A method of producing seaweed paste having... Agent: Mark D. Saralino (general) Renner, Otto, Boisselle & Sklar, LLP

20090028901 - Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents: The present invention relates, in general, to a screening method for identifying novel viral proteins with interferon antagonizing function using a transfection-based assay, and the use of such proteins in isolating various types of attenuated viruses for the development of vaccine and pharmaceutical formulations. The invention also relates to the... Agent: Jones Day

20090028900 - West nile viruses with mutations in the 3' terminal stem and loop secondary structure for use as live virus vaccines: The invention provides West Nile (WN) viruses and chimeric WN viruses having one or more mutations in the 3′ terminal stem loop secondary structure (3′SL) that results in decreased neurovirulence, methods of making such WN viruses, and methods for using these WN viruses to prevent or treat WN virus infection.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090028902 - Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090028903 - Novel use: The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease. In particular the invention relates to vaccine formulations comprising an oil-in-water emulsion adjuvant and optionally 3D-MPL, their use in medicine, in particular their use in augmenting immune responses to influenza antigens, and to methods... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090028904 - Novel cochleate formulations: A process for producing a small-sized, lipid-based cochleate. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2+ or Zn2+, forms a... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090028905 - Method for treatment of laminitis in animals: The present invention generally relates to methods for treating the sequela of laminitis in hoofed animals. Benefits are obtained by administering to the animals to be treated injections of Botulinum Toxin in the limb to be treated. In one embodiment, about 100 Units to 600 Units of Type A Botulinum... Agent: William H. Hollimon

20090028907 - Botulinum toxin treatment: The invention relates to the use of a liquid or semi-solid formulation of botulinum toxin for the preparation of a medicament intended to treat a disorder characterised by bladder spasms (e.g. urinary incontinence due to unstable bladder or unstable detrusor sphincter, voiding complications due to detrusor overactivity or unstable detrusor... Agent: Jacobson Holman Pllc

20090028908 - Methods for treating neurogenic inflammation: The present invention relates to methods for treating neurogenic inflammation pain. The methods include administering an effective amount of a composition which includes a botulinum toxin component and a substance P component to a patient, thereby treating the neurogenic inflammation pain.... Agent: Allergan, Inc.

20090028906 - Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in a solid form: The present invention relates to a method for providing a muscle relaxant at temperatures above 20° C., wherein said muscle relaxant is a solid dry composition comprising the neurotoxic component of botulinum toxin free of complexing proteins.... Agent: The Firm Of Hueschen And Sage

20090028909 - Intranasal vaccine for use against disease caused by enterotoxigenic escherichia coli: The disclosure relates to an intranasal peptide vaccine for use against infection caused by enterotoxigenic Escherichia coli (ETEC), containing a common linear protein epitope known as CLE which is recognized by sera of patients infected with the bacteria and which is associated with a mucosal adjuvant comprising cholera toxin subunit... Agent: Miller, Matthias & Hull

20090028912 - Materials for dissolution-controlled release: A controlled release substance containing organosilica sol-gels is provided. The organosilica sol-gels may be further functionalized with amino groups to control the rate of release of encapsulated molecules. The controlled release substance may be utilized as a controlled release fabric care substance, including at least one active fabric care substance... Agent: Harness, Dickey, & Pierce, P.l.c

20090028910 - Methods for fabrication isolated micro-and nano-structures using soft or imprint lithography: The presently disclosed subject matter describes the use of fluorinated elastomer-based materials, in particular perfluoropolyether (PFPE)-based materials, in high-resolution soft or imprint lithographic applications, such as micro- and nanoscale replica molding, and the first nano-contact molding of organic materials to generate high fidelity features using an elastomeric mold. Accordingly, the... Agent: Alston & Bird LLP

20090028911 - Process for the production of pigment-bearing leads: A process for the production of pigment-bearing and/or effect substance-bearing leads, comprising the following steps: a) pigments and/or effect substances are at least partially mixed with a fluid wetting agent so that a kneadable material is produced, b) further ingredients and optionally remaining pigments and/or effect substances are added and... Agent: Bachman & Lapointe, P.c.

20090028913 - Water-in-oil type emulsion sunscreen cosmetics: The water-in-oil type emulsion sunscreen cosmetic in the present invention is characterized by comprising (a) 0.2 to 14% by mass of methoxycinnamate ester, (b) 0.02 to 14% by mass of octocrylene, (c) 0.2 to 14% by mass of dimethylpolysiloxane, (d) 0.02 to 14% by mass of monoester oil represented by... Agent: Rankin, Hill & Clark LLP

20090028916 - Loaded microspheres: The invention relates to loaded microspheres with a mean diameter of 0.001 to 1 mm, and loaded with one or more absorbed or adsorbed active principles, which are obtained by mixing fine-particle polymethyl methacrylate or methyl methacrylate cross polymer with lipophilic or hydrophilic active principles until they have been absorbed... Agent: Fox Rothschild LLP

20090028915 - Material having antimicrobial activity when wet: An article is applied to the surface of an article, animal housing environment or animal (including humans) to provide antimicrobial activity when activated with a liquid comprising alcohol. The article may comprise a water and/or alcohol absorbent material; and a composition that reacts with water and/or alcohol to produce molecular... Agent: Mark A. Litman & Associates, P.a.

20090028914 - Medical devices incorporating collagen inhibitors: Provided herein are implantable or insertable biomedical devices comprising a substrate and a collagen inhibitor on or in said substrate, and methods of treatment using the same. In some embodiments, the device is an absorbable esophageal or tracheal stent. In some embodiments, the device is a vascular stent. Wound closure... Agent: Myers Bigel Sibley & Sajovec

20090028917 - Micronized wood preservative formulations: The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20090028918 - Gynecological pharmaceutics- containing microspherical vascular suppository of sodium alginate and its preparation method: The present invention relates to a kind of sodium alginate microsphere vascular embolus containing gynecological drug and its preparation. The preparation of it consists of the following steps: preparing the solution of gynecological drug, sodium alginate and dilvalent metal cations such as BaCl2, Mg Cl2 or CaCl2 etc. by order;... Agent: Michael N. Lau Lau & Associates, Llc

20090028921 - Electrospun ceramic-polymer composite as a scaffold for tissue repair: The present invention relates to compositions and methods of preparing a three-dimensional matrix of micron sized electrospun fibers, wherein the electrospun fibers are formed from a electrospun composite comprising a bioactive ceramic component and a polymer component. The matrix provides an osteoconductive and osteoinductive scaffold supporting osteogenesis and thereby facilitates... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20090028919 - Systems and methods of promoting engraftment of a hybrid lower limb artery bypass vascular graft in a mammal: Hybrid synthetic grafts and embodiments of systems and methods for producing hybrid vascular grafts that can yield implantable grafts that combine synthetic grafts with living cells. Embodiments of systems can include a pressure/flow loop subsystem having an external flow loop system coupled to a specimen holder, where the pressure/flow loop... Agent: Rene A. Vazquez Williams Mullen

20090028920 - Urological devices incorporating collagen inhibitors: Provided herein are implantable or insertable biomedical devices comprising a substrate and a collagen inhibitor on or in said substrate, and methods of treatment using the same. In some embodiments, the device is a urethral, ureteral, or nephroureteral catheter or stent. Kits comprising the same are also provided.... Agent: Myers Bigel Sibley & Sajovec

20090028922 - Local delivery method and composition: This invention provides a rapidly degrading composition for local delivery of a medicament, such as, an antibiotic. Additionally, this invention provides a method that can be used on the battlefield to deliver antibiotics as a preliminary treatment through the use of a rapidly degrading composition.... Agent: Susan B. Fentress

20090028923 - Implantable devices and methods for treating sinusitis and other disorders: Devices, systems and methods for stenting, spacing, draining, ventilating and/or delivering drugs and other therapeutic or diagnostic substances to desired locations within the bodies of human or non-human animal subjects, including methods and systems for treating paranasal sinusitis and ethmoid disease.... Agent: Stout, Uxa, Buyan & Mullins LLP

20090028924 - Use of a polysaccharide which is excreted by the vibrio diabolicus species for the regeneration and protection of the periodontium: The invention relates to the use of a polysaccharide which is excreted by the Vibrio diabolicus species for the re-generation and protection of the non-mineralised connective tissue of the periodontium.... Agent: Marshall, Gerstein & Borun LLP

20090028925 - Novel phosphinic acid-containing thyromimetics: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090028926 - Method and mixture for in vivo photochemical cross-linking of collagen: A method and a composition for photochemical cross linking of collagen by photoactive agent in-vivo are presented. The method includes a non-toxic photoactive formulation of the composition with collagen, which is administered to treatment area locally; followed by irradiation with suitable wavelength. In one of the embodiment liposomal formulated mTHPC... Agent: Bolesh J. Skutnik Ceramoptec Industries, Inc.

20090028927 - Poly(vinyl alcohol) - bacterial cellulose nanocomposite: Hydrogel-bacterial cellulose nano-composite materials are created using a hydrogel and never dried bacterial cellulose fibers. Such materials are suitable for a broad range of soft tissue replacement applications. In addition controlled release of bioactive agents properties can be designed into medical devices fabricated from such composite materials.... Agent: Ralph A. Dowell Of Dowell & Dowell P.c.

20090028928 - Patch and patch preparation: The present invention provides a patch containing a support and an adhesive layer provided on at least one surface of the support, wherein the adhesive layer contains a synthetic rubber component other than polyisobutylene and solid at 25° C., a liquid rubber component having a crosslinkable functional group in a... Agent: Wenderoth, Lind & Ponack, L.l.p.

20090028930 - Bruise amelioration composition and method of use: A bruise amelioration composition that can be applied for one hour to an affected site, such as a bruise, contusion or blister, in the form of a gel, liquid or adhesive bandage. The composition includes at least 40% by weight of glycerin and at least 2% by weight of primrose... Agent: Ladas & Parry LLP

20090028929 - Transdermal patch: A transdermal patch suitable for the administration of nitroglycerin.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20090028933 - Compositions and methods for treating lymphoma: The present invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of leukemias, including acute lymphoblastic leukemia (ALL). These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, in combination with dexamethasone to a mammal with a leukemia.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090028931 - Liposomal compositions for parenteral delivery of agents: The invention provides methods and compositions for loading an agent, such as econazole, onto a liposome for parental delivery. The loading of the agent into a liposome comprises combining the agent with a micelle-forming compound to form a micelle including the agent, where the agent is releasable from the micelle-forming... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20090028932 - Vaccine formulations for leishmania: The present invention involves the use of Leishmania antigens and nucleic acids coding therefor as vaccines. It also provides a method of inducing protective immune responses in a subject through the use of specific delivery systems such as protein and/or DNA vaccines and Listeria monocytogenes vectors.... Agent: Fulbright & Jaworski L.l.p.

20090028934 - Granular, gastro-resistant product based on niacin or derivates thereof and process for the production of such a product: A granular, gastro-resistant product based on niacin or derivatives thereof comprises an internal part in which the niacin is substantially concentrated and an external coating, provided to cover and protect the internal part, made up of a matrix having a total weight fraction of long-chain C16-C22 saturated fatty acids of... Agent: Castellano Pllc

20090028935 - Carvedilol forms, compositions, and methods of preparation thereof: Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.... Agent: Cantor Colburn, LLP

20090028938 - Dosage forms with improved bioavailability: A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>ΔHtr (1) (wherein ΔHtr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product is used for... Agent: Edwards Angell Palmer & Dodge LLP

20090028939 - Solid preparation: The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active... Agent: Foley And Lardner LLP Suite 500

20090028937 - Tablet comprising ornithine hydrochloride: The present invention has an object to provide a tablet capable of comprising ornithine hydrochloride in a higher content; and a process for producing the same, and provides the tablet comprising ornithine hydrochloride and maltose, or a linear or cyclic dextrin; and the process for producing a tablet comprising ornithine... Agent: Fitzpatrick Cella Harper & Scinto

20090028936 - Tablets containing enrofloxacin and flavouring agents and/or flavours: The present invention relates to tablets for animals, which tablets comprise enrofloxacin as well as flavourings and/or aromatizing substances.... Agent: Bayer Healthcare Llc

20090028940 - Pharmaceutical compositions of rifaximin: A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release.... Agent: Merchant & Gould Pc

20090028941 - Pulsatile gastric retentive dosage forms: Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent into the stomach and upper gastrointestinal tract subsequent to administration of the dosage form. The dosage forms find particular use... Agent: King & Spalding LLP

20090028942 - Sustained release compositions of alfuzosin: The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers.... Agent: Bio Intellectual Property Services (bio Ips) Llc

20090028943 - Pharmaceutical compositions: Pharmaceutical compositions comprising AZD2171 or a pharmaceutically acceptable salt thereof, including pharmaceutical compositions comprising AZD2171 or a pharmaceutically acceptable salt and a plastic filler with a high surface area, excluding lactose.... Agent: Morgan Lewis & Bockius LLP

20090028944 - Pharmaceutical compositions comprising mesalamine: Pharmaceutical compositions comprising mesalamine, wherein the compositions are free of a liphophilic matrix, and processes for preparing pharmaceutical compositions comprising mesalamine and being free of a liphophilic matrix.... Agent: Dr. Reddy''s Laboratories, Inc.

20090028945 - Immunoisolative encapsulation system: A fundamental deficiency with current biological cell encapsulation technology is that passive material barriers cannot protect biological cells from exposure to cytokines and other small, diffusible cytotoxic molecules produced by activated immune cells, subsequently leading to biological cell destruction. The present invention provides an immunoisolative encapsulation system that actively and... Agent: Townsend And Townsend And Crew, LLP

20090028946 - Photo-responsive delivery system: A photo-responsive delivery system useful to deliver a compound to a target site is provided. The system includes a physiologically compatible matrix crosslinked with a photo-responsive matrix cross-linking agent. A method of making the delivery system and a method of delivering a compound to a target site using the system... Agent: Valentine A Cottrill Susan Tandan

20090028949 - Calcium phosphate-based adhesive formulation for bone filling with swelling properties: p

20090028951 - Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof: A composition suitable for oral administration for sustained-release of glutathione, the composition having from about 50% by weight to about 90% by weight glutathione; from about 0% by weight to about 10% by weight binder; from about 10% by weight to about 50% by weight of at least one sustained... Agent: Knobbe Martens Olson & Bear LLP

20090028950 - Granule dispersion composition, process for producing the same, and granular material and medicine: The subject matter of the present invention is to provide a new particulate material dispersion composite in which a material poorly soluble in water is micronized and dispersed. For the above purpose, a particulate material dispersion composite is produced in the present invention, wherein a particulate material containing a specific... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090028952 - Hydroxy sulfonate of quinone compounds and their uses: The present invention provides sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6-tetrahydro-2H-benzo(h)chromene-6-sulfonate, and its synthesis and uses in the treatment of cancer.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090028953 - Method of treatment using microparticulate biomaterial composition: Compositions of microspheres formed of stabilized hyaluronic acid are disclosed. The unique biological properties of hyaluronic acid provide for very inert properties when exposed to tissues. Microsphere formulations of hyaluronic acid have medical utility due to the resultant properties of flowability, physical stability, and degradability. High concentration formulations of the... Agent: Gregory Smith & Associates

20090028948 - Nanoparticle composition and methods of synthesis thereof: The present invention relates to improved therapeutically active nanocomposite microstructure compositions, including nanoparticle compositions and nanoparticle preparations. Preferred embodiments include nanoparticle compositions comprising nanoparticles of a therapeutically active agent dispersed in a carrier matrix. The invention also relates to a method for preparing said compositions and preparations using solid-state mechanochemical... Agent: Mark J. Rosen P.c.

20090028954 - Precursor for the preparation of a pasty bone replacement material by admixture of a liquid: The precursor is used for the preparation of a pasty bone replacement material by admixture of a liquid. The precursor comprises a biocompatible substance swellable by the action of water or of an aqueous solution thereby forming a hydrogel; and solid particles made of a substance which is suitable as... Agent: Rankin, Hill & Clark LLP

20090028947 - Using of nanosilver in poultry, livestock and aquatics industry: Nanosilver material is disclosed. Said material is nano silver based disinfectant and disease preventer for poultry, livestock and aquatics. The material contains silver nano particle and pure water and can be used as a surface disinfectant, water disinfectant and therapentic material for poultry, livestock and aquatic disease caused by bacteria's... Agent: Barry Choobin

20090028955 - Ophthalmic emulsions containing an immunosuppressive agent: Ophthalmic oil-in-water emulsions, which comprises colloid particles having an oily core surrounded by an interfacial film, the emulsion comprising an 10 immunosuppressive agent, an oil, preferably at least 50% of which being MCT, and tyloxapol. Use of such an emulsion for the manufacture of medicament for treatment of eye conditions,... Agent: Young & Thompson

20090028956 - Polypeptide microparticles: The invention provides polypeptide microparticles and methods for the preparation thereof using a nucleating agent.... Agent: Kagan Binder, Pllc

20090028957 - Implantable tissue-reactive biomaterial compositions and systems, and methods of us thereof: The invention pertains to biomaterial compositions and implantable systems for application to a tissue site in a living mammalian body. The compositions and systems react with tissue surfaces and components present in physiological fluids at the region of implantation, obviating the need to remove such fluids and improving the adhesion... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090028958 - Cosmetic makeup and/or care process: The present invention relates mainly to a cosmetic process for making up and/or caring for keratin material(s), comprising the application, on contact with a keratin material, of at least one cosmetic composition comprising at least 75% by weight, relative to its total weight, of compound(s) approved for food use and... Agent: Oliff & Berridge, Plc

20090028959 - Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries: A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages or injuries caused by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (I). The active ingredient compound is capable of (a) increasing viability of myogenic precursor... Agent: Evan Law Group Llc

20090028960 - Calcium phosphate-based adhesive formulation for bone filling: p

20090028961 - Decontamination solution and its use for denaturation, modification, degradation, solubilisation and removal of proteins, nucleic acid molecules and microorganisms: The invention concerns a three component system comprising surface-active substances, vitamins and metal ions for efficient destruction and removal of contaminating proteins, nucleic acids and microorganisms from surfaces like for example laboratory benches, floors, equipment and instruments. These non-corrosive and non-toxic solutions for removal of proteins, nucleic acids and microorganisms... Agent: Joyce Von Natzmer Pequignot + Myers Llc

20090028962 - Methods and compositions for enhancing iron absorption: The present invention generally relates to methods and compositions useful in enhancing iron absorption in a patient. The methods and compositions of the present invention may be used independently to promote and/or maintain iron absorption in a patient or may be used in combination with one or more other compositions... Agent: Kv Pharmaceutical Company

20090028964 - Container and kit for the preparation, storage and dispensing of compounded suppositories: A container suitable for the preparation, storage and dispensing of compounded suppositories is provided. Methods of preparing, storing and dispensing compounded suppositories utilizing such a container and related kits are also provided.... Agent: Wolf Greenfield & Sacks, P.c.

20090028963 - Polyphenol coxib combinations and methods: Contemplated compositions and methods utilize a combination of a polyphenol and a non-polyphenol cyclooxygenase-2 inhibitor. Preferably, the compositions are pharmaceutical and/or nutraceutical compositions and formulated in a dosage form and amount such that the polyphenol and the non-polyphenol cyclooxygenase-2 inhibitor are effective to reduce tumor incidence and/or multiplicity. In preferred... Agent: Fish & Associates, Pc Robert D. Fish

20090028965 - Multi-part disinfectant: Disclosed is a multi-part disinfectant composition, wherein the parts thereof are solid and are packaged separately prior to use, and wherein the separately-packaged parts, when combined in the presence of water or an aqueous solution, react to form chlorine dioxide.... Agent: Barnes & Thornburg LLP

20090028966 - Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation: Biocompatible polymers having polymer backbones with at least one secondary amine suitable for diazeniumdiolation are disclosed. Specifically, methods for providing secondary amines-containing polymers using epoxide-opening reactions are provided. More specifically, nitric oxide-releasing medical devices made using these polymers are disclosed.... Agent: Medtronic Vascular, Inc. Ip Legal Department

20090028967 - Fluid konjak material and its production and use: A fluid konjak material, which can be mixed with any other edible material uniformly at a high concentration while sufficiently keeping the gelling power and the biological effect intrinsic to konjak mannan, is provided by swelling and dissolving konjak flour in water, treating the resultant with alkali at a pH... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090028969 - Compostion for treating skin: A combination comprising verbascoside and luteolin, and its use in a cosmetic or pharmaceutical composition for pigmentation modulation.... Agent: Bayer Healthcare Llc Consumer Care Division

20090028968 - Pharmaceutical platform technology for the development of natural products: The present invention provides a set of in vitro and in silico methodologies for predicting in vivo pharmacokinetics and pharmacodynamics of multiple components; the methodologies comprise mathematical models for solving multiple unknowns which are linearly independent and/or interacting with each other. The present invention can be applied to develop phytomedicines... Agent: Law Offices Of Albert Wai-kit Chan, Pllc

20090028970 - Antiallergic composition: It is an object of the present invention to provide an antiallergic composition that is moderate for the human body and skin, and has reduced side-effects. In order to achieve this object, there is provided the antiallergic composition comprises a cold-water extract from hop tissue or flavonoid glucosides separated from... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090028971 - Method for obtaining natural oils from plant constituents: The invention relates to a method for obtaining natural oils from plant constituents, said method being essentially carried out using compressed C2-C4 hydrocarbons. Residues from the crop and fruit treatment, especially from the treatment of pips and berries, are used as starting materials. Unlike previous extraction methods using organic solvents,... Agent: Fulbright & Jaworski, LLP

20090028972 - Treating neoplasms with neurotoxin: The present invention provides a method of treating a cancer using a neurotoxin, preferably Botulinum toxin (“BTX”). The application of a neurotoxin around a cancer acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze cancer cells through efferent channels leaving the cancer vicinity to... Agent: Greenberg Traurig, LLP

20090028974 - Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction: The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.... Agent: Sheridan Ross Pc

20090028973 - Use of nocardia rubra cell wall skeleton in the preparation of anti-hpv infection medicaments: The invention refers to use of Nocardia Rubra Cell Wall Skeleton, especially the new use of the same in the preparation of Anti-HPV medicaments.... Agent: Morrison & Foerster LLP

20090022655 - Nanotubes for cancer therapy and diagnostics: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.... Agent: Winstead Pc

20090022656 - Lipidated glycoprotein particles and methods of use: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090022663 - Antibodies and related molecules that bind to 161p2f10b proteins: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B... Agent: Agensys C/o Morrison & Foerster LLP

20090022659 - Antibodies to tnf alpha and use thereof: The present invention is directed to antibodies and fragments thereof having binding specificity for TNF-α. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also... Agent: Hunton & Williams LLP Intellectual Property Department

20090022660 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.a.

20090022661 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.a.

20090022662 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.a.

20090022658 - Modified antibodies and methods of use: Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090022657 - Novel cxcl8 antagonists: Novel antagonists of the chemokine CXCL8 (also known as Interleukin-8) can be obtained by generating mutants having specific combinations of non-conservative substitutions of basic amino acids located in the C-terminal region. Compounds prepared in accordance with the present invention can be used to block CXCL8 activity in vivo, thereby providing... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090022664 - Radiolabelling via fluorination of aziridines: The present invention relates to novel compounds suitable for or already radiolabelled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging.... Agent: Millen, White, Zelano & Branigan, P.c.

20090022665 - Evaluation of immediate-effect skin molding agents using disc: The present invention pertains to methods of characterizing the effects on the skin of skin-molding agents and to methods of characterizing the physical behavior of the skin-molding agents themselves. A preferred embodiment of the present invention uses a non-invasive, in vivo form of digital image speckle correlation to track deformation... Agent: The Estee Lauder Cos, Inc

20090022666 - Methods and systems relating to mitochondrial dna information: The present application relates, in general, to a system or a method for detection or treatment. In some aspects, a system includes at least one computer program for use with at least one computer system and wherein the computer program includes a plurality of instructions including but not limited to... Agent: Searete Llc Clarence T. Tegreene

20090022667 - Methods of treating cognitive disorders by inhibition of gpr12: The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or Gpr12 function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating Gpr12-dependent... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090022668 - Mri contrast agents endowed with concentration independent responsiveness: The present invention relates to a method for the in vivo, ex vivo, or in vitro determination of physical or chemical parameters of diagnostic interest by use of a slow tumbling paramagnetic agent that is responsive to changes of said physical or chemical parameter through changes in the R2p/R1p ratio... Agent: Bracco Research Usa Inc.

20090022669 - Compositions for protein delivery via the pulmonary route: Novel formulations comprising therapeutic agents, a surface tension-controlling agent, and a component that comprises both a humectant and a viscosity-controlling agent for use in thermal droplet ejecting devices are disclosed. The formulations are useful for maintaining controlled and reliable dosage of the therapeutic agent via pulmonary delivery.... Agent: Paul, Hastings, Janofsky & Walker LLP

20090022670 - Novel compounds: v

20090022671 - Treatment methods: Disclosed are methods of treating rhinosinusitis of the upper airway passages in patients afflicted with said disease, which comprises administering at least once-a-day to the surfaces of said passages of said patients an amount of aerosolized particles of mometasone furoate as a monotherapy effective for treating said disease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090022672 - Fluoride composition and methods for dental mineralization: The present invention relates to compositions and methods for mineralizing a dental surface or subsurface including providing a composition including stabilized ACP and a source of fluoride ions.... Agent: Merchant & Gould Pc

20090022673 - Composition and packaging method for animal dental care: A comestible, water-based composition containing natural ingredients provides an effective amount of at least one active ingredient selected to reduce the proliferation of bacteria in the mouth of animals to treat and improve the dental health of animals. The composition can be administered to animals in the form of their... Agent: Morriss Obryant Compagni, P.c.

20090022674 - Cosmetic or dermatological preparations comprising oligopeptides for lightening the skin of age marks and/or for preventing tanning of the skin, in particular tanning of the skin caused by uv radiation: Cosmetic or pharmaceutical preparations which are distinguished by an effective content of one or more monomeric or homo- or heterodimeric or homo- or heterotrimeric or homo- or heterotetrameric oligopeptides, where these oligopeptides are based on a Structure Val-Val-Arg-Pro SEQ ID NO: 1 as homo- or heteromonomer.... Agent: Greenblum & Bernstein, P.L.C

20090022675 - Esters with warming properties: and wherein x+y, x+y+z or w+x+y+z, or combinations thereof, has an average value ranging from about 6 to about 100; wherein R is a hydrocarbon or mixture of alkyl groups comprising from about 3 to about 19 carbons, wherein n is an integer ranging from about 2 to about 4,... Agent: Law Offices Of Mitchell P. Novick

20090022677 - Methods for identifying treatments that treat and/or prevent uv irradiation induced photoaging: Methods are provided for ascertaining and measuring RPTP-κ activity in response to insults such as UV irradiation and with respect to administration of a treatment and/or composition. Attenuation of EGFR activity by RPTP-κ affects aspects of photoaging, including damage to the skin, suppression of the immune system, DNA damage, and... Agent: Harness, Dickey & Pierce, P.L.C

20090022678 - Polyurethane dispersions for use in personal care products: t

20090022676 - Shear thinning hydrocarbon gel compositions and uses thereof: The present invention relates generally to gels that flow through an orifice. Specifically the invention relates to gels that are dispensed through a trigger spray nozzle or aerosol spray valve. Still more specifically, the invention relates to nonaquious gels containing polymers whose instantaneous viscosity reversibly decreases when the gel experiences... Agent: Arthur M Dula Law Office Of Arthur M Dula

20090022679 - Solid cosmetic composition: e

20090022681 - Hair care composition: Hair care composition comprising from about 0.1% to about 20% of a sulfopropyl(meth)acrylate compound, an alpha methylene lactone, or a mixture thereof, wherein the sulfopropyl(meth)acrylate compound and the alpha methylene lactone each have a molecular weight of less than 500 grams/mole; and a dermatologically acceptable carrier.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090022680 - Oil-in-water emulsion containing an amphiphilic polymer: A composition for topical application, in the form of an oil-in-water emulsion, containing at least one nonionic emulsifier with a melting point of less than 45°C. and at least one 2-acrylamido-2-methylpropanesulfonic acid polymer. The composition shows very good stability.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090022682 - Fragrance delivery system: Disclosed are apparatuses and methodologies for respectively delivering fragrances to desired environments. Formulations including volatile methylsiloxane fluid provide a clear, VOC-exempt, low surface tension fluid that will evaporate completely at room temperature. Because methylsiloxane fluid is itself an odorless fluid, it does not obscure or alter combined fragrances being otherwise... Agent: Dority & Manning, P.a.

20090022683 - Biodegradable and thermosensitive poly(organophosphazene) hydrogel, preparation method thereof and use thereof: The present invention relates to a biodegradable and thermosensitive poly(organophosphazene) with a functional group, a preparation method thereof, and a use thereof for delivery of bioactive substances. According to the present invention, poly(organophosphazene) is a phosphagen-based polymer showing biodegradability, thermosensitivity, and sol-gel phase transition depending on temperature change, whereby when... Agent: Lexyoume Ip Group, Llc

20090022684 - Methods for hematopoietic stimulation: e

20090022685 - Orthotopic, controllable, and genetically tractable non-human animal model for cancer: This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations (e.g., in oncogenes and tumor suppressor genes) that lead to chemoresistance or poor prognosis, and in identifying... Agent: Ropes & Gray LLP

20090022686 - Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome: The present invention relates to the use of certain benzimidazoles for preparing a pharmaceutical composition for the treatment of systemic inflammatory response syndrome and particularly sepsis.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090022687 - Novel pharmaceuticals that use anti-hla antibodies: The present inventors tested the effects of interferons on the expression of HLA-A in cells and cell injury caused by anti-HLA class I antibodies, by using a 2D7-DB antibody as an anti-HLA class I antibody and the IM-9 cell line as the cells to be tested. As a result, the... Agent: Fish & Richardson Pc

20090022689 - C4-spiro-pyrrolidine antivirals: e

20090022688 - Inhibitors of serine protease, particularly hcv ns3-ns4a protease: or a pharmaceutically acceptable salt, or mixtures thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable... Agent: Vertex Pharmaceuticals Inc.

20090022690 - Bacterial translocation inhibitor and method of inhibiting bacterial translocation: A bacterial translocation inhibitor containing live Bacillus subtilis cells as an active ingredient, and a method for inhibiting bacterial translocation comprising the step of orally administering the bacterial translocation inhibitor.... Agent: Darby & Darby P.c.

20090022699 - Method of genotypically modifying cells by administration of rna: A method of inducing genotypic modification in a cell, which comprises providing isolated RNA comprising RNA extractable from source tissue to the cell under conditions whereby the desired induction of genotypic modification is achieved, wherein the RNA is isolated polyA positive RNA in substantially pure form.... Agent: Woodcock Washburn LLP

20090022691 - Bacterial delivery of biologically active polypeptides: The present invention relates to methods for the delivery of biologically active polypeptides to a subject by colonising non-pathogenic Gram negative bacteria. Also provided by this invention are methods of treating or preventing diseases by administering colonising Gram negative bacteria that express one or more biologically active polypeptides. The colonising... Agent: Bozicevic, Field & Francis LLP

20090022700 - Cosmetic water-soluble film: The present invention relates to a composition which is in the form of a water-soluble anhydrous film comprising at least one water-soluble or water-dispersible film-forming polymer, and at least one live, in particular probiotic, microorganism. It also relates to a kit containing such a composition, as a combination with a... Agent: Oliff & Berridge, Plc

20090022698 - Composition for treatment of articular cartilage damage: Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem... Agent: Sughrue Mion, Pllc

20090022695 - Method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with specific cancer types: Methods for treating a patient suffering from a neoplastic disease are disclosed and described. A number of diseases can be treated under the present methods, including without limitation gall bladder cancer, hepato cellular cancer, ovarian cancer, small intestine cancer, lung cancer, mesothelioma, breast cancer, kidney cancer, pancreas cancer, prostate cancer,... Agent: Thorpe North & Western, LLP.

20090022693 - Method forisolating stem cells from cryopreserved dental tissue: The invention relates to a method for isolation of multipotent stem cells from dental tissue in which the stem cells are extracted from a tissue structure and then cultured. The invention also relates to stem cells isolated by means of the method according to the invention as well as bone... Agent: Joyce Von Natzmer Pequignot + Myers Llc

20090022696 - Methods for immortalizing cells: The present invention provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, said methods comprising culturing the precursor cells in the presence of a Notch agonist and one or more growth factors that support the proliferation but not differentiation of the non-terminally differentiated cells.... Agent: Townsend And Townsend And Crew, LLP

20090022694 - Sirt1 inhibition: A method of culturing cells in the presence of a SIRT1 inhibitor is described.... Agent: Lowrie, Lando & Anastasi, LLP E2023

20090022697 - System for the implantation of cardiac staminal cells with the \"ciuro? method\": The system is composed of two inseparable parts that both make up one Device: I) A container for collecting staminal cells and for their growth factors which is the same as the portcat system with sylicon button to enable the entrance of the Huber needle through a hole. 2) “Active... Agent: Lindsay S. Adams Day Pitney

20090022692 - Therapeutic agent for heart disease using map kinase tnni3k: An object to be achieved by the present invention is to provide a therapeutic means for heart disease such as myocardial ischemia or myocardial infarction. The present invention provides a therapeutic agent for heart disease which comprises a myocardial progenitor cell expressing MAP kinase TNNI3K at a high level as... Agent: Greenblum & Bernstein, P.L.C

20090022701 - Recombinant human cln2 protein and methods of its production and use: The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2... Agent: Klauber & Jackson

20090022702 - Methods for introducing mannose 6-phosphate and other oligosacharides onto glycoproteins: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose 6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090022703 - Lysyl oxidase-like 1 (loxl1) and elastogenesis: Described are methods of treating and preventing conditions associated with a loss of elastic fibers. Also provided herein are methods of screening for agents useful in treating such conditions, and animal models of conditions associated with a loss of elastic fibers.... Agent: Fish & Richardson Pc

20090022704 - Method for the treatment of gout or pseudogout: The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.... Agent: Womble Carlyle Sandridge & Rice, Pllc

20090022705 - Chloroplasts engineered to express pharmaceutical proteins in edible plants: Disclosed herein are compositions for conferring oral tolerance in mammals to autoimmune disorders such as diabetes, as well as vectors and methods for plastid transformation of plants to produce a CTB-Pins protein for oral delivery. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof.... Agent: Beusse Wolter Sanks Mora & Maire

20090022706 - Substituted cyclohexenes: Disclosed herein are substituted cyclohexene TLR4 signaling pathway modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20090022713 - Anti-pro87299 antibodies: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease... Agent: Genentech, Inc.

20090022707 - Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease... Agent: Fish & Richardson P.c.

20090022712 - Compositions and methods for inhibiting leukocyte function: The present invention provides compositions and methods for regulating leukocyte migration and function. The present invention also provides compositions and methods for preventing and inhibiting lung injury and damage associated with neutrophil infiltration of the lung.... Agent: University Of Virginia Patent Foundation

20090022709 - Control of sorbose utilization genes and uses thereof: This invention relates generally to the discovery of a novel control of sorbose utilization (CSU) genes. The invention further relates to the detection of these genes and their use in the diagnosis and treatment of fungal infections.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090022711 - Methods of modulating cell death based on the bit-1/aes regulatory pathway: The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that... Agent: Mcdermott, Will & Emery

20090022710 - Nuclear factor of activated t cells receptor: The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (‘NFAT’) receptor, and related compositions and methods.... Agent: Nikolaos C. George Jones Day

20090022708 - Trefoil factors and methods of treating proliferation disorders using same: The present invention relates to methods of regulation of cellular proliferation and/or survival, particularly methods for the treatment of proliferative disorders. The invention also relates to agents and compositions of use in such methods.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20090022717 - Antibodies that bind cxcr7 epitopes: Antibodies that bind CXCR7 epitopes, as well as methods of identifying CXCR7 modulators are described.... Agent: Townsend And Townsend And Crew, LLP

20090022715 - Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090022714 - Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist: The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGFR antagonist and an EGFR antagonist.... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090022716 - Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist: The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation, chemotherapy, and/or an additional receptor antagonist.... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090022718 - Methods of treating a blood pathology using anti-tnf antibodies and fragments thereof: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20090022719 - Preventive and/or therapeutic method for systemic lupus erythematosus comprising anti-il-6 receptor antibody administration: A preventive and/or therapeutic agent for systemic lupus erythematosus comprising an anti-interleukin-6 (IL-6) receptor antibody as an active ingredient.... Agent: Foley And Lardner LLP Suite 500

20090022720 - Conjugate of an antibody against cd4 and antifusogenic peptides: The current invention is related to a conjugate comprising two or more antifusogenic peptides and an anti-CD4 antibody (mAb CD4) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CD4 antibody and to the pharmaceutical use of... Agent: Grant D. Green Roche Palo Alto Llc

20090022721 - Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the... Agent: Wolf Greenfield & Sacks, P.c.

20090022722 - Cytotoxicity mediation of cells evidencing surface expression of cd59: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Mchale & Slavin, P.a.

20090022723 - Anti-il-tif antibodies and methods of using in inflammation: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases,... Agent: Zymogenetics, Inc. Intellectual Property Department

20090022724 - Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof: The present disclosure provides attractin/mahogany-like polypeptides and fragments thereof, polynucleotides encoding such polypeptides and fragments, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides or fragments, and assays and methods employing these polypeptides, antibodies, and polynucleotides.... Agent: Immunex Corporation Law Department

20090022725 - Il-17 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090022727 - Injectable, nonaqueous suspension with high concentration of therapeutic agent: An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer... Agent: Durect Corporation Thomas P. Mccracken

20090022726 - Method of using il6 antagonists with proteasome inhibitors: The invention is directed to a method of treating a cancerous disorder or condition, or an IL-6related disorder or condition, in a mammal in need of such treatment, which comprises co-administering a proteasome inhibitor in combination with an IL-6antagonist... Agent: Philip S. Johnson Johnson & Johnson

20090022728 - Methods of treating ophthalmic diseases: Methods of using inhibitors (including monoclonal antibodies) directed against amyloid-beta peptide for the treatment of ophthalmic diseases such as age-related macular degeneration are described.... Agent: Pfizer Inc

20090022730 - Methods and compositions for assessing acute rejection: The invention relates to the analysis and identification of genes that are up-regulated simultaneously in transplant rejection. This simultaneous up-regulation of genes provides a molecular signature to accurately detect transplant rejection.... Agent: Novartis Corporate Intellectual Property

20090022729 - Methods and compositions for treating cardiac dysfunctions: The present invention provides methods and pharmaceutical compositions for treating or preventing cardiac dysfunctions (e.g., cardiac hypertrophy, cardiac remodeling, or heart failure) in subjects who have or are likely to develop cardiomyopathies. Some of the methods are directed to therapeutic or prophylactic treatment of cardiac dysfunctions in subjects having undergone... Agent: Catalyst Law Group, Apc

20090022731 - Arthritis-associated b cell gene expression: The invention features methods and compositions benefiting from differential gene expression observed in arthritis-associated B cells.... Agent: Wyeth Patent Law Group

20090022732 - Crystal of a cytochrome-ligand complex and methods of use: The teachings relates to the three-dimensional structure of a crystal of a cytochrome protein complexed with a ligand. The three-dimensional structure of four cytochrome P450 2A6-ligand complexes are disclosed. Cytochrome P450 2A6-ligand crystal structures, wherein the ligand is an inhibitor molecule, are useful for providing structural information that may be... Agent: Spencer Fane Britt & Browne LLP

20090022733 - Methods for treating disease with an il-1r antibody: The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-1 by administering an IL-1 antagonist, such as soluble type II IL-1 receptor.... Agent: Immunex Corporation

20090022734 - Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis: The invention provides a method of improving the expanded disability status scale (EDSS) score achieved by mammals affected by multiple sclerosis in which a substance effecting increased and/or prolonged activation and/or stimulation of the erythropoietin (EPO) receptor is administered to the mammal. In certain embodiments, the substance is administered in... Agent: Leydig Voit & Mayer, Ltd

20090022735 - Receptor binding polypeptides: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating... Agent: Occhiuti Rohlicek & Tsao, LLP

20090022736 - Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use: The invention features compositions relating to antibodies that specifically bind to the protective antigen of Bacillus anthracis, fragments thereof, and nucleic acids encoding same. The invention further features methods of using such compositions.... Agent: Bozicevic, Field & Francis LLP

20090022737 - Aldos as modifiers of the igf pathway and methods of use: Human ALDO genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of ALDO are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090022739 - Modulating the kv1.1 voltage-gated potassium channel in t-cells for regulating the synthesis and secretion of tumor necrosis factor alpha (tnf-alpha) and treating human disease or injuries mediated by detrimentally high or low levels of tnf-alpha: Blocking the voltage-gated potassium channel Kv1.1 of T-cells causes the robust and exclusive production of TNF-α, and thus can be used for eradication of cancer, improved eradication of infectious organisms, increased permeability of blood vessels and the blood brain barriers to given molecules and cells, and improved neuronal features, regeneration... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090022738 - Multispecific deimmunized cd3-binders: The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and... Agent: Foley And Lardner LLP Suite 500

20090022740 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20090022741 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20090022742 - Compounds and methods for diagnosis and immunotherapy of tuberculosis: Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more Mycobacterium proteins and DNA molecules encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable... Agent: Townsend And Townsend And Crew, LLP

20090022744 - Modified fc molecules: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.... Agent: Amgen Inc.

20090022743 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells: The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.... Agent: Goodwin Procter LLP

20090022745 - Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof: Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that... Agent: Ropes & Gray LLP

20090022746 - Complexes for transferring nucleic acids into cells: The invention relates to complexes of cationic polymers and nucleic acids, to the use of such complexes for introducing nucleic acids into cells and organisms, to the use of the complexes as pharmaceuticals, and to novel polymers which can be used to prepare the complexes.... Agent: Bayer Material Science Llc

20090022747 - B7-h3 and b7-h4, novel immunoregulatory molecules: The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.... Agent: Fish & Richardson P.c.

20090022749 - Pcv2 immunogenic compositions and methods of producing such compositions: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090022750 - Pcv2 immunogenic compositions and methods of producing such compositions: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090022751 - Pcv2 immunogenic compositions and methods of producing such compositions: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090022752 - Pcv2 immunogenic compositions and methods of producing such compositions: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090022748 - Unique associated kaposi's sarcoma virus sequences and uses thereof: This invention provides an isolated peptide encoded by a nucleic acid which is at least 30 nucleotides in length and has a sequence which uniquely defines a herpesvirus associated with Kaposis' sarcoma, which herpesvirus is present in and recoverable from the HBL-6 cell line (ATCC Accession No. CRL 11762).... Agent: Cooper & Dunham LLP

20090022754 - Recombinant antigen for diagnosis and prevention of murine typhus: The invention relates to a recombinant immunogenic composition from Rickettsia typhi. The invention also relates to a method for the use of the recombinant proteins in detection and diagnostic assays and as a component in formulations for the induction of an anti-R. typhi immune response.... Agent: Naval Medical Research Center Attn: (code 00l)

20090022756 - Recombinant f1-v plague vaccine: Disclosed herein is a composition comprising a purified fusion protein comprising all or part of F1 antigen of Yersinia pestis fused to the amino terminus of all of V antigen of Yersinia pestis, Yersinia enterocolitica, or Yersinia pseudotuberculosis that is isolated from its expression vector.... Agent: Office Of The Staff Judge Advocate (sks) U.s. Army Med. Research & Materiel Command

20090022753 - Surface proteins of streptococcus pyogenes: β-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing β-hemolytic streptococcal infection, and for detecting β-hemolytic streptococci... Agent: Wyeth Patent Law Group

20090022755 - Vaccines against chlamydial infection: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090022757 - Method for treating photoreceptor cell degeneration: The present invention provides a method for treating photoreceptor cell degeneration in a mammal. The method includes orally administering a composition comprising germination activated sporoderm-broken Ganoderma lucidum spore oil (“GLS oil”) or a mixture of GLS oil and docosahexaenoic acid (DHA), to a mammal suffering from photoreceptor cell degeneration.... Agent: Andrews Kurth LLP Intellectual Property Department

20090022758 - Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilization of glycemia: The invention relates to agents and preparations for the treatment or prevention of hyperglycemia, or for the stabilization of glycemia, based on the cell walls of yeast and preparation of a corresponding therapeutic composition.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090022759 - Adenovirus vector and method to manipulate the adenovirus genome: Adenoviruses (Ads) and vectors derived thereof have been used for somatic gene therapy, gene therapy of cancer and gene therapy of infectious diseases/vaccination. To date, almost all trials are based on the well established Ad5-based vectors. Pre-existing immunity and the limited targeting specificity of Ad5 makes it desirable to exploit... Agent: Knobbe Martens Olson & Bear LLP

20090022760 - Alphavirus replicon particles matched to protein antigens as immunological adjuvants: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and... Agent: Greenlee Winner And Sullivan P C

20090022761 - Enhancement of immune response to vaccine by interferon alpha: Exogenous cDNA capable of expressing interferon″ activity, exogenous interferon″ protein, inducers of endogenous interferon″ protein activity, inducers of endogenous interferon $ protein activity, inducers of endogenous interferon′ activity, or inducers of other immune-enhancing activity can be combined with a vaccine to enhance an immune response. Specifically disclosed are adjuvant and... Agent: Greenlee Winner And Sullivan P C

20090022762 - Polyvalent influenza virus-like particle (vlp) compositions: Polyvalent influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these polyvalent VLPs as well as methods of making and using these VLPs.... Agent: Robins & Pasternak

20090022763 - Animal product free media and processes for obtaining a botulinum toxin: Media and processes for the fermentation of Clostridium botulinum and obtaining a botulinum toxin for use in formulating botulinum toxin pharmaceutical compositions. The growth media can contain significantly reduced levels of meat or dairy by-products using non-animal based products to replace the animal-derived products. Preferably, the media used are substantially... Agent: Allergan, Inc.

20090022765 - Cosmetic pigment composition containing gold or silver nano-particles: The present invention relates to a cosmetic pigment composition exhibiting colors in the visible region, which comprises an effective amount of nanoparticles or a mixture of two or more nanoparticles selected from the group consisting of (a) gold nanoparticles exhibiting red color; (b) silver nanoparticles exhibiting yellow color; (c) gold-silver... Agent: Intellectual Property / Technology Law

20090022766 - Metal-enhanced fluorescence nanoparticles: The present invention relates to nanoparticles comprising a metallic core with a surface coating, wherein the coating comprises at least an excitable radiative molecule attached thereto or impregnated therein, and wherein the excitable molecule is positioned at a sufficient distance from metallic core to enhance emissions when excited. The nanoparticles... Agent: Moore & Van Allen Pllc

20090022764 - Organic compounds: e

20090022767 - Composition, device and method for transdermal delivery of insect repellent: A composition, device and method for the transdermal delivery of effective amounts of insect repellent provide a transdermal patch having a backing layer formed of a breathable, skin-like material such as urethane, a removable liner layer and a drug formulation and adhesive disposed between the backing layer and the liner... Agent: Duane Morris LLP - Chicago Ip Department

20090022768 - Continuous flow chamber device for separation, concentration, and/or purification of cells: The present invention relates to methods and apparatuses for neutralizing cancer cells. In particular, the invention relates to separating of cancer cell type from a mixture of different cell types based on the differential rolling property of cancer cell on a substrate coated with a first molecules that exhibits adhesive... Agent: Blank Rome LLP

20090022772 - Bioabsorbable elastomeric arterial support device and methods of use: The invention provides bioabsorbable elastomeric arterial support devices fabricated using elastomeric polymer networks and semi-interpenetrating networks in which a linear polymer is crosslinked by ester or alpha-amino-acid containing cross-linkers that polymerize upon exposure to active species. The invention devices are designed for implant into curved segments of artery and can... Agent: Dla Piper LLP (us)

20090022771 - Biomaterial: A process for the preparation of a composite biomaterial comprising an inorganic material and an organic material, the process comprising: (a) providing a first slurry composition comprising a liquid carrier, an inorganic material and an organic material; (b) providing a mould for the slurry; (c) depositing the slurry in the... Agent: Senniger Powers LLP

20090022770 - Chitosan compositions: This invention relates to an orthopaedic composition comprising porous chitosan particles suspended in a liquid medium wherein the liquid medium further comprises a biocompatible polymer. The invention also provides a process for preparing a solid or semi-solid orthopaedic material by drying the orthopaedic composition. The resulting solid or semi-solid orthopaedic... Agent: Mcdermott Will & Emery LLP

20090022776 - Composition and method for treatment and prevention of restenosis: Compositions and methods are disclosed which employ PARIS proteins that are useful for suppressing proliferation of smooth muscle cells. Preferred PARISs are soluble proteins that are secreted by vascular smooth muscle cells, and include PARIS-1 (neuronal pentraxin 1), PARIS-2 (SBP (MIC-1, GDF-15), PARIS-3 (BTG2) and PARIS-4 (soluble fractalkine). Methods of... Agent: Conley Rose, P.c. David A. Rose

20090022769 - Medical devices comprising polymeric drug delivery systems with drug solubility gradients: Disclosed are drug delivery systems comprising drugs admixed with polymers having drug solubility gradients and methods of making the polymers. Also disclosed are medical devices having coatings thereon comprising the drug solubility gradient-containing polymers and at least one drug.... Agent: Medtronic Vascular, Inc. Ip Legal Department

20090022774 - Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances for treatment of vascular disorder: s

20090022775 - Polymer backbone for producing artificial tissue: The invention relates to polymer scaffolds suitable for producing artificial tissues, in particular polysaccharide scaffolds, to processes for their preparation, to their use for producing artificial tissues, and to artificial tissues produced on the basis of such polymer scaffolds.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090022773 - Porous and biocompatible carrier material for treating bone and/or cartilage defects: A porous and biocompatible carrier material for treating bone and/or cartilage defects, including a collagen of animal origin that has an active substance complex.... Agent: Ip Group Of Dla Piper Us LLP

20090022777 - Methods for progenitor cell recruitment and isolation: The invention relates to the use of one or more growth factors in a drug delivery system, optionally with an external mesh housing, to recruit and optionally harvest progenitor cells. These cells include those that normally reside in the bone marrow.... Agent: Wolf Greenfield & Sacks, P.c.

20090022778 - External plaster containing flurbiprofen: In a plaster for external use for transdermal absorption in which an adhesive layer is laminated on a plastic backing, the adhesive layer contains a styrene-isoprene-styrene block copolymer (SIS), a tackifying resin and a softener which are essential ingredients, and further contains flurbiprofen blended as an active ingredient. The present... Agent: Ostrager Chong Flaherty & Broitman Pc

20090022780 - Hydrogel: The invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds.... Agent: Darby & Darby P.c.

20090022779 - Phenytoin formulations, and uses thereof in wound healing: A formulation of phenyloin suitable for topical application to a wound comprises a reservoir of phenyloin entrapped within a stabilising matrix, and an amount of dissolved phenyloin, wherein the dissolved phenyloin is in chemical equilibrium with the phenyloin entrapped within the stabilised matrix. The stabilised matrix may comprise a gel... Agent: Wolf Greenfield & Sacks, P.c.

20090022781 - Delivery means: A delivery means, for example a dressing, for delivering an antibacterial metal, for example silver, comprises the metal in combination with a hydrophilic polymer. The polymer may be cross-linked by a butylidene polymer to define a gel. In the examples, silver nitrate may be reduced to metallic silver, protected using... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20090022782 - Blood retainable device exhibiting selective degradability in tumor tissue: A phospholipid derivative useful for the preparation of liposomes for efficient uptake of an antitumor agent or a gene intracellularly by a target tumor cell, which comprises a residue of an alcohol compound and a residue of a phospholipid, and comprising a peptide between the residue of an alcohol compound... Agent: Greenblum & Bernstein, P.L.C

20090022783 - Sirna microbicides for preventing and treating diseases: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1... Agent: David S. Resnick

20090022784 - Systems, devices, and methods for iontophoretic delivery of compositions including liposome-encapsulated insulin: Systems, devices, and methods for delivering one or more active ingredients to intradermal tissues, deep regions of pores, and intradermal tissues in the vicinity of pores. In some embodiments, a composition is provided including a plurality of liposomes including a cationic lipid, and an amphiphilic glycerophospholipid having a saturated fatty... Agent: Seed Intellectual Property Law Group Pllc

20090022786 - Oral pharmaceutical dosage form and manufacturing method thereof: The present invention provides an coated oral pharmaceutical dosage form comprising a composition of a non-steroidal anti-inflammatory drug (NSAID) as multilayered spherical granule combined with a composition of prostaglandin, and a film coating. The present invention also provides a method for manufacturing the dosage form, which comprising the steps of... Agent: Howrey LLP-ca

20090022785 - Permeable capsules: The present invention relates to permeable capsules comprising at least one cell comprising a recombinant nucleic acid molecule with a heat inducible promoter operably linked to a nucleic acid encoding for a protein, a peptide or a functional nucleic acid molecule and at least one heat emitting agent capable to... Agent: Fulbright & Jaworski L.l.p.

20090022788 - Dietary supplement for healing or regressing symptoms of gastroesophageal reflux disease, gastritis and ulcers: The current invention presents a dietary supplement obtained from a mixture of melatonin, vitamins and aminoacids for healing or regressing symptoms of gastroesophageal reflux disease (such as heartburn, regurgitation, dysphagia, coughing, hoarseness, chest pain and odynophagia), gastritis and several types of ulcerations.... Agent: Cantor Colburn, LLP

20090022787 - Pharmaceutical composition comprising 11-deoxy- prostaglandin compound and method for stabilizing the compound: e

20090022789 - Enhanced formulations of lamotrigine: A once-a-day, extended-release formulation of lamotrigine, exhibiting a significantly similar release rate throughout the GI tract irrespective of the pH of the environment, is provided. The formulation comprises lamotrigine, an organic acid, a release enhancing polymer and a release controlling polymer. The use of the formulation for the treatment of... Agent: Foley And Lardner LLP Suite 500

20090022790 - Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same: The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing... Agent: Duane Morris LLP - Ny Patent Department

20090022793 - Mesalamine suppository: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of... Agent: Darby & Darby P.c.

20090022791 - Porous cellulose aggregate and molding composition thereof: A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to 2.625 cm3/g, containing I-type crystals and having an average particle size of over 30 to 250 μm, a specific surface area of... Agent: Staas & Halsey LLP

20090022792 - Vitamin d content uniformity in pharmaceutical dosage forms: New dosage forms of vitamin D and calcium carbonate having improved content uniformity are described. The improvements are realized through modifications to the formulation, the raw material specifications, and the process of manufacture.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090022796 - Novel substituted benzimidazole dosage forms and method of using same: The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor, including preparations of s-omeprazole, and at least one buffering agent. Also provided is a pharmaceutical composition comprising a parietal cell activator, an... Agent: Mayer Brown LLP

20090022795 - Stable pharmaceutical formulation of an acid labile compound and process for preparing the same: The disclosed invention provides oral pharmaceutical formulations of an acid labile benzimidazole derivative comprising (a) a core comprising an acid labile benzimidazole derivative, (b) a seal coating layer, and (c) an enteric coating layer, wherein the core of the composition is devoid of any disintegrant.... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090022794 - Topiramate tablet formulation: The invention provides pharmaceutical compositions comprising as active ingredient topiramate, which are suitable for manufacturing tablet formulations by direct compression. The compositions preferably comprise spray-dried granulated mannitol and provide tablets of desired friability and hardness.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20090022797 - Stabilized tolterodine tartrate formulations: A pharmaceutical composition contains tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used to make various types of immediate release and controlled release dosage forms.... Agent: Kramer & Amado, P.c.

20090022798 - Formulations of nonopioid and confined opioid analgesics: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably... Agent: Paul D. Yasger Abbott Laboratories

20090022800 - Coating for small bodies: Coated bodies and a process, apparatus and article of manufacture for coating bodies in a non-fluidized state, including tablets, by producing an upward spray of coating fluid by means of a two-fluid nozzle as defined herein and contacting said bodies with said spray of coating fluid in a non-fludized state;... Agent: Miles & Stockbridge Pc

20090022799 - Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use: This application for patent discloses β-Glucan containing compositions, dosage forms, delivery methods, and techniques for the purposes of preventing and treating mucositis through wound healing and tissue re-organization, as well as the treatment of immune disorders such as Alzheimer's disease, Multiple Sclerosis and Parkinson's disease. β-Glucan containing compositions, dosage forms... Agent: Cameron International Corporation

20090022802 - Cardiomyopathy therapeutic agent: The present invention provides a cardiomyopathy therapeutic agent that contains hepatocyte growth factor (HGF) and gelatin hydrogel, and gradually releases HGF, which is useful in treating cardiomyopathy.... Agent: Osha Liang L.l.p.

20090022801 - Compositions and methods for promoting the healing of tissue of multicellular organisms: Methods are provided for promoting the healing of tissue of a multicellular organism. The methods can include administering a therapeutically effective amount of a polysulfonated material in a liquid mixture to reduce one or both of inflammation and cancerous cell growth. The methods may alternatively or additionally include internally administering... Agent: Wells St. John P.s.

20090022804 - Chemoembolisation: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.... Agent: Sughrue Mion, Pllc

20090022803 - Oral formulations for delivery of catecholic butanes including ndga compounds: The present invention provides for compositions, kits and methods for treatment of diseases, where the compositions contain catecholic butanes, including NDGA compounds, such as NDGA derivatives, for example tetra-O-methyl NDGA. The present invention also provides for solubilizing agents and excipients that are suitable for administration of the present compounds into... Agent: Lott & Friedland, P.a.

20090022805 - Polypeptide microparticles having sustained release characteristics, methods and uses: The invention provides polypeptide microparticles having control release features, particular methods for the preparation of such microparticles, and drug delivery systems that include polypeptide microparticles.... Agent: Kagan Binder, Pllc

20090022806 - Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20090022807 - Drug formulations having inert sealed cores: A drug composition comprising a coated bead is used in the manufacture of immediate release and/or controlled release drug compositions. In a specific embodiment, the bead includes an inert core of a water-soluble or water-swellable material, which has been coated with a seal layer formed from a non-polymeric hydrophobic material.... Agent: Kramer & Amado, P.c.

20090022808 - Coated hyaluronic acid particles: The present invention generally relates to particles comprising hyaluronic acid, wherein the particles are coated or encapsulated with a coating. The coating preferably comprises a polymer, protein, polysaccharide, or combination thereof that decreases the rate of degradation of the hyaluronic acid once the particles are placed in an aqueous environment,... Agent: Allergan, Inc.

20090022809 - Stable taste masked formulations of cephalosporins: A stable taste masked, pharmaceutical composition comprising a plurality of coated, non-disintegrating discrete dosage units, said units comprising of a core comprising one or more cephalosporins such as cefuroxime axetil and cefpodoxime proxetil and one or more coating layers. Cefuroxime axetil is in α-crystalline and amorphous forms, where at least... Agent: Merchant & Gould Pc

20090022810 - Emunotm bar, by nutra-shieldtm: The invention, Emuno Bar by NutraShield, is a nutraceutical food bar composed of all natural ingredients that are rich in antioxidants and fortified with the patented Formulation 100 (U.S. Pat. No. 6,667,063, B2). The invention is a dedicated delivery system for U.S. Pat. No. 6,667,063, B2 and designed to boost... Agent: Nhance, Llc

20090022811 - Mineralized guided bone regeneration membranes and methods of making the same: The present invention provides a method for mineralizing commercially available guided bone regeneration membranes. The method comprises the steps of (a) providing a commercially available guided bone regeneration membrane, (b) applying a mineralizing solution, and (c) microwaving the membrane. The method may further comprise (d) rinsing the membrane in a... Agent: Klauber & Jackson

20090022812 - Liquid detergent composition: A liquid detergent composition containing (a) hydrogen peroxide or a compound for forming hydrogen peroxide in water, (b) a compound selected from boric acid, borax, a boric acid salt in an amount of from 0.05 to 1% by mass as a boron atom, (c) a compound having one or more... Agent: Birch Stewart Kolasch & Birch

20090022813 - Composition for improving membrane composition and functioning of cells: c) a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system,... Agent: Banner & Witcoff, Ltd.

20090022814 - Cancer treatment method: Invented is a method of treating cancer in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a TPO cell cycle activator and a chemotherapeutic agent to such mammal.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090022815 - Halogenated composition, method for preparing same and uses thereof: A method of stimulating tissue healing in humans or animals includes administering to a human or animal a pharmaceutically effective amount of a pharmaceutical composition which includes (i) at least one halogenated compound, and (ii) at least one N-halogenated derivative of at least one compound selected from zwitterionic compounds and/or... Agent: Ip Group Of Dla Piper Us LLP

20090022816 - Storable, consumable pre-nascent iodine: This discovery is storable, pre-nascent iodine that activates and: produces nascent iodine over a two-to-three-hour period within the body when diluted in water and consumed. The iodine is in a low concentration in a tincture of grain alcohol. A quantity of tincture is submerged in a glass container in an... Agent: John S. Brookshire

20090022817 - Methods of modifying myocardial infarction expansion: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from... Agent: Blakely Sokoloff Taylor & Zafman LLP

20090022818 - High-foaming, viscous cleanser composition with a skin care agent: A liquid cleansing composition comprising a cleansing surfactant, an adsorbed skin-care agent, adsorptive polymeric particles having an adsorption capacity of at least 2 g of skin care agent per gm of dry polymeric particles, a polymeric thickening agent having a molecular weight in the range of 500,000-10,000,000 Dalton, a water-soluble... Agent: Marshall, Gerstein & Borun LLP

20090022819 - Bacterial extracts cultured in thermal waters for the treatment of dry skin: Dryness of keratin materials, in particular dryness of the skin, and especially disorders associated with dry and/or hyposeborrheic skin are treated by administering to individuals afflicted therewith, thus effective amounts of at least one extract of a non-photosynthetic and non-fruiting filamentous bacterium cultured in a medium which includes at least... Agent: Buchanan, Ingersoll & Rooney Pc

20090022820 - Compositions for sterilizing spores of spore -forming microorganisms comprising the extracts of torilidis fructus: Disclosed are a composition comprising an organic acid extract of Torilidis Fructus, which has a sterilization effect on spores of spore-forming microorganisms including fungi and bacteria, and a method of sterilizing spores and vegetative cells using the composition.... Agent: Hunton & Williams LLP Intellectual Property Department

20090022821 - Compositions from wax myrtle for the treatment of cancer, cardiovascular and inflammatory diseases: The present invention relates to the use of certain novel compositions from wax myrtle (Morella cerifera) which are inhibitors of nuclear factor kappa B (NF-kB), oxidative stress (activation of Nerf2) and the activity of the endothelin receptor. In particular, it relates to useful enriched fractions and pharmaceutical compositions from wax... Agent: Passe' Intellectual Property, Llc

20090022822 - Extract of ogalpi, erectile dysfunction fanning healthy food and erectile dysfunction treating agent containing the same: The present invention relates to an alcohol extract of ogalpi, erectile dysfunction improving health food and a treating agent containing the same, more precisely, an alcohol extract of ogalpi having an effect of improving erectile dysfunction, erectile dysfunction improving health food and an erectile dysfunction treating agent containing the same.... Agent: Lucas & Mercanti, LLP

20090022823 - Methods for administering active agents to cyp3a4 sensitive patients: e

20090022824 - Pesticidal formulations: The present invention discloses formulations that are effective for controlling pests. More particularly, the present invention discloses the use of at least one phenol and at least one isothiocyanate in methods and formulations for increasing the mortality or decreasing the growth of pests or for repelling pests.... Agent: Stout, Uxa, Buyan & Mullins LLP

20090022825 - Method for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease: The invention provides methods of diagnosing mild cognitive impairment (MCI) in a patient and methods of predicting cognitive decline in patients who have MCI. The invention also provides methods for predicting if a patient who has MCI will develop Alzheimer's Disease (AD).... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090022826 - Multi-step method of pain and/or inflammation treatment: e

20090022827 - Agent and method for eliminating malignance of cancer cells without harmful effect to normal cells: A pharmaceutical composition including an extract from Geum japonicum and a method of treating cancer using the extract. In vitro and in vivo experimental data demonstrated that the extract can induce selectively apoptosis of cancer cells and kill the cancer cells without affect normal cells.... Agent: Wang & Ho

20090022828 - Methods and compositions for inhibiting angiotensin converting and chymase enzymes: The present invention relates to medicinal products, as well as to health and wellness food products, and particularly to a medicinal product or a health and wellness food product for inhibiting Angiotensin Converting Enzyme and Chymase enzyme pathways.... Agent: Kirton & Mcconkie A Professional Corp.

20090022829 - Lubricant additive to enhance staying power of male erectile function: Present invention provides an efficient way of enhancing male erectile function, without the fear of unknown long-term ill-effect as a result of taking medication orally. The additive of present invention can be used by condom manufacturers directly as part of the lubricant coating. The composition of the additive pursuant to... Agent: Law Offices Of J.f. Lee

20090022830 - Morinda citrifolia leaf extract compositions and methods of obtaining the same: Methods and compositions relating to leaf extracts obtained from removing liquids from relatively dry Morinda citrifolia leaves. Methods and compositions relating to a leaf serum created from combining leaf extract and fruit juice from the Morinda citrifolia L. plant. Methods and compositions relating to leaf extract compositions comprising one or... Agent: Kirton And Mcconkie

20090022832 - Method of treating inflammation disorders using extracts of passion fruit: An extract of the skin or peel of passion fruit is prepared. The extract has the effect of ameliorating the symptoms of inflammation disorders, including asthma and osteoarthritis, in mammals, including humans, when administered in an effective amount.... Agent: Davis, Brown, Koehn, Shors & Roberts, P.c. The Financial Center

20090022831 - Use of fructus schisandrae and extracts thereof in preventing and decreasing toxic and side effects of antineoplastic drugs: Use of Fructus schisandrae in preparation of medicaments for preventing and reducing toxicity and side effects of antineoplastic agents. The toxicity and side effects of antineoplastic agents are cardiovascular toxicity, hepatotoxicity, nephrotoxicity, suppression of bone marrow, immunosuppression, or alopecia etc induced by antineoplastic agents. Fructus schisandrae and extracts thereof, especially... Agent: Osha Liang L.l.p.

20090016956 - Labeled macrophages and methods of use thereof: Methods of making and using labeled macrophages are described.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090016957 - Polypeptides: This invention relates to polypeptides which bind to EGFR family receptors and to applications of those polypeptides in medicine, veterinary medicine, diagnosis diagnostics and imaging.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090016958 - Nucleoside based proliferation imaging markers: Disclosed herein are novel radiolabeled nucleosides and methods for detecting cellular proliferation in a mammal, the method comprising administrating an effective amount of a radiolabeled nucleoside; the method comprising: a) administering to the mammal a diagnostically effective amount of the nucleoside to the mammal; b) allowing the nucleoside to distribute... Agent: Siemens Corporation Intellectual Property Department

20090016962 - Compositions and methods for the treatment of cancer: Provided are nanostructures comprising a charged outer surface and an inner core comprising a cancer therapeutic agent or imaging agent, wherein the charged outer surface is selectively removable. Further provided are methods of treating subjects having cell proliferative disorders, e.g., cancer, and kits comprising the above nanostructures.... Agent: Ewards Angell Palmer & Dodge LLP

20090016959 - Delivery of antibodies to the central nervous system: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptide derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides. The present invention also relates to the use of these polypeptide for transporting an antibody... Agent: Clark & Elbing LLP

20090016961 - Stem cell fusion model of carcinogenesis: Methods for modeling cancer cell migration, screening drugs for effects on tumor cell migration, and detecting the potential for tumor cell migration relating to the fusion of a bone marrow derived stem cell with a genetically altered cell (FIG. 1). Antibodies against ubiquitin are shown to inhibit tumor cell migration.... Agent: Quarles & Brady LLP

20090016960 - System and method for using glass microspheres containing a positron-emitting isotope to image blood flow and distribute a radiomedical treatment species: A method for imaging the blood flow in a patient receiving radiomedical treatment, including forming a first and a second plurality of generally spherical biologically stable members, with each respective member of the first plurality includes a first non-radioactive isotope distributed substantially uniformly therein that, upon being subjected to an... Agent: Brannon & Associates PC

20090016963 - Genes involved in neurodegenerative conditions: The invention discloses suitable gene and polypeptide targets for the development of new therapeutics to treat, prevent or ameliorate neurodegenerative conditions. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor, as well as to a method to identify compounds with therapeutic usefulness... Agent: Novartis Institutes For Biomedical Research, Inc.

20090016964 - Hyperpolarization methods, systems and compositions: The invention provides various methods and systems for providing hyperpolarized materials as well as the hyperpolarized materials so provided. In addition, a method of providing hyperpolarized materials, such as agents, to end users from a remote location is also provided.... Agent: Edwards Angell Palmer & Dodge LLP

20090016965 - Internal image antibodies for optical imaging and therapy: Methods using internal image antibodies for photodiagnosis and/or phototherapy. The internal image antibodies are conjugated with a photoactive molecule such as a dye or photosensitizer, to target specific regions, such as biological receptors. The photoactive molecules are then activated for diagnosis or therapy. Advantageously, the internal image antibody is specific... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090016966 - Air-freshening device: A sprayable air-freshening composition comprising active particles for removing malodours, said active particles comprising at least one metal supported on a solid particulate support, wherein the at least one metal is selected from Groups 3 to 12 and the Lanthanide series of the periodic table.... Agent: Norris, Mclaughlin & Marcus

20090016967 - Compositions and methods for the treatment of respiratory disorders: Methods and compositions are provided for the treatment of acute lung injury and pulmonary fibrosis by administering inhibitors of IGF-1R signaling activity.... Agent: Nixon Peabody LLP - Patent Group

20090016971 - Aqueous fluid photoprotective compositions comprising tertiary-amide-terminated polyamide polymers: (b) at least one tertiary-amide-terminated polyamide (ATPA) polymer, formulated into a topically applicable, cosmetically acceptable aqueous support therefor; the subject anti-sun/sunscreen compositions are especially provided as sprays, notably for the purpose of increasing the sun protection factor (SPF) and/or of reducing or even eliminating the fluffing effect thereof.... Agent: Buchanan, Ingersoll & Rooney PC

20090016968 - Composition and method for prevention and treatment of type i diabetes: A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a fusion protein selected from the group consisting of GLP-1/IgG or variant or fragment thereof and an Ex4/IgG or variant or fragment thereof and an autoimmune suppressor for silencing an autoimmune response against... Agent: Bereskin And Parr

20090016970 - Continuous spray scalp therapy and dispensing systems for same: A spray delivery system in combination with a scalp medication is provided which includes a portable container having a gas imperious container wall, a pressure source disposed within the container, and a selectively operable valve assembly affixed to the container. The scalp medication is in liquid form and is disposed... Agent: Duane Morris LLP - PhiladelphiaIPDepartment

20090016969 - Pharmaceutical composition for topical application of poorly soluble compounds: The present invention provides a formulation which contains a poorly water soluble pharmaceutically active compound at a concentration of 50 mg per 100 g formulation or above. The solubility is achieved by a mixture of solvents as described herein. Moreover the formulation as described herein may be used as a... Agent: Millen, White, Zelano & Branigan, P.C.

20090016972 - Oral cavity care curative and prophylactic composition: The invention relates to stomatology and perfume industry in particular to therapeutic formulation for oral cavity care. The invention refers to oral hygiene means and can be applied for preparation of medical and prophylactic tooth-pastes, gels, liquids for oral care as well as other compositions like chewing gums, jellies, etc.... Agent: Mikhail Utkin

20090016973 - Composition and method for the prevention of oral disease: The discovery of use of stabilized chlorine dioxide at a concentration range of about 0.5% to about 0.9% (w/v) as a composition for the prevention of oral disease through bactericidal and bacteriostatic properties within a microbial environment is disclosed. The bactericidal properties of stabilized chlorine dioxide are further expanded to... Agent: C. Robert Von Hellens Cahill, Von Hellens & Glazer P.L.C

20090016974 - Application of dehydroascorbic acid or derivatives/isomers thereof for artificially coloring the skin: e

20090016975 - Fade-resistant coloring composition containing an acid dye and a cationic conditioning agent for a keratin-containing substrate: The invention relates to a coloring composition for depositing colors to a keratin-containing substrate, said composition comprising: (a) one or more acid dyes; and (b) one or more cationic quaternary ammonium compounds, said quaternary ammonium compound being present in an amount which provides conditioning benefits but which is insufficient to... Agent: Philip S. Johnson Johnson & Johnson

20090016978 - Antiperspirant compositions: An antiperspirant composition comprising a carrier substance and a water-soluble or water-dispersible thiolated polymer.... Agent: Unilever Patent Group

20090016976 - Citral and citronellal derivatives: Improved citral and citronellal derivatives, and fragrance and flavorings including the derivatives, that have a longer useful shelf life than citral and citronellal and/or fragrances and flavoring including citral and citronellal, are disclosed. In particular, the derivatives maintain the fragrance characteristics of citral and citronellal, while lowering the allergic properties,... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090016977 - Deodorant compositions and methods for making same: Deodorant compositions comprising an emulsion including a continuous polar solvent phase and a discontinuous oil phase are provided. The oil phase comprises an oil ingredient and a fragrance material. Methods for making such deodorant compositions are also provided.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090016979 - Aluminum and aluminum-zirconium compositions of enhanced efficacy containing reduced buffer and/or reduced zirconium: According to present invention, the interactions between amino acid such as glycine and aluminum species in BAC and aluminum-zirconium solutions greatly reduce the effective amount of aluminum monomer species, which attributed to the reduced efficacy and stability of the corresponding solutions. The aluminum and aluminum-zirconium antiperspirant salt compositions of enhanced... Agent: Arthur J. Plantamura, Esq. General Chemical Performance Products LLC.

20090016980 - Method of pre-treating hair prior to coloring: The present invention relates to the field of hair coloring. More specifically, the present invention relates to a method of pre-treating hair prior to the application of a hair colorant. The method comprises the steps of applying a pre-treatment composition, comprising a monoalkyl quat, a cellulose thickener, and a quaternary... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090016981 - Therapeutic compounds: e

20090016983 - Hair conditioning composition comprising polysaccharide polymer and aminosilicone: Disclosed is a hair conditioning composition comprising: a cationic or nonionic polysaccharide polymer; an aminosilicone; a cationic surfactant; and a high melting point fatty compound. The composition of the present invention can provide hair volume-up benefit and ease-to-rinse feel, while providing improved conditioning benefits. The present invention also relates to... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090016982 - Cosmetic composition comprising an alkyl phosphate and a fatty alkyl ether of polyethylene glycol, processes therefor and uses thereof: Composition containing an aqueous phase and an emulsifying system, where the emulsifying system contains at least one C10-C30 alkyl phosphate and at least one C8-C24 fatty alkyl ether of polyethylene glycol, the ether comprising from 1 to 19 ethylene glycol units and having an HLB<8 at 25° C. Process for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090016984 - Drug for hyperphospheremia and its preparative method: This invention reports a drug for hyperphospheremia and its preparative method. The preparation includes active constituents, lanthanum polystyrene sulfonate, and excipients. The preparative method in the invention can be summarized as follows: Polystyrene sulfonic acid is obtained by treating polystyrene sulfosalt with hydrochloric acid, soaked or eluted with water soluble... Agent: GlobalIPServices

20090016985 - Polymeric drug delivery system containing a multi-substituted aromatic moiety: The present invention provides polymeric delivery systems including a multi-substituted aromatic moiety. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20090016986 - Cosmetic composition, a pharmaceutical composition and a process for preparing said compositions: The present invention relates to a cosmetic composition and to a pharmaceutical composition that comprise several agents of topical use and optionally sunscreens. This composition comprises an aqueous medium containing at least one highly polar substance without, however, having the inconveniences noticed in similar compositions of the prior art. These... Agent: Alston & Bird LLP

20090016988 - Modified pore-forming protein toxins and use thereof: The present invention provides modified pore-forming protein toxins (MPPTs), capable of being used to kill cancer cells. The MPPTs according to the present invention comprise a modification of the naturally occurring activation sequence comprising one or more general cleavage sites, each of which is cleavable by general activating agent, or... Agent: Klarquist Sparkman, LLP

20090016987 - Pharmaceutical composition and therapeutic method: The object of the present invention is, based on the finding of a novel effect of IL-18, to provide pharmaceutical compositions containing IL-18 and therapeutic methods, for preventing, improving, or treating inflammatory diseases such as systemic inflammatory response syndrome (SIRS). Inflammatory diseases, such as SIRS, can be prevented, improved, or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090016989 - Antibodies to human somatostatin receptor and methods of use: The invention provides isolated antibodies, including monoclonal and polyclonal antibodies, and the antigen-binding portions thereof, that specifically bind to the extracellular loop 2 (ecl2) of human somatostatin receptor (hSSTR) subtype 1, 2, 3, 4, or 5. The antibodies and antigen-binding portions of the present invention can possess hSSTR agonist-like and/or... Agent: Darby & Darby P.C.

20090016990 - Antimicrobial compositions: The present invention relates in part to a composition comprising a compound of Formula I or Formula II and at least one other antimicrobial agent. The invention also relates in part to a pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier or excipient. The invention... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090016991 - Rxr antagonist treatment against multiple sclerosis: Retinoids with retinoid antagonistic activities, especially Retinoid X Receptor antagonists called RXR antagonists, pharmaceutically acceptable salts and pharmaceutically acceptable esters and amides thereof, have been found to be effective in the treatment of multiple sclerosis, especially by systemic such as oral administration of RXR antagonists.... Agent: Volpe And Koenig, P.C.

20090016992 - Pcv2 immunogenic compositions and methods of producing such compositions: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090016993 - Medicinal formulation for the treatment for hepatitis c: A composition for the treatment of Hepatitis C infection is disclosed. The composition comprises a homogenized mixture of at least one serially diluted and potentized substance, as herein described, selected from: Hepatitis C Genotype 1, Hepatitis C Genotype 2, Hepatitis C Genotype 3, Hepatitis C Genotype 4, Hepatitis C Genotype... Agent: Lucas & Mercanti, LLP

20090016997 - Autologous/allogeneic human dna grafting, anti-and reverse aging stem cell, and bone marrow compositions/methods: Anti-aging compositions and methods for delivering (engrafting) younger compatible human DNA to tissues, through the systematic periodic introduction of younger primordial whole (nucleated) stem cells and bone marrow into a recipient, resulting in re-establishment of an earlier relative biological clock set-point, with respect to the number of cell generations-divisions are... Agent: Hogan & Hartson LLP

20090016999 - Embryonic cell compositions for wound treatment: Compositions including formulations comprising stem cells, such as umbilical cord blood stem cells, or embryonic germ cell derivatives, or embryonic stem cells, are provided for enhancement of wound healing. Methods for using the compositions and formulations for enhancing would healing are also provided. Wounds to both soft and bony tissues... Agent: Pearl Cohen Zedek Latzer, LLP

20090016995 - Method of treating cognitive decline and synaptic loss related to alzheimer's disease: A method treating a subject with Alzheimer's disease wherein Aβ-reactive immune cells, splenocytes and lymphocytes, are generated in vitro or in vivo, re-stimulated in vitro, and then adoptively transferred into the cognitively-impaired subject. The population of immune cells can be derived from a donor with a natural or adaptive immune... Agent: Smith Hopen, Pa

20090016998 - Novel method of prenatal administration of mammalian umbilical cord stem cells for the intrauterine treatment of mammalian lysosomal storage diseases: A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood in a form suitable for intravenous administration; a b. administering the human umbilical cord... Agent: Smith Hopen, Pa

20090016994 - Preparation of fibroblast-populated connective tissue substitute: Disclosed is a method for in vitro growing of connective tissue substitute, said connective tissue substitute being populated with fibroblasts, a connective tissue substitute obtainable by such a method, as well as a method for closing of a wound, wherein such connective tissue substitute is applied onto a wound.... Agent: Paul, Hastings, Janofsky & Walker LLP

20090017000 - Preparation of inactivated artificial antigen presenting cells and their use in cell therapies: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a... Agent: Philip S. Johnson Johnson & Johnson

20090017001 - Ambient stored blood plasma expanders: A liquid plasma expander or resuscitation fluid composition for use in a subject in need thereof, comprising, consisting of; or consisting essentially of: (a) a keratin derivative (preferably alpha keratose, gamma keratose, or combinations thereof, and with basic alpha keratose preferred over acidic alpha keratose); and (b) an electrolyte solution,... Agent: Myers Bigel Sibley & Sajovec

20090017002 - Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes: The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the... Agent: Foley And Lardner LLP Suite 500

20090017003 - Thiosulfonate anti-inflammatory agents: The present invention relates to novel thiosulfonates derivatives. The present invention also provides methods for preventing, treating and/or reducing inflammation-associated diseases in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous or cutaneous systems as well as infective and tumoral diseases employing said compounds.... Agent: Schneck & Schneck

20090017004 - Polymeric drug delivery systems containing an aromatic allylic acid: The present invention provides polymeric delivery systems including an aromatic allyllic acyl group. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20090017005 - Delivery of therapeutic compounds to the brain and other tissues: The present invention relates to the intrathecal (IT) administration of recombinant enzyme to treat lysosomal storage disorders. In an exemplary embodiment, intrathecal administration of human α-L-iduronidase (rhIDU) injections in MPS I affected animals resulted in significant enzyme uptake, significant rh-iduronidase activity in brain and meninges and a decrease of glycosaminoglycan... Agent: Marshall, Gerstein & Borun LLP

20090017006 - Use of a compound for enhancing the expression of membrane proteins on the cell surface: The present invention is directed to the use of Bortezomib and/or a pharmaceutically acceptable salt or ester thereof for the manufacture of a medicament for enhancing the expression of membrane proteins on the cell surface. Especially, the invention is directed to the use of Bortezomib for the manufacture of a... Agent: Fitzpatrick Cella Harper & Scinto

20090017007 - Liquid factor vii composition: Storage-stable aqueous pharmaceutical compositions comprising a Factor VII or Factor Vila polypeptide, a buffering agent, and zinc ions (Zn2+) as a stabilizer.... Agent: Bayer Healthcare LLC

20090016996 - Hair mesenchymal cells: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or... Agent: Dardi & Associates, PLLC

20090017008 - Compositions and methods for altering bone density and bone patterning: By exploiting cross-species sequence comparisons with in vitro and in vivo enhancer assays we were able to identify enhancer elements that drives human SOST expression in the adult mouse skeleton, and discovered a novel function for sclerostin during limb development. The enhancer elements and reagents described in the present invention... Agent: Lawrence Berkeley National Laboratory

20090017014 - Compositions and methods for the treatment of immune related diseases: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090017009 - Method for the diagnosis and prognosis of malignant diseases: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.... Agent: Evan Law Group LLC

20090017012 - Methods of diagnosing and treating cancer: The invention relates to methods of determining an appropriate cancer therapy for a subject based on intratumoral expression levels of Ribonucleotide Reductase M1 (RRM1) and thymidylate synthase (TS) gene expression, as well as to methods of predicting clinical outcome (prognosis) based on cytoplasmic levels of TS protein. Compositions and kits... Agent: Fish & Richardson PC

20090017011 - Modulation of vegf-c/vegfr-3 interactions in the treatment of rheumatoid arthritis: The present invention relates to methods for treating an individual exhibiting symptoms of chronic arthridites, as identified by an elevated level of VEGF-C expression at synovial sites, and provides materials and methods for the modulation of VEGF-C/VEGFR-3 ligand-receptor interactions as a treatment for chronic arthridites.... Agent: Marshall, Gerstein & Borun LLP

20090017013 - Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung: Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained... Agent: Bose Mckinney & Evans LLP

20090017010 - Novel artemis/dna-dependent protein kinase complex and methods of use thereof: In the present invention, it is disclosed that Artemis forms a complex with the 469 kDa DNA-dependent protein kinase (DNA-PKcs) in vitro and in vivo in the absence of DNA. The purified Artemis protein alone possesses single-strand specific 5′ to 3′ exonuclease activity. Upon complex formation, DNA-PKcs phosphorylates Artemis, and... Agent: Hogan & Hartson L.L.P.

20090017015 - Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders: The invention relates to the use of a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof for the prevention, delay of progression or the treatment of neurodegenerative disorders, cognitive disorders and for improving memory (both short term and long term) and learning ability.... Agent: Novartis Corporate Intellectual Property

20090017016 - Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy: The present invention relates generally to a method of treatment and/or prevention of hypersensitivity including anaphylaxis in patients receiving replacement therapy molecules that elicit an IgE-mediated response by administering an anti-IgE antibody or a binding fragment thereof. Anti-IgE antibodies inhibit IgE-mediated allergic reactions in the mammals and can also lower... Agent: Nikolaos C. George Jones Day

20090017017 - Anti-rhesus d recombinant polyclonal antibody and methods of manufacture: The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090017025 - Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic: The present invention provides a combination comprising a compound A of formula (I) as set forth in the specification or a pharmaceutically acceptable salt thereof, and an antibody inhibiting a growth factor or its receptor and/or an antimitotic agent or a derivative or prodrug thereof, useful in the treatment of... Agent: Scully, Scott, Murphy & Presser, P.C.

20090017023 - Fcgammariib specific antibodies and methods of use thereof: The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to... Agent: Edell, Shapiro & Finnan, LLC

20090017021 - Methods and compositions for inducing innate immune responses: The invention relates to TLR ligand formulations that comprise immune stimulating complexes and their use in inducing innate immunity.... Agent: Wolf Greenfield & Sacks, P.C.

20090017019 - Methods and compositions for modulating bmp-10 activity: Methods and compositions for modulating cardiac, renal and vascular cell function and homeostasis using agonists and antagonists of BMP-10 are disclosed. In particular, methods for treating, preventing and/or diagnosing BMP-10-associated vascular, renal, fibrotic and cardiac conditions and/or disorders are disclosed. Screening methods for evaluating BMP-10 modulators, e.g., agonists and antagonists,... Agent: Lowrie, Lando & Anastasi, LLP W2023

20090017024 - Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders: Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject.... Agent: Wilson Sonsini Goodrich & Rosati

20090017020 - Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090017022 - Sulfatases and methods of use thereof: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of... Agent: Bozicevic, Field & Francis LLP

20090017018 - Uses of mammalian cytokine: related reagents: Provided are methods of modulating dendritic cell activity using agonists or antagonists of a mammalian cytokine. Also provided are methods of treating immune disorders.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090017028 - Antibodies against monocyte chemotactic proteins: The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.... Agent: Biogen Idec / Finnegan Henderson, LLP

20090017026 - Fcgammariib specific antibodies and methods of use thereof: The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to... Agent: Edell, Shapiro & Finnan, LLC

20090017027 - Fcgammariib specific antibodies and methods of use thereof: The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to... Agent: Edell, Shapiro & Finnan, LLC

20090017029 - Methods and compositions for treating ocular disorders: The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis... Agent: Wolf Greenfield & Sacks, P.C.

20090017030 - Endothelial cell expression patterns: To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified.... Agent: Banner & Witcoff, Ltd.

20090017034 - Antibodies that inhibit tslp activity: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.... Agent: Immunex Corporation Law Department

20090017035 - Human antibodies to human delta like ligand 4: An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds hDll4 with an affinity of 300 pM or better, as measured by surface plasmon... Agent: Regeneron Pharmaceuticals, Inc

20090017032 - Mammalian cx3c chemokine antibodies: Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090017033 - Methods for interfering with rankl signaling: Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL.... Agent: Immunex Corporation Law Department

20090017031 - Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury: A method for preventing or treating tissue damage associated with ischemia-reperfusion injury and thoraco-abdominal aortic aneurysm (TAAA) repair by administering a tissue damage preventing or treating amount of a complement inhibitor to a patient likely to suffer from or suffering from tissue damage associated with ischemia-reperfusion injury or TAAA repair.... Agent: Nikolaos C. George Jones Day

20090017036 - Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders: The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists and endothelin-antagonists, processes for preparing the compositions and the use thereof as medicament in the... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090017037 - Human timp-1 antibodies: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.... Agent: Bayer Healthcare LLC

20090017038 - Sigma-2 receptor, method of screening of specific ligands and use of the same in diagnostic or therapeutic methods: The present invention relates to the identification, isolation and characterization of the proteins forming the sigma-2 receptor. The invention further relates to the utilization of said proteins for preparing a screening for the sigma-2 receptor, as well as assay of specific candidate ligands to the use of the ligands for... Agent: Beusse Wolter Sanks Mora & Maire

20090017040 - Monoclonal antibody: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The... Agent: Foley And Lardner LLP Suite 500

20090017041 - Monoclonal antibody: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The... Agent: Foley And Lardner LLP Suite 500

20090017039 - Sp35 antibodies and uses thereof: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090017043 - Connective tissues growth factor antibodies: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those... Agent: Fibrogen, Inc. Intellectual Property Department

20090017042 - Process for the determination of the primary structure of the messenger rna coding for the human recombinant endooligopeptidase a (heopa) [af217798]: This invention refers to the recombinant human endooligopeptidase (hEOPA), polynucleotide which codes for the hEOPA, polynucleotide which allow the expression of the EOPA in prokaryotes and eukaryotes, including the human beings; use of the synthetic substrates for the determination of the proteolytic activity of the hEOPA, or of its chaperon... Agent: Birch Stewart Kolasch & Birch

20090017044 - Antibodies to the human prolactin receptor: This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and... Agent: Fish & Richardson PC

20090017045 - Polynucleotides encoding growth differentiation factor-8: A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-8 (GDF-8) chromosomally integrated into the germ cells of the animal is disclosed. Also disclosed are methods... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20090017046 - Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof: Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that... Agent: Ropes & Gray LLP

20090017049 - Betagbp, compositions comprising betagbp, and related methods and uses thereof: The invention relates to β-galactoside binding protein (βGBP) and compositions, including pharmaceutical compositions, comprising βGBP for use in therapy and related applications. In particular, the invention relates to use of βGBP and the manufacture of medicaments for the treatment or prevention of conditions in which disease associated cell division occurs,... Agent: Klauber & Jackson

20090017050 - Egfr antigen-binding molecules and uses thereof: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the... Agent: Klarquist Sparkman, LLP

20090017048 - Novel brachyspira hyodysenteriae vaccine: The present invention relates to nucleic acid sequences encoding a 61 kD and a 20 kD Brachyspira hyodysenteriae lipoprotein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such lipoproteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such... Agent: Intervet/schering-plough Animal Health Patent Department

20090017047 - Preparation for the prevention and treatment of stress conditions as well as functional and organic disorders of the nervous system and metabolic disorders: Disclosed is a preparation for preventing and treating stress conditions as well as functional and organic disorders of the nervous system and metabolic disorders, to be used by people suffering from actinic dermatitis, against sunburn, as a regenerative agent for damaged cells/cell systems, and for the well-being of humans and... Agent: Duane A Stewart Iii Buchanan Ingersoll & Rooney

20090017051 - Allergy vaccines and their preparation: The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are identical to at least three amino acids which appear... Agent: Dobe Law Group, LLC

20090017052 - Methods of determining lethality of pathogens and malignancies involving replikin peak genes: The present invention provides methods of identifying lethal, virulent and rapidly replicating viruses, organisms, and malignancies comprising comparing Replikin concentrations among different viruses, organisms, or malignancies. The present invention further provides isolated Replikin Peak Genes associated with increased lethality, virulence and rapid replication, for diagnostic, therapeutic and predictive purposes.... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20090017053 - Composition and method for preventing or treating a virus infection: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections.... Agent: Licata & Tyrrell P.C.

20090017054 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Mr. Reza Yacoob Aventis Pasteur Limited

20090017055 - Plasmodium liver stage antigens: The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090017056 - Skin immunization using lt-sta fusion proteins: This invention includes fusion proteins comprising a bacterial ADP-ribosylating exotoxin (bARE), or a variant or portion thereof, fused to a STa exotoxin, or a portion or variant thereof. Optionally, the exotoxins are fused via a peptide linker. The invention also includes compositions formulated for transcutaneous immunizations and/or induction of an... Agent: Morgan Lewis & Bockius LLP

20090017057 - Stimulation of an immune response by cationic lipids: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.... Agent: Wood, Herron & Evans, LLP

20090017058 - Viscosupplementation with algal polysaccharides in the treatment of arthritis: A joint-lubricating composition for treating degenerative joint disorders is provided, comprising algal polysaccharides in an aqueous solution, wherein the polysaccharides are stable and non-immunogenic. Further provided is a method for treating a joint disorder by injecting into the joint a viscous aqueous solution of a polysaccharide, wherein disorder is, for... Agent: Merchant & Gould PC

20090017060 - Cleavable vaccine compositions and uses thereof and methods of making and using the same: The invention relates to methods for making vaccines using linkages that are cleavable under lysosomal processing conditions, and vaccine compositions obtained therefrom. In some embodiments, the vaccines comprise a tumor antigen, an immunogenic carrier and a linker covalently linking the tumor antigen and the immunogenic carrier by a thio ether... Agent: Suzannah K. Sundby (uc) Smith, Gambrell & Russell, LLP

20090017059 - Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090017061 - Mycobacteria with mannose cap-deficient lipoarabinomannan: The present invention relates to mycobacterial lipoarabinomannan cap-specific mannosyl transferases and nucleic acid encoding such transferases. The invention further relates to Mycobacteria in which the lipoarabinomannan cap-specific mannosyl transferases have been inactivated and that therefore express mannose cap-deficient lipoarabinomannan. Such Mycobacteria with mannose cap-deficient lipoarabinomannan may be used as more... Agent: Morgan Lewis & Bockius LLP

20090017063 - Edible vaccine: The object of the present invention is to provide an edible vaccine which is effective for human papilloma virus (HPV) type 16 and available in large amounts inexpensively. An edible human papilloma virus vaccine obtained by culturing a transformant of an avirulent fission yeast host, wherein the transformant carries a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090017062 - Methods and compounds to alter virus infection: The invention provides a method to identify an agent that alters parvovirus transduction of mammalian cells. Also provided is a method to enhance transgene expression in a mammalian cell, as well as a method to identify an agent that alters NADPH oxidase activity in parvovirus transduced mammalian cells.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090017064 - Methods and compositions for immunizing pigs against porcine circovirus: The present invention relates to compositions and methods of eliciting a cross-protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 1-type 2 chimeric porcine circovirus vaccine. The chimeric vaccine utilized for cross-protection may be administered as a single dose... Agent: Wyeth Patent Law Group

20090017065 - Vectors and cells for preparing immunoprotective compositions derived from transgenic plants: The inventions is drawn towards vectors and methods useful for preparing genetically transformed plant cells that express immunogens from pathogenic organisms which are used to produce immunoprotective particles useful in vaccine preparations. The invention includes plant optimized genes that encode the HN protein of Newcastle Disease Virus. The invention also... Agent: Edwards Angell Palmer & Dodge LLP

20090017067 - Emulsion vaccine compositions comprising antigen and adjuvant in the aqueous phase: Emulsion vaccine formulations containing an antigen and an adjuvant in the aqueous phase are used for the vaccination of animals wherein the adjuvant is an acrylic polymer and/or dimethyl dioctadecyl ammonium bromide (DDA). These formulations can be prepared by mixing an aqueous phase containing the antigen and adjuvant with an... Agent: Wyeth Patent Law Group

20090017066 - Novel vlps derived from cells that do not express a viral matrix or core protein: The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090017068 - Vaccines against west nile virus: Described are vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and... Agent: Trask Britt

20090017069 - Sars vaccine compositions and methods of making and using them: Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090017070 - In vitro model for hepatitis c virion production: The invention is related to a construct comprising a hepatitis C virus (HCV) nucleic acid sequence that comprises from 5′ to 3′ on the positive-sense nucleic acid a 5′ untranslated region (UTR), a full-length open reading frame (ORF) encoding an HCV polyprotein whose cleavage products form functional components of HCV... Agent: Knobbe, Martens, Olson & Bear, LLP

20090017071 - Methods for treating neurogenic inflammation: The present invention relates to methods for treating neurogenic inflammation pain. The methods include administering an effective amount of a composition which includes a botulinum toxin component and a substance P component to a patient, thereby treating the neurogenic inflammation pain.... Agent: Allergan, Inc.

20090017072 - Vaccine: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090017073 - Method for modulating nod1 activity, use of a mtp related molecule for modulating nod1 activity, and therapeutic applications thereof: A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1: and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090017074 - Culture medium for haemophilus influenzae type b: The invention relates to a culture medium for Haemophilus influenzae type b, characterized in that the source of protein nitrogen is of non-animal origin and comprises at least one plant peptone and in that the heme source consists of protoporphyrin IX. This medium serves in particular for the production of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090017075 - Immunomodulatory compositions, methods of making, and methods of use thereof: The invention relates to new immunomodulatory compositions which comprise a cationic condensing agent, an immunomodulatory compound, and a stabilizing agent. The compositions of the invention typically form particles which have increased immunomodulatory activity as compared to immunomodulatory compounds not formulated in the compositions of the invention. Also provided are methods... Agent: Morrison & Foerster LLP

20090017076 - Treatment for cd5+ b cell lymphoma: The present invention provides methods for increasing expression of cell surface molecules of CD5+ B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5+ B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response... Agent: Wolf Greenfield & Sacks, P.C.

20090017077 - Compounds and methods for immunotherapy and diagnosis of tuberculosis: Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M.... Agent: Townsend And Townsend And Crew, LLP

20090017078 - Anhydrous topical formulation for polyphenols: The present invention discloses a composition of matter, and method to formulate same, which is an anhydrous topical cream, gel or ointment base, a polyphenol and a suitable adsorbent binding carrier to which the polyphenol will bind for purposes of even disbursement within the cream, gel or base and which... Agent: Dla Piper LLP (us)

20090017082 - Colored metallic pigment, process for producing the same, and coating composition and cosmetic preparation containing said colored metallic pigment: This invention provides a colored metallic pigment, which can develop a variety of colors and varied interference colors while maintaining good lightfastness, weatherfastness and hiding power, a process for producing the same, a coating composition containing the colored metallic pigment and capable of providing a coating film having excellent finished... Agent: Birch Stewart Kolasch & Birch

20090017079 - Foam-like preparation and process for the production thereof: A foam-like preparation in the form of an emulsion comprises a continuous phase, a discontinuous phase, and a gas, wherein the continuous phase comprises a thickening system being formed by the continuous phase and a thickening agent, and wherein the discontinuous phase comprises a structuring agent, wherein the thickening system... Agent: Bachman & Lapointe, P.C.

20090017080 - Personal care kit having skin care compositions with a readily perceptible difference: A personal care kit comprises a first series of unit-dose packages containing a first skin care composition and a second series of unit-doses packages containing a second skin care composition, wherein the first skin care composition and the second skin care composition exhibit a readily perceptible difference. The readily perceptible... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090017081 - Water-in-oil type emulsion sunscreen cosmetics: The water-in-oil type emulsion sunscreen cosmetic in the present invention is characterized by comprising 1 to 30% by mass (a) hydrophobized titanium oxide and/or zinc oxide, 0.1 to 10% by mass (b) phenylbenzimidazole sulfonate, 50% by mass or more (c) triethanolamine with respect to the component (b), 0.1 to 10%... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090017083 - Bioswellable sutures: Swellable, coated sutures have a swellable polymeric coating and a fibrous component, wherein the coating is formed of an absorbable or non-absorbable polymer, while the fibrous component is formed of a synthetic absorbable or non-absorbable monofilament yarn, synthetic absorbable or non-absorbable braided multifilament yarn, braided silk multifilament yarn or combinations... Agent: Leigh P. Gregory

20090017084 - Dermally applicable liquid formulations for controlling parasitic insects on animals: The present invention relates to novel skin-friendly dermally applicable liquid formulations comprising permethrin and agonists or antagonists of nicotinic acetylcholine receptors of insects for controlling parasitic insects on animals.... Agent: Bayer Healthcare LLC

20090017086 - Anti microbial sheet products and preparation process: Anti-microbial sheet, and derived product like tile, in particular for medical application, includes a polymeric base including a support layer and an anti-microbial additive in a cover—or anti-microbial layer of significantly lower thickness as compared to the support. The anti-microbial layer is of a composition including the support material and... Agent: Young & Thompson

20090017085 - Self-supporting films for pharmaceutical and food use: Rapidly dissolving self-supporting films for food or pharmaceutical use comprising: a) a filmogenic substance consisting of a maltodextrin; b) a plasticiser; c) an active principle for food or pharmaceutical use, characterised in that said films are free of hydrocolloids.... Agent: Jay S. Cinamon Abelman, Frayne & Schwab

20090017088 - Implant and system of an implant and a excitation device: An implant comprising a body (1), at least one active pharmaceutical substance (4) and an element (5, 15, 35, 45, 55) deflectable in relation to the body, serving to release the at least one active pharmaceutical substance (4) during or after an external excitation of the deflection. Also disclosed is... Agent: Powell Goldstein LLP

20090017087 - Osseoinductive metal implants for a living body and producing method thereof: This invention provides an Osseo-inductive metal implant for a living body and the producing method thereof and, more particularly, the Osseo-inductive metal implant for a living body according to the present invention is produced by forming, on the surface of the metal implant, the layer of metal oxide and the... Agent: Banner & Witcoff, Ltd.

20090017090 - Devices and methods for delivering active agents to the osteomeatal complex: Described here are devices, methods, and kits for treating sinusitis and related respiratory conditions by locally delivering active agents to the osteomeatal complex over a sustained period of time. The devices may be passively fixed within the osteomeatal complex and/or include one or more features that actively fix it within... Agent: Morrison & Foerster LLP

20090017089 - Multiple active agents such as anthelmintics sustained release delivery device: A method of treating animals characterised by the step of introducing to the animal a single delivery device containing two or more active agents, wherein the delivery device is configured to release an effective amount of active agents over a defined time period of 3-14 days.... Agent: Knobbe Martens Olson & Bear LLP

20090017092 - Novel class of cell-interactive material and process of preparation of artificial tissues of human and animal origin: An artificial extra cellular matrix product and artificial human and animal tissue product comprising tissue specific cells.... Agent: The Webb Law Firm, P.C.

20090017091 - Sterile hyaluronic acid polymer compositions and related methods: The present application provides sterile hyaluronic polymer compositions than are useful, e.g., as medical devices, biomedical adhesives, and sealants. Generally, provided are sterile dry compositions comprising a thiol-derivatized hyaluronic acid and one or more stabilizing excipients. Also provided are related kits and methods. The compositions described herein are particularly robust... Agent: King & Spalding LLP

20090017095 - Composition for filling a bone defect: The invention relates to a composition for filling a bone defect, characterized in that it comprises allogenic bone powder, calcium sulfate, a binder selected from starch or a starch derivative and a mixing solution. The invention more particularly relates to a composition for filling a bone defect, characterized in that... Agent: Cantor Colburn, LLP

20090017093 - Gelatinous material for filling bone and/or cartilage defects: Disclosed is a goal gel-type material for filling bone and/or cartilage defects. Said gel-type material comprises at least one gelatinizing component and collagen in at least one liquid dispersing agent. The collagen contains an active substance complex. Preferably, the inventive material is provided with osteoconductive and osteoinductive properties.... Agent: Antonelli, Terry, Stout & Kraus, LLP

20090017094 - Method of fabricating a tissue engineering scaffold: A method of fabricating a highly porous structure is provided. The method includes the step of compounding a biodegradable polymer, a water-soluble polymer and a porogen to form a composite blend. A foaming agent is dissolved into the composite blend and the composite blend is injected into a mold so... Agent: Boyle Fredrickson S.c.

20090017096 - Porous non-biodegradable hydrogel admixed with a chemoattractant for tissue replacement: A non-biodegradable hydrogel matrix containing microspheres of a biodegradable polymer for the purpose of treating, repairing, or replacing damaged biological tissue is described. The biodegradable phase can be admixed with a chemoattractant. Examples of degradable polymers include degradable polyesters such as 50:50 PLA:PGA, the degradation profiles of which are well... Agent: Morgan & Finnegan, L.L.P.

20090017097 - Hydrogel polymeric compositions and methods: Some aspects of this disclosure relate to a method of treating an opthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.... Agent: Dardi & Associates, PLLC

20090017098 - Composition and method for the prevention and relief of the symptoms of an incompetent or patulous eustachian tube: A composition and methods for the treatment of symptoms due to disorders, disease or trauma that impairs normal function of die Eustachian tube and alters vital structures or tissues of the middle ear. This includes diseases and disorders of the Eustachian tube altered by tubal incompetence, inflammatory phenomenon as rhinitis,... Agent: Felix L. Fischer, Attorney At Law

20090017099 - Cholesterol-rich composite food that is rendered substantially non-cholesterolemic using phytosterols: A composite food is described that includes a single serving portion of a cholesterol-rich food component (abbreviated CRFC) such as a hamburger or hot dog, and a cholesterol-compensating flour-based baked bun configured and sized to hold the CRFC. The bun contains a sufficient amount of phytosterols to compensate for the... Agent: Wesley B. Ames

20090017100 - Pharmaceutical composition, food or drink, or feed for intestinal disease: It is intended to provide a pharmaceutical composition, a food or drink, or a feed which has an effect on the prevention and/or treatment of an intestinal disease such as ulcerative colitis, Crohn's disease or irritable bowel syndrome. A preferred embodiment is the pharmaceutical composition, food or drink, or feed... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090017101 - Compositions for removing stains from dental surfaces and methods of making and using the same: Stain-removing oral compositions, such as gum compositions are herein provided. The compositions include a chelating agent and a surfactant. The surfactant includes a fatty acid salt and at least one component selected from nonionic and anionic surfactants. The fatty acid salt may have at least one hydroxyl functionality. The oral... Agent: Hoffmann & Baron, LLP

20090017102 - Enhancing transdermal delivery of opiod antagonists and agonistis using codrugs links to bupropion or hydroxybupropion: The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.... Agent: Buchanan, Ingersoll & Rooney PC

20090017106 - Adjuvants on the basis of bisacyloxypropylcystene conjugates and derivatives and their uses in pharmaceutical compositions: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new conjugates of the bisacyloxycysteine type useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20090017103 - Antisense oligonucleotides for prevention of metastasis formation of cancer cells: Described are antisense oligonucleotides targeted to the gene encoding osteopontin, bone sialoprotein II and/or osteonectin, wherein said oligonucleotides inhibit the expression of said gene(s). Moreover, the therapeutic use of said antisense oligonucleotides is described, e.g., for the treatment or prevention of cancer/metastasis, preferably osteolytic metastasis or metastasis of breast cancer... Agent: Howrey LLP-ca

20090017104 - Compositions containing retinoid and beta-aminoisobutyic acid derivatives: The present invention relates to a composition including at least one retinoid and at least one beta-aminoisobutyric acid derivative and the use thereof for the preparation of an article to be used for the topical application to skin, hair or nails.... Agent: Philip S. Johnson Johnson & Johnson

20090017108 - Liposome compositions for treatment of hepatitis c: In the present invention compositions and methods are described for treating patients with a hepatitis C viral infection typically using interferon-alpha and/or ribavirin which are incorporated into liposomes, wherein the liposomes typically contain at least one carbohydrate moiety on the surface, such as a mono-, di-, oligo-, or polysaccharide moiety... Agent: Pearl Cohen Zedek Latzer, LLP

20090017107 - Novel composition to increase libido: The present invention relates to a composition for increasing testosterone physiological levels comprising a sufficient amount of at least two ketosteroid derivatives of testosterone metabolism in association with a liposomal carrier bound to a saliva-absorbing carrier, wherein said increase in testosterone levels increases libido.... Agent: Bereskin And Parr

20090017105 - Proliposomal and liposomal compositions of poorly water soluble drugs: Concentrates or proliposomal compositions of poorly water-soluble drugs and compounds, comprising of one or more membrane forming lipids, a membrane stabilizing agent, in a suitable vehicle, and optionally containing a Polyethylene Glycol (PEG)-coupled phospholipid or a mixture thereof and further, optionally containing pharmaceutically acceptable excipients such as antioxidants, buffering agents,... Agent: Schwegman, Lundberg & Woessner, P.A.

20090017109 - Method of reducing somnolence in patients treated with tizanidine: An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090017110 - Modified release formulations of anti-irritability drugs: Modified or extended release formulations containing mesalamine compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved mesalamine formulations such as PENTASA®.... Agent: Hunton & Williams LLP Intellectual Property Department

20090017111 - Tolterodine bead: A controlled release tolterodine bead is formed having a microcrystalline cellulose core, a PVP-containing water soluble coating, a tolterodine drug layer, and a controlled release layer.... Agent: SynthonIPInc

20090017112 - Compounds for inhibiting beta-amyloid production: Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's... Agent: King & Spalding

20090017113 - Duloxetine formulations: Duloxetine pellets having an enteric coating containing a polymethacrylate polymer can be formed with desirable release rates/profile and stability.... Agent: SynthonIPInc

20090017114 - Tranexamic acid formulations with reduced adverse effects: Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release... Agent: Davidson, Davidson & Kappel, LLC

20090017115 - Removal of material from a preformed tablet: A system and method of removing material from pharmaceutical tablets, utilizing mechanical or laser energy and a conveyance, to produce a score or other defect in said tablet.... Agent: Accu-break Technologies, Inc.

20090017116 - Extended release gliclazide formulations: The present invention relates to an extended release (XL) pharmaceutical tablet composition for oral administration and methods of its manufacture. More particularly, the present invention relates to an extended release gliclazide formulation which does not increase the blood glucose level in human patients.... Agent: Arent Fox LLP

20090017117 - Pellet formulation for the treatment of the intestinal tract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090017118 - Coated tablets, their methods of preparation, and related uses: The present invention relates to a tablet comprising a tabletted core comprising a triglyceride granulate, and an enteric coating surrounding said tabletted core. The invention particularly relates to a tablet wherein the tabletted core contains esterified omega-3 fatty acids such as eicosapentaenoic acid and/or docosahexaenoic acid.... Agent: Marshall, Gerstein & Borun LLP

20090017119 - Modifications of solid 3-sn-phosphoglycerides: Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.... Agent: Wolf Greenfield & Sacks, P.C.

20090017120 - Phase stable lecithin organogel composition: A lecithin organogel composition used to deliver pharmaceutical products transdermally as well as a method for producing the lecithin organogel composition, which may contain up to 40% additive ingredients. Preferred embodiments of the invention may include lecithin organogel compositions which provide high penetrating power, which are ready-to-use, which have improved... Agent: Jackson Walker LLP

20090017121 - Gastric retained gabapentin dosage form: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.... Agent: King & Spalding LLP

20090017123 - Dermal regeneration enhancer: An object of the present invention is to provide a novel dermal regeneration enhancer. In accordance with the present invention, there is provided a dermal regeneration enhancer as a novel pharmaceutical use of lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090017122 - Drug forms having controlled bioavailability: The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and have controlled bioavailability, and to processes for their preparation.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090017124 - Nucleic acid microparticles for pulmonary delivery: The present disclosure is related to microparticle compositions, in which the microparticles are made of nucleic acids and non-polymeric cations, which are suitable for administration to moist or aqueous target locations (e.g., the lung tissue), where the substantially spherical nucleic acid microparticles release the nucleic acids through dissolution, allowing the... Agent: Baxter Healthcare Corporation

20090017125 - Drug carrier pellet production process: The invention provides a process for the production of drug carrier pellets comprising spray-dried pellets comprising spray-drying a solution of a physiologically tolerable cellulosic binder containing a physiologically tolerable inert particulate carrier having a particle size D (v.0.5) of less than 50 μm.... Agent: Patrick J. Halloran, Ph.d., J.d

20090017126 - Modified release dosage forms of skeletal muscle relaxants: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090017127 - Modified release dosage forms of skeletal muscle relaxants: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090017128 - Carbon dioxide removal from whole blood by photolytic activation: Apparatus and methods for removing carbon dioxide from whole blood. Hydrogen ions are generated from water in the blood, resulting in the formation and release of carbon dioxide from the blood.... Agent: Fay Sharpe LLP

20090017129 - Dead sea minerals enriched anti-inflammatory pharmaceutical composition for treatment of cutaneous dryness, itching, peeling and tightness, especially in hemodialysis patients and preparation and treatment methods thereof: This invention relates to Dead Sea anti-inflammatory medicaments or cosmetics for treatment of anti-inflammatory conditions; for example, cutaneous dryness, itching, peeling, and tightness, especially in hemodialysis patients. Methods for the preparation of and methods of treatment using these medicaments or cosmetics are also provided.... Agent: Fleit Gibbons Gutman Bongini & Bianco Pl

20090017130 - Compositions and methods for altering stool quality in an animal: The present invention provides compositions and methods for improving stool quality of a puppy by adjusting the balance of metabolizable cations to metabolizable anions consumed by the puppy.... Agent: Colgate-palmolive Company

20090017131 - Disinfectant cleaning composition and method: Various embodiments of disinfectant cleaning compositions and the method of using them are provided. In one embodiment of the present invention, the disinfectant cleaning composition comprises, by weight, from about 0.5% to about 6% hydrogen peroxide and from about 0.5% to about 20% aloe vera and/or active thereof, and from... Agent: Roetzel & Andress

20090017132 - Disinfectant cleaning composition and method: Various embodiments of disinfectant cleaning compositions and the method of using them are provided. In one embodiment of the present invention, the disinfectant cleaning composition comprises, by weight, from about 0.5% to about 35% hydrogen peroxide and from about 0.5% to about 25% aloe vera or active thereof, and from... Agent: Roetzel & Andress

20090017133 - Pharmaceutical formulation comprising lanthanum compounds: This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced... Agent: Darby & Darby P.C.

20090017134 - Method for controlling fire ants: A method for controlling fire ants is described, which includes applying a silver-containing composition to an area infested by fire ants or threatened by an infestation. The composition is applied to the area and reduces or eliminates the colony within a period of about two to four weeks and prevents... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20090017135 - Method for controlling fire ants: The present invention relates to combinations of 4-bromo-2-(4-chloro-phenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, and copper or zinc compounds which provide an improved protecting effect against fouling organisms. More particularly, the present invention relates to compositions comprising a combination of 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, together with one or more copper or... Agent: Philip S. Johnson Johnson & Johnson

20090017136 - Formulation to prevent and treat fibromyalgia, depression and other muscle and nervous system disorders: The formulation provides for the treatment and prevention of fibromyalgia, depression and other muscle and nervous system disorders. The formulation combines Coenzyme Q10, vitamin B1, 5-Hydroxytryptophan, magnesium, Vitamin D, Vitamin C, Selenium and Zinc. Each component has an effect on its own combined with a synergistic effect with other components.... Agent: Hoffman Wasson & Gitler, P.c Crystal Center 2, Suite 522

20090017137 - Methods and compositions for the prevention and treatment of anemia: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a... Agent: Amgen Inc.

20090017138 - Topical medicament: New topical medicaments are provided. The medicaments comprise menthol and camphor, preferably provided as part of a base gel, supplemented with potassium and a source of oxygen. The most preferred base gel is sold under the name SOMBRA, while the most preferred source of oxygen is a chlorite (e.g., sodium... Agent: Hovey Williams LLP

20090017139 - Iodine therapy dosing for treating medical conditions: A method for therapeutically treating medical conditions requiring chronic therapy such as fibrocystic breast disease, endometriosis, ovarian cysts, uterine fibroids and including the treatment of women considered to be at risk to breast and/or ovarian cancer without causing an overt thyroid disease by first administering to a patient a daily... Agent: Baker & Hostetler LLP Attn: Jim Coffman

20090017143 - Composition for treatment of alcoholism: A composition effective in the treatment of alcoholism comprising one or more alcohol craving blocker components such as Kudzu and Rhodiola Rosea, one or more antidepressant components such as St. John's Wort (Hypericin), 5-Hydroxytryptophanm SAMe, Melatonin and Taurine, and/or one or more anti-anxiety components such as Vitamin B complex, Glutamine,... Agent: Rogers Towers, P.A.

20090017142 - Essential oils inhibit mold on wood: Methods of treating wood lumber to inhibit growth of mold fungi by surface treating the wood lumber with an essential oil, diluted or undiluted, being geranium Egyptian, thyme, dill weed or rosemary. Various surface treatments include dipping, spraying, brushing and vapor exposure.... Agent: Janet I. Stockhausen Usda Forest Service

20090017140 - Maytenus abenfolia extract and methods of extracting and using such extract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Maytenus abenfolia to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of... Agent: Cox Smith Matthews Incorporated

20090017141 - Topical composition for the treatment of hyperpigmented skin: The present invention relates to novel, topically applied, cosmetic/dermatological compositions for the treatment of hyperpigmentation disorders and photodamaged human skin. The subject compositions combat hyperpigmented skin. In addition, the compounds described can be used in the treatment of many other pathologies. Due to a high degree of gentleness, along with... Agent: Akerman Senterfitt

20090017144 - Bioactive botanical cosmetic compositions and processes for their production: The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin... Agent: Heslin Rothenberg Farley & Mesiti PC

20090017145 - Tri ascorbate formulation: An oral formulation that is a combination of three mineral ascorbates and metabolites for antioxidant protection against free radical damage, healthy skin maintenance, support for vision health, healthy joint support, cardiovascular support, and maintenance of the immune system.... Agent: Hoffman Wasson & Gitler, P.c Crystal Center 2, Suite 522

20090017146 - Beta vulgaris-based products: Products based on beta vulgaris and especially red beet and methods for producing the same are provided. The orally administered beta vulgaris based products are adapted to be used for reducing homocysteine levels as well as reducing the cholesterol levels in the blood among other therapeutic effects.... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20090017147 - Cosmetic or dermopharmaceutical composition comprising an euglena extract: The invention provides a cosmetic or dermopharmaceutic composition containing an Euglena extract, its use to activate the cellular metabolism and in particular to protect and/or improve the state of the skin and to reduce the signs of ageing in particular and/or cutaneous fatigue... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090010839 - Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy: Dimers of avidin and streptavidins (diavidins) are described wherein the linker is suberate, which in turn, is bound to different functional groups (—NH2 o-COOH) of avidin. As compared to avidin, the diavidins have shown the ability to increase the amount of labelled biotin on the target, when used in an... Agent: Nixon & Vanderhye, PC

20090010838 - Pyridylacetylenes for use as radiotracers and imaging agents: m

20090010840 - Bispecific single chain fv antibody molecules and methods of use thereof: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.... Agent: Beyer Weaver LLP

20090010842 - Methods for the early diagnosis of ovarian cancer: The present invention discloses the protease stratum corneum chymotryptic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies.... Agent: Benjamin Aaron Adler, Ph.d, J.d.

20090010843 - Methods of identifying antibodies to ligands of orphan receptors: Described is a method of identifying antibodies against hitherto unknown ligands of orphan receptors or other orphan ligands, i.e., receptors or other ligands where the counter-ligand has not yet been identified. The availability of antibodies binding to the unknown ligand significantly facilitates their isolation and characterization, and the identified antibodies... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090010841 - Prostate cancer specific internalizing human antibodies: This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate... Agent: Beyer Weaver LLP

20090010844 - Imaging infection with compounds that bind to thymidine kinase: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound,... Agent: Edwards Angell Palmer & Dodge LLP

20090010845 - Polybiotin compounds of magnetic resonance imaging and drug delivery: The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090010846 - Nitro-imidazole hypoxia imaging agents: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging... Agent: Siemens Corporation Intellectual Property Department

20090010848 - Recombinant peptides derived from the mc3 anti-ba46 antibody, methods of use thereof, and methods of humanizing antibody peptides: The present invention also provides methods for the humanization of antibodies such as murine monoclonal antibodies. The novel humanization methods are applied to the production of humanized Mc3 antibodies and it is shown that these humanized antibodies retain the ability to engage in high affinity binding to their cognate antigen.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20090010850 - Formulations and methods for treating dry eye: The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20090010849 - Methods of screening an agent for an activity in an isolated eye of a teleost: The present invention provides methods of screening an agent for an activity in an isolated organ, e.g., eye, from a teleost, e.g., zebrafish. Methods of isolating eyes from zebrafish are provided. Methods of screening an agent for an ocular activity in the isolated eye are provided. Methods of screening an... Agent: Townsend And Townsend And Crew, LLP

20090010853 - Contrast agents: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention... Agent: Ge Healthcare, Inc.

20090010852 - Process and apparatus for preparing a diagnostic or therapeutic agent: Provided are a preparation process of a diagnostic or therapeutic agent having a step of adding, to a first fine emulsion having a particle size of 0.5 μm or less prepared by applying a predetermined pressure to a first mixture containing a first hydrophobic compound, an emulsifying agent, and an... Agent: Mattingly, Stanger, Malur & Brundidge, P.C.

20090010851 - Fluorescent pyrazine derivatives and methods of using the same in assessing renal function: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 of Formulas I and II may be characterized as electron withdrawing groups, while Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of... Agent: Mallinckrodt Inc.

20090010855 - Cationic polymers and fixative applications therefor: This invention relates to cationic Cassia polymers and to their use in hair fixative applications. The cationic Cassia polymers demonstrate superior stiffness profiles and a high level of curl retention when subjected to high humidity conditions for extended periods of time.... Agent: Legal Department Lubrizol Advanced Materials, Inc

20090010856 - Composition, comprising hydrofluoric acid, for inhibiting dental erosion: The present invention relates to a composition, for inhibiting dental erosion, and the use thereof. The composition comprises an aqueous solution of hydrofluoric acid, in which the concentration of hydrofluoric acid is 0.05%-2.00% and the pH is between 2.5 and 4.5.... Agent: Ladas & Parry LLP

20090010857 - Toothpaste comprising calcium carbonate and zinc citrate: Toothpaste and method for making such, the toothpaste comprising calcium carbonate as abrasive, water and zinc salt substantially all of which is in the form of water-solubilised zinc citrate.... Agent: Unilever Patent Group

20090010858 - Oral cavity disinfectant and oral cavity disinfecting method: Provided is an oral cavity disinfectant prepared by using a mixed aqueous solution containing a substance for dissolving proteins deposited on the tooth surface to sterilize microbes and a calcium salt-precipitating substance, respectively, at predetermined concentrations, that can be used to remove the bio film easily in a manner similar... Agent: Masuvalley & Partners

20090010859 - Oral composition: A visually clear gel toothpaste composition comprising a sparingly soluble divalent metal salt, characterised in that the sparingly soluble divalent metal salt is fully solubilised by a chelating agent for the metal salt, the chelating agent having a log Ks1 for the divalent metal ion as herein defined of from... Agent: Unilever Patent Group

20090010862 - Foaming oil compositions: A personal care composition comprising an oil and a siloxane resin foam stabilizer, said composition being substantially free of surfactants and propellants, is provided. The composition is capable of foaming, and is advantageously clear and non-greasy.... Agent: Philip S. Johnson Johnson & Johnson

20090010860 - Merocyanine derivatives: p

20090010861 - Modified plant gums for preparations of active ingredients: The present invention relates to compositions containing (fat-soluble) active ingredients and/or colorants in a matrix based on modified plant gums, i.e. plant gums that have been submitted to hydrolysis to degrade either the protein portion and/or where appropriate, the polysaccharide, and to a process for preparing these compositions as well... Agent: Stephen M. Haracz Bryan Cave

20090010863 - Cosmetic compositions: There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises two or more active ingredients selected from the group consisting of a) dipalmitoyl hydroxyproline, salts and esters thereof; b) carnitine; and c) an extract of Haematococcus pluvialis. Compositions prepared in accordance with the invention... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090010864 - Low residue deodorant or antiperspirant stick based on an ethanol-containing oil-in-water dispersion/emulsion: Deodorant or antiperspirant sticks based on an ethanol-containing oil-in-water dispersion/emulsion for application on the skin.... Agent: Paul & Paul

20090010865 - Process for preparing polymers in aqueous solvents: The present invention relates to methods of producing polymers which comprise, in copolymerized form, 50-95% by weight of at least one ester of (meth)acrylic acid, 5-50% by weight of at least one olefinically unsaturated, free-radically polymerizable anionogenic or anionic compound and 0 to 30% by weight of at least one... Agent: Connolly Bove Lodge & Hutz LLP

20090010866 - Hair care compositions: e

20090010868 - Composition combining a silicone polymer and a tackifying resin:

20090010867 - Skin cleansing composition: To provide a skin cleanser having superior lather quality at cleansing and improved moist and soft feeling after cleansing. A skin cleansing composition comprising an amphoteric terpolymer which consists of, 5 to 15 mass % of an anionic monomer (ex. acrylic acid), 15 to 40 mass % of a cationic... Agent: Rankin, Hill & Clark LLP

20090010870 - Hydrophobic flourinated polymer surfaces:

20090010871 - Method for production of a transformed cell: The invention relates to a method for incorporation of a biomolecule into a cell including the method steps: i) production of a complex from a biomolecule, preferably a nucleic acid and a polymer which may be obtained by reaction of an amine monomer having at least two amine groups with... Agent: Occhiuti Rohlicek & Tsao, LLP

20090010872 - Chimeric soluble hyper il-11 and use thereof: The present invention concerns a new designer cytokine termed H11, which is constructed by fusion of two soluble components, soluble interleukin 11 receptor (sIL-11 R) and interleukin 11 (IL-11) using their natural sequence and its use for the production of a medicament for treating or preventing a disease selected from... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090010875 - Il-7 fusion proteins: The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7).... Agent: Goodwin Procter LLP Patent Administrator

20090010877 - Methods for treatment prostate cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20090010873 - Methods of cell therapy, neurogenesis and oligodendrogenesis: A method is provided for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells, which comprises administering to an individual in need a neuroprotective agent such as a nervous system (NS)-specific antigen, a peptide derived therefrom, T cells activated therewith, poly-YE, microglia activated... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090010874 - Modified il-4 mutein receptor antagonists: This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals... Agent: Dla Piper LLP (us)

20090010878 - Pulsatile dosing of gossypol for treatment of disease: This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090010879 - Receptor based antagonists and methods of making and using: The present invention provides a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex. It also provides a nucleic acid sequence encoding the fusion polypeptide and methods of making and uses for the fusion polypeptide.... Agent: Regeneron Pharmaceuticals, Inc

20090010876 - Visfatin and uses thereof: The invention is directed to methods for treating, inhibiting or prevent the incidence of vascular disease in a subject or in a non-human animal by administering visfatin. Particularly, the invention provides for methods to prevent phagocyte cell death due to ER-stress by the administration of visfatin. The invention also encompasses... Agent: Wilmerhale/columbia University

20090010880 - 2-amino-2,7-dideoxy-alpha-d-glycero-d-gluco-heptopyranosyl inhibitors of positive sense single-stranded rna envelope viruses: The present invention is directed to compounds, compositions and methods comprising the aminoglycoside moiety represented by Formula II for treating and preventing the spread of positive sense single-stranded RNA envelope viral infections. One embodiment of the present invention uses geneticin or its analogs, including 2-amino-2,7-dideoxy-alpha-D-glycero-D-gluco-heptopyranose, as the antiviral agent. The... Agent: Fox Rothschild LLP

20090010882 - Polymorphs of sodium 4-4[(4-chloro-2-hydroxybenzoyl) amino] butanoate: The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target.... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.C.

20090010881 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20090010883 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20090010884 - Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion: The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.... Agent: Pepper Hamilton LLP/wyeth

20090010885 - Methods for detecting and treating autoimmune disorders: The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an... Agent: Klarquist Sparkman, LLP

20090010887 - Method and composition for enhancing anti-angiogenic therapy: The present invention relates to the surprising discovery that agents that increase intracellular accumulation of NADH+H+ enhance the anti-cancer effects of angiogenesis inhibitors. Furthermore, treatment of a mammal with a combination of at least one angiogenesis inhibitor and at least one agent that enhances intracellular accumulation of NADH+H+ allows for... Agent: David S. Resnick

20090010886 - Method for the treatment of myeloproliferative diseases using(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4- acetylaminoisoindoline-1,3- dione: Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells.... Agent: Jones Day

20090010889 - Treatment using herpes simplex virus: The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of said HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and/or pharmaceutical is administered at an extratumoural location, is disclosed.... Agent: Swanson & Bratschun, L.L.C.

20090010888 - Use of cytochrome p450 reductase as insecticidal target: The invention provides a method of enhancing the effectiveness of pesticides, as well as pesticidal formulations. Furthermore, it also provides the means for the de novo rational design of pesticides. The present invention also relates to a method of screening agents for potential use in insecticides, particularly against mosquitoes.... Agent: Nixon & Vanderhye, PC

20090010900 - Embryonic stem cell derivatives, and methods of making and using the same: The presently disclosed subject matter provides embryonic stem (ES) cell derivatives that can be employed in therapeutic methods. Also provided are methods for generating and using the ES cell derivatives.... Agent: Davis Wright Tremaine LLP/los Angeles

20090010901 - Primary cultured adipocytes for gene therapy: The present invention relates to primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells. This invention provides cells suitable for gene therapy, which can replace bone marrow cells and liver cells used for conventional ex vivo... Agent: Townsend And Townsend And Crew, LLP

20090010893 - Canine probiotic bifidobacteria globosum: According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria globosum obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria globosum of the present invention are also provided.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090010892 - Hyperlipidemia treatment agent: To provide a cholesterolemia treatment agent comprising, as an active ingredient, a bacterial mixture of three bacterial types consisting of lactic acid bacteria, butyric acid bacteria, and glycation bacteria which are effective in lowering serum cholesterol. And to provide a triglyceridemia treatment agent comprising, as an active ingredient, a bacterial... Agent: Edell, Shapiro & Finnan, LLC

20090010891 - Sepsis treatment agent: To provide a bacterial translocation preventive for humans and animals comprising a probiotics formulation which has lactic acid bacteria, butyric acid bacteria, and saccharifying bacteria as the main components thereof. And to provide a sepsis treatment agent for humans and animals comprising a probiotics formulation which has lactic acid bacteria,... Agent: Edell, Shapiro & Finnan, LLC

20090010890 - Storage stable compositions of biological materials:

20090010902 - Tlr4 transcription activity suppressor:

20090010903 - Ferulate esterase producing strains and methods of using same: Ferulate esterase producing bacterial strains or functional mutants thereof and methods of using ferulate esterase producing bacterial strains as forage additives are disclosed.... Agent: Pioneer Hi-bred International, Inc.

20090010904 - Immunostimulating agent and method for production thereof: The object is to provide: a safe immunomodulating agent which can be used as a pharmaceutical or a food material; a method for production of the immunomodulating agent; and a novel application of a coffee extract residue. Disclosed is an immunomodulating agent comprising a coffee extract as an active ingredient.... Agent: Ogilvie Law Firm

20090010905 - Protection of plants against their pathogenic agents: This invention relates compositions and methods for protecting plants against various pathogenic agents such as fungi, viruses and bacteria. The invention can be used alone or in alternation and/or in combination with other plant protection means, and is suitable for the treatment of multiple plant species.... Agent: Sughrue Mion, PLLC

20090010894 - Methods and systems for identifying compounds that modulate alpha-synuclein aggregation: This invention relates to the field of determining the ability of agents to interfere with, reverse, or prevent α-synuclein aggregation and α-synuclein-related pathology and behavior. This invention also relates to methods for screening candidate agents for their potential as human medicaments.... Agent: Wilson Sonsini Goodrich & Rosati

20090010895 - Isolated cells and populations comprising same for the treatment of cns diseases: An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090010898 - Method for treating a mammal having damaged articular cartilage tissue: A method for treating a mammal having damaged articular cartilage tissue includes harvesting a tissue sample from the mammal, growing articular cartilage cells from the tissue sample, and transplanting the articular cartilage cells into the damaged tissue. Growing the articular cartilage cells from the tissue sample can be accomplished by... Agent: Patrick R. Scanlon Preti Flaherty Beliveau & Pachios LLP

20090010896 - Methods and compositions for optimized expansion and implantation of mesenchymal stem cells: Compositions and methods are provided for the optimized expansion and implantation of mesenchymal stem cells into a patient in need thereof. Autologous mesenchymal stem cells (MSCs) to a patient in need of MSCs are harvested, expanded within novel growth parameters under the influence of autologous growth factors located on the... Agent: Swanson & Bratschun, L.L.C.

20090010899 - Methods related to surgery: The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as... Agent: Linda O. Palladino

20090010897 - Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20090010907 - Dnazymes for inhibition of japanese encephalitis virus replication: The present invention relates to synthetic catalytic DNA molecules or DNAzymes which specifically cleave the RNA sequences of the Japanese Encephalitis Viral genome and is useful in treating Japanese Encephalitis infection. The DNAzyme comprises of a chemical modification, a catalytic domain and two hybridizing arms. The DNAzymes are 29-45 nucleotides... Agent: Lowe Hauptman Ham & Berner, LLP

20090010908 - Materials and methods for diagnosis and treatment of chronic fatigue syndrome: The invention relates to materials and methods for diagnosis and treatment of chronic fatigue syndrome/myalgic encephalitis. A number of genes are identified which are expressed at abnormal levels in patients affected by CFS/ME as compared to normal healthy individuals. These genes include those encoding defensin α1, haemoglobin γ, CXCR4, tubulin... Agent: Dann, Dorfman, Herrell & Skillman

20090010909 - Novel gpcr and methods of use of the same: The present invention relates to methods of identifying antagonists of GPR22, a G protein-coupled receptor (GPCR) and related compositions and methods. Antagonists of GPR22 are useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.... Agent: Biotechnology Law Group C/o Portfolioip

20090010906 - Peroral dosage forms to achieve a sustained-release effect after medicament dosage with a meal: The present invention relates a retard formulation for oral administration together with a meal comprising at least one active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipient(s) as well as an amount of an agent being able to form a gas (hereinafter also referred to as gas forming... Agent: Renner Otto Boisselle & Sklar, LLP

20090010910 - Compositions and methods for dermatological wound healing: The invention relates to compositions for debriding damaged skin comprising at least one enzymatic debriding agent and at least one antiseptic compound comprising heavy metal ions. The present invention further relates to kit and methods for topical debridement of damaged skin, particularly of burned skin.... Agent: Fennemore Craig

20090010913 - Natural liniment for treatment of skin cancers: A liniment composition for reversing or retarding the growth of cancerous skin tumors comprising primarily, pancreatin, pepsin, betaine HCL, emulsified vitamin A, and zinc, pancrelipase, fenugreek, papain, amylase and ox bile extract, with optional trace amounts of other ingredients.... Agent: Lewis, Brisbois, Bisgaard & Smith LLP

20090010911 - Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities: The present invention relates to drug screening assays, therapeutic protocols and pharmaceutical compositions designed to target non-receptor tyrosine family kinases and components of the tyrosine kinase family signal transduction pathways. It has been previously reported by the inventors that a substrate SH2 domain docking mechanism apart from the kinase active... Agent: Mckee, Voorhees & Sease, P.L.C

20090010912 - Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers: The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090010915 - Methods for conducting metabolic analyses: The present invention provides methods and apparatus for purifying metabolites of interest and conducting metabolic analyses. The methods generally involve determining metabolic flux values for a plurality of target analytes by monitoring the relative isotope abundance of a stable isotope in a substrate labeled with the stable isotope and/or one... Agent: Townsend And Townsend And Crew, LLP

20090010914 - Use of oligouronates for treating mucus hyperviscosity: The invention provides a method of treatment of a human or non-human subject to combat mucosal hyperviscosity in the respiratory tract, which method comprises application to a mucosal surface in said tract in said subject of an effective amount of a physiologically tolerable oligouronate.... Agent: Knobbe Martens Olson & Bear LLP

20090010916 - C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis: A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous conversion to tcuPA in blood at therapeutic concentrations. Two-chain M5 was shown to form complexes with C1-inhibitor, which was the principal inhibitor of tcM5 in plasma. The effect of supplemental additions of C1-inhibitor on fibrinolysis... Agent: Kevin M. Farrell Pierce Atwood

20090010917 - Therapeutic agents comprising pro-apoptotic proteins: The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.... Agent: Fulbright & Jaworski, L.L.P.

20090010918 - Methods for treatment using collagenase: Methods for treatment by collagenase injections are provided, which are effective in dissolving and lysing a collagenase septa network to treat carpal tunnel, plantar fasciitis and lateral epicondylitis conditions. The methods treat such conditions by injecting or otherwise delivering purified collagenase to the afflicted region of the patient, as well... Agent: Elmore Patent Law Group, PC

20090010847 - Connective tissue growth factor-4: The present invention relates to a novel human protein called Connective Tissue Growth Factor-4, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090010854 - Pulmonary insulin crystals: The present invention provides methods and compositions for treating diabetes by administering acylated insulin or an acylated insulin analog via a pulmonary route. The insulin or insulin analog may be in the form of a dry powder or a solution.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090010869 - Compositions for topical enzymatic debridement: Formulations are described for the treatment by enzymatic debridement of wounds and ulcers. The formulations have a clear, transparent composition that allows for easy visualization of the wound, and are non-staining for easy clean up. These formulations can also exhibit increased enzymatic debridement activity, improved post-treatment lubricity and coating occlusivity,... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090010921 - Antigen binding molecules with increased fc receptor binding affinity and effector function: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090010922 - Compositions and methods for binding sphingosine-1-phosphate: The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.... Agent: Biotechnology Law Group C/o Portfolioip

20090010919 - Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap): The invention provides a human FAP which is associated with the cardiovascular diseases, respiratory diseases, cancer, dermatological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases and endocrinological diseases. The invention also provides assays for the identification of compounds useful in the treatment or... Agent: Banner & Witcoff, Ltd.

20090010920 - Fc variants having decreased affinity for fcyriib: The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20090010923 - Treatment of cancer with anti-muscarinic receptor agents: The present invention relates to methods of treating proliferative disorders of colon cells. The methods comprise administering to the cells an effective amount of at least one agent to reduce M3 muscarinic receptor-mediated transactivation of at least one epidermal growth factor receptor.... Agent: Morgan Lewis & Bockius LLP

20090010924 - Apoptotic anti-ige antibodies: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.... Agent: Genentech, Inc.

20090010928 - Anti-anthrax antibody, formulations thereof, and methods of use: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090010930 - Antibodies to vla-1: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.... Agent: Lowrie, Lando & Anastasi, LLP

20090010925 - Antibody variants: Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.... Agent: Genentech, Inc.

20090010931 - Compositions and methods for restoring sensitivity to treatment with her2 antagonists: Methods and compositions for restoring growth inhibition sensitivity to a tumor cell resistant to growth inhibition by HER2 antagonists. The methods involve administering a PCDGF antagonist to the cell in an amount effective to stimulate or restore growth inhibition sensitivity to HER2 antagonists. The invention also provides treatment regimens, and... Agent: Connolly Bove Lodge & Hutz LLP

20090010926 - Extended treatment of multiple sclerosis: Methods for extended treatment of multiple sclerosis are described.... Agent: Lowrie, Lando & Anastasi, LLP B2047

20090010932 - Gb virus c (hepatitis g virus) for the treatment of hiv: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.... Agent: Fulbright & Jaworski L.L.P.

20090010927 - Mapkap kinase-2 as a specific target for blocking proliferation of p53-defective cells: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.... Agent: Clark & Elbing LLP

20090010929 - Therapeutic antibodies, antibody fragments and antibody conjugates: The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment... Agent: Fenwick & West LLP

20090010933 - Methods for using chimeric vascular endothelial growth factor receptor proteins: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial... Agent: Jones Day

20090010934 - Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders: A ligand derived from, e.g., a Fab fragment of a monoclonal antibody obtainable from the cell line deposited with the Belgian Coordinated Collections of Micro-Organisms under accession number LMBP 5108CB binds to the human platelet glycoprotein GPIb and prevents the binding of von Willebrand factor to said GPIb without inducing... Agent: Clark & Elbing LLP

20090010935 - Compositions and methods of treating tumors: Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is... Agent: Woodcock Washburn LLP

20090010936 - Novel stra6 polypeptides: The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention... Agent: Merchant & Gould PC

20090010937 - Membrane attack complexes associated with circulating immune complexes: The invention relates to demonstrate the presence of non covalently linked complement proteins with CIC. Invention demonstrate the presence of C5 and MAC on CIC. The invention provides methods to measure M complement proteins C1q, C3, C4, C5 bound to CIC as markers of disease activity and pathogenicity for complement... Agent: Sonnenschein Nath & Rosenthal LLP

20090010938 - Short immunomodulatory oligonucleotides: The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred... Agent: Keown & Zucchero, LLP

20090010939 - Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies,... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090010940 - Parathyroid hormone analogues and methods of use: The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20090010941 - Methods for treating hiv: The invention relates to methods of treating HIV by administering a TRAIL receptor activator. The invention also relates to methods for inducing apoptosis in an HIV reservoir cell by contacting the cell with TRAIL receptor activator such as an M-CSF effector kinase inhibitor.... Agent: Wolf Greenfield & Sacks, P.C.

20090010942 - Novel primate chitinases and uses therefor: Novel primate chitinases (pNC) and nucleic acids encoding these chitinases are disclosed. The pNCs of the invention are homologous to human acidic mammalian chitinases (hAMCase) and human chitotriosidase, in terms of their exon/intron genomic structure and conserved catalytic sites. The polypeptides and nucleic acids of the invention can be used... Agent: Lowrie, Lando & Anastasi, LLP W2023

20090010943 - Peptides associated with hla-dr mhc class ii molecule and involved in rheumatoid arthritis: Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an increased affinity for HLA-DR molecules and associated with Rheumatoid Arthritis. These novel peptides provide the basis for new methods of diagnosis and... Agent: Summa, Allan & Additon, P.A.

20090010944 - Oligosialic acid derivatives, methods of manufacture, and immunological uses: The invention relates to methods of producing, and compositions comprising, an isolated alpha (2→8) or (2→9) oligosialic acid derivative bearing a non-reducing end enriched for one or more de-N-acetyl residues and resistant to degradation by exoneuraminidase. A representative production method involves: (i) treating an alpha (2→8) or (2→9) oligosialic acid... Agent: Bozicevic, Field & Francis LLP

20090010945 - Partially loaded antibodies and methods of their conjugation: A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radiometals, chelating... Agent: Townsend And Townsend And Crew LLP

20090010948 - Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10: It has been discovered that reducing, inhibiting or preventing the expression of immunosuppressive cytokines or tolergenic agents in antigen presenting cells improves the ability of the antigen presenting cell to promote an immune response. One embodiment provides a genetically engineered antigen presenting cell that has reduced or no expression of... Agent: Patrea L. Pabst Pabst Patent Group LLP

20090010950 - Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof: Ex-vivo isolated human CD25+CD4+ T regulatory cells, CD25+CD4+ Tr cell clones derived therefrom, a method of isolating clones and the use of ex-vivo isolated human CD25+CD4+ Tr cells or cell-clones as immunomodulators, immunosuppressive agents or for the identification of molecules that modulate the immune response.... Agent: Young & Thompson

20090010946 - Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use: Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090010949 - Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting: The present invention relates to compositions and methods of their production and use, including use in increasing de-N-acetyl sialic acid antigen of a mammalian cell and methods that exploit the increase in deNAc sialic acid antigen on such cells.... Agent: Bozicevic, Field & Francis LLP

20090010947 - Red microalgae expressing exogenous polypeptides and methods of generating and utilizing same: A method of transforming red microalgae is provided. The method is effected by: (i) culturing red microalgae cells under predetermined light/dilution conditions to thereby generate competent red microalgae cells; and (ii) introducing at least one exogenous polynucleotide into said competent red microalgae cells, thereby transforming the red microalgae.... Agent: Martin D. Moynihan Prtsi

20090010951 - Epitope/peptide recognized by hla-a2402-restricted ep/cam-specific ctl and use of the same: A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1... Agent: Sughrue Mion, PLLC

20090010953 - Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods: Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.... Agent: Leydig, Voit & Mayer, Ltd.

20090010952 - Pharmaceutical compound for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt or erp57 translocation: Anthracyclines-treated tumor cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclines induce the rapid, pre-apoptotic translocation of calreticulin (CRT) and/or ERP57 to the cell surface. Knock down of CRT and/or ERP57 suppressed... Agent: Samuel A. Kassatly

20090010954 - Prevention and treatment of sub-clinical pcvd: The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090010955 - Vaccines containing canine parvovirus genetic variants: Canine parvovirus vaccines and diagnostics and methods for their use are provided. The vaccines are effective against emerging dominant canine parvovirus variants.... Agent: Fellers Snider Blankenship Bailey & Tippens

20090010956 - Ehrlichia ewingii proteins, nucleic acids, and methods of their use: The novel omp-1 gene cluster encoding twenty one Ehrlichia ewingii (EE) proteins was isolated and sequenced completely. This invention relates to isolated E. ewingii (EE) polypeptides, isolated polynucleotides encoding EE polypeptides, probes, primers, isolated antibodies and methods of their production, immunogenic compositions and vaccines, as well as methods of using... Agent: Calfee Halter & Griswold, LLP

20090010957 - Immunogenic mycoplasma hyopneumoniae polypeptides: Mycoplasma hyopneumoniae polypeptides and nucleic acids, as well as nucleic acid expression vectors and host cells containing nucleic acid vectors are provided. In addition, compositions containing M. hyopneumoniae polypeptides and nucleic acids are provided for use in methods of treating swine to prevent enzootic pneumonia. Furthermore, the invention provides diagnostic... Agent: Fish & Richardson P.C.

20090010958 - Compositions effective in altering the perception of malodor: A method of modifying perception of a malodor, such as the stench associated with putrefying flesh, by selectively affecting specific olfactory receptors in an individual is disclosed. Disclosed are articles of manufacture and especially innovative compositions effective in implementing the method of the present invention including at least three plant... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090010959 - Pneumococcal polysaccharide conjugate vaccine: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090010961 - Avirulent, immunogenic flavivirus chimeras: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second... Agent: Klarquist Sparkman, LLP

20090010960 - Bacteriophage-mediated immunisation against hepatitis: The present invention relates to vaccines comprising a bacteriophage which has been engineered to express an immunogenic protein/peptide and wherein the surface of the bacteriophage has not been modified to contain proteins/peptides designed to target the phage to receptors on the surface of specific cell types.... Agent: Myers Bigel Sibley & Sajovec

20090010962 - Genetically engineered swine influenza virus and uses thereof: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1... Agent: Jones Day

20090010963 - Raccoon poxvirus expressing rabies glycoproteins: The present invention relates to recombinant raccoon poxvirus vectors that express the rabies virus glycoprotein gene at the hemagglutinin (ha) locus of the poxvirus genome or express the glycoprotein gene of the same or different rabies strains at the thymidine kinase (tk) and the hemagglutinin (ha) loci of the poxvirus... Agent: Wyeth Patent Law Group

20090010964 - Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines: The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of... Agent: Schwegman, Lundberg & Woessner, P.A.

20090010965 - Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin: e

20090010966 - Modified diphtheria toxins: The present application relates to compositions of modified diphtheria toxin and fusion proteins containing modified diphtheria toxin that reduce binding to vascular endothelium or vascular endothelial cells, and therefore, reduce the incidence of Vascular Leak Syndrome, as well as methods of making the compositions. The present application also relates to... Agent: Wilson Sonsini Goodrich & Rosati

20090010967 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting... Agent: Allergan, Inc.

20090010974 - Alcohol-in-oil type emulsion comprising a multivalent metal salt: The present invention relates to emulsion science, especially within the area of alcohol-in-oil type emulsion, where the level of ions comprised in the alcohol-in-oil type emulsion is relatively high. In particular, the invention relates to a stable alcohol-in-oil type emulsion comprising a multivalent metal salt that may act as an... Agent: Foley And Lardner LLP Suite 500

20090010976 - Cosmetic or dermopharmaceutical compositions containing kombucha: Cosmetic or dermopharmaceutical compositions which contain kombucha are disclosed. The present invention further relates to the use of kombucha and cosmetic or dermopharmaceutical compositions containing the same, alone or in combination, for the care of the skin, mucosae and skin appendages, and in particular for preventing the signs of endogenous... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090010972 - Deodorant compositions: Deodorant compositions comprising an emulsion including a continuous polar solvent phase and a discontinuous oil phase are provided. The oil phase contains a water insoluble oil ingredient and a fragrance composition, each of which are chosen such that at least some of the fragrance components preferentially associate with the oil... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090010971 - Disintegratable zinc oxide powder and method for producing the same: The method for producing a disintegratable zinc oxide powder of the present invention is characterized by comprising: neutralizing an aqueous solution containing a water-soluble zinc salt and a carboxylic acid or an aqueous solution containing a water-soluble zinc carboxylate with an alkali carbonate to produce precipitate; and firing the precipitate... Agent: Rankin, Hill & Clark LLP

20090010970 - Dissolvable tooth whitening strip: The present invention provides a dissolvable strip for whitening teeth. The strip, which is preferably a single layer, has a whitening agent and a water-soluble or water dispersible polymer system. The dissolution of the whitening composition is controlled by interaction of the whitening composition with an oral environment containing saliva.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090010969 - Methods and materials for skin care: The invention provides a cosmetic method for, preventing, minimizing and removing wrinkles and providing for smoother and more robust skin surfaces comprising applying a material incorporating water-insoluble copper compounds which release Cu+ ions, Cu++ ions or combinations thereof upon contact with a fluid to a body surface to be treated.... Agent: Townsend And Townsend And Crew, LLP

20090010975 - Non-transparent composition for film: The present invention provides a non-transparent film composition that has light-shielding properties and can thereby maintain the stability and quality of products, such as formulations, for a long period of time; and formulations using this film composition, and particularly filled capsules. The non-transparent film composition contains a water-soluble metal compound... Agent: Fitch, Even, Tabin & Flannery

20090010973 - Silicas: An amorphous precipitated silica with controlled abrasivity and effective cleaning properties for use in an oral composition produced through comminution and classification of the silica to form particles with an oil absorption value of 150 cm 3/100 g or less, a weight median particle diameter dso of less than 3... Agent: Demont & Breyer, LLC

20090010968 - Spot-on formulation useful for cosmetology and dermatology:

20090010978 - Green tea jewelry: A method for making green tea jewelry is provided. The jewelry may be worn as a transdermal source of green tea components used as an alternative to or in addition to ingestion of green tea liquid or solids. Also provided is a kit for providing green tea jewelry in a... Agent: MastermindIPLaw PC

20090010977 - Insect repellant fabrics having nanocapsules with insecticide: The present invention relates to method of manufacturing a prytheroid-treated fabric and manufactured products created thereby. Through the development and application of prytheroid nanocapsules to a fabric, the fabric exhibits insecticidal properties, even following successive washings and solar exposure.... Agent: Attn: Maquita Wong The Hong Kong Polytechnic University

20090010979 - Method of controlling termites: The present invention provides a method of controlling termites and other social insects by treating a locus which locus comprises a location treated by termiticide and a location treated by a termite attractant composition.... Agent: Bayer Cropscience Lp

20090010981 - Antimicrobial material for implanting in bones: The invention relates to an antimicrobial material and method for inhibiting bacterial growth. The antimicrobial material may be used for implanting in bones and for coating or producing an implant or an implantable medical device, whereby particles formed from an antimicrobial material are remotely dispersed inside a matrix material that... Agent: Pearne & Gordon LLP

20090010980 - Materials coatings and methods for self-cleaning and self-decontamination of metal surface: A composite structure exhibiting the ability to degrade chemical or biological agents upon contact comprising a substrate to be protected from the deleterious effects of chemical or biological agents possessing surface groups capable of deactivating materials having the ability to degrade chemical or biological agents, a buffer film, coated onto... Agent: Naval Research Laboratory Associate Counsel (patents)

20090010983 - Alginate coated, polysaccharide gel-containing foam composite, preparative methods, and uses thereof: The invention relates to composites comprising a polysaccharide gelled within pores of a foam and an polysaccharide coating, methods of preparation, and uses thereof, for example, in biomedical applications such as cell culture media and implants, controlled release delivery systems, food applications, industrial applications, and personal care applications such as... Agent: Patent Administrator Fmc Corporation

20090010985 - Article with lubricated surface and method: Articles having reduced sliding frictional force comprising a lubricant applied to one or more surfaces of the article, and the lubricant-coated surface treated by exposing the surface to an energy source, wherein the energy source is an ionizing gas plasma at about atmospheric pressure. The ionizing gas plasma may be... Agent: David P. Hendricks Law Office Of David P. Hendricks

20090010982 - Biocompatible adherent sheet for tissue sealing: A biocompatible adherent sheet for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The biocompatible adherent sheet includes a carrier sheet including a biocompatible polymer and a modified chitosan evenly disposed on one or both sides of the carrier sheet. Methods of... Agent: Schwegman, Lundberg & Woessner, P.A.

20090010986 - Polymeric gel delivery system for pharmaceuticals: Implantable, injectable, insertable, or otherwise administrable compositions that form hydrogels when implanted, injected, inserted, or administered into or onto living tissues comprise a pharmaceutically effective compound wherein the pharmaceutically effective compound is a codrug, or pharmaceutically acceptable salt or prodrug thereof in admixture with a hydrogel-forming compound. The pharmaceutically effective... Agent: Ropes & Gray LLP

20090010984 - Steroid lipid-modified polyurethane as an implantable biomaterial, the preparation and uses thereof: A modified polyurethane including a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of the modified polyurethane, methods of preparing modified polyurethanes and the use thereof as an implantable biomaterial.... Agent: Ratnerprestia

20090010989 - Coating for implants and implants with improved osteointegration, and manufacturing method: A coating on an implant, said implant being intended for implantation in/on an implantation area, is provided. The coating comprises nitric oxide (NO) for obtaining an anti-viral, anti-fungal, and anti-bacterial effect, and for promotion of osteo-integration of the implant, bone healing, bone growth, and wound healing at said implantation area.... Agent: Knobbe Martens Olson & Bear LLP

20090010988 - Composition of bone formation with phsrn-rgd containing oligopeptide: A PHSRN-RGD-containing oligopeptide and a composition for promoting bone formation, which contains such oligopeptide as an effective ingredient. The oligopeptide promotes osteoblastic cell adhesion and differentiation and enhances bone regenerative ability, so that the inventive oligopeptide can be effectively used in regenerative treatment of bone tissue and periodontal tissue.... Agent: Intellectual Property / Technology Law

20090010987 - Methods and devices for reducing tissue damage after ischemic injury: Methods and devices are provided for the local delivery of anti-ischemic agents which reduce myocardial tissue damage due to ischemia or reperfusion, in combination with compounds that sensitize the response of the tissue to the anti-ischemic agent. The therapeutic agents are delivered to the myocardial tissue over an administration period... Agent: Intellectual Property Department Conor Medsystems, Inc.

20090010990 - Process for depositing calcium phosphate therapeutic coatings with controlled release rates and a prosthesis coated via the process: A method of coating a substrate wherein the crystallinity of a calcium phosphate substance in a coating material is controlled, the calcium phosphate substance is loaded with a therapeutic agent, and the loaded calcium phosphate is deposited onto at least a portion of the substrate.... Agent: Iandiorio Teska & Coleman

20090010991 - Nasal passage stent: A drug coated nasal stent implant that provides filtration of environmental pollutants and airborne allergens from inhaled air regulating the air before it is ingested into the remainder of the respiratory tract. The coatings include but are not limited to a variety of allergenic-specific antigen targeted antibodies as well as... Agent: Julian Prabhu

20090010993 - Composition comprising polyphenol: A food product, being a spread comprising from 10-85 wt % of fat or a dairy based drink comprising from 0.05 to 1 wt % of kaempferol can advantageously be used to control blood pressure. Specifically kaempferol may be used for vasorelaxation.... Agent: Unilever Patent Group

20090010992 - Drug formulations for oral transmucosal delivery to pediatric patients: Improved compositions, methods and systems for oral transmucosal administration of small volume bioadhesive drug dosage forms to pediatric subjects are provided. The drug dosage form is easily administered and may be delivered using a single dose applicator or a device.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090010994 - Wound dressing comprising an anti-inflammatory pain-killing agent and a complex of silver ion and a transitional element of group iv of the periodic system of elements: A wound dressing comprising one or more absorbent elements capable of absorbing wound exudates, a non-steroid anti-inflammatory pain-killing agent and a complex of silver ion and a transitional element of group IV of the periodic system of elements.... Agent: Jacobson Holman PLLC

20090010996 - Human antibiotic proteins: The invention relates to proteins, notably SAP-2 and SAP-3, having an antibiotic action. The invention also relates to a method for purifying certain antimicrobial proteins, as well as to a use of said antimicrobial proteins for antibiotic therapy or to a use of cells which were transfected with a DNA... Agent: Clark & Elbing LLP

20090010997 - Multi-layer medical patch with impermeable center: A muco-adhesive patch for delivery of drugs into mucous membranes. On the muco-contact side, a water impermeable layer covers the center of the patch and less than half of the muco-contact side of the patch. Drugs may be added by mixing the drug with an adhesive material and placing a... Agent: Graybeal Jackson LLP

20090010995 - Patch and patch preparation: m

20090010998 - Drug-delivery patch comprising a dissolvable layer and uses thereof: The present invention provides a drug-delivery patch having at least one dissolvable layer comprising an active material and an adhesive backing or cover. The present invention also provides a method of transdermally vaccinating an animal by ablating an area of the stratum corneum of the animal and applying the patch... Agent: Benjamin Aaron Adler Adler & Associates

20090010999 - Complex particles and coated complex particles: The present invention provides, for example, a method of inhibiting aggregation of complex particles in which a drug is adhered to lead particles, characterized by containing a lipid derivative or a fatty acid derivative of one or more substance(s) selected from sugars, peptides, nucleic acids and water-soluble polymers or a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090011003 - Composition for suppressing expression of target gene: The present invention has its object to provide a composition for suppressing the expression of a target gene and the like, and provides a composition, comprising an RNA-encapsulated liposome which comprises complex particles comprising as constituent components a lead particle and an RNA comprising a sequence consisting of 15 to... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090011004 - Improved carriers for delivery of nucleic acid agents to cells and tissues: This invention relates to drug delivery and specifically to the preparation and use of functionalized carriers such as nanopolymers and nanovesicles for improved delivery of nucleic acid agents (NAA) to tissues and cells. These compounds have broad applicability for treating numerous diseases and disorders, including neurodegenerative and neuromuscular disorders. The... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090011000 - Inhibitors of infection: Fusion inhibitor peptides are provided comprising a sequence derived from an HR2 domain. In preferred embodiments, the peptides are capable of oligomerization. Also provided are nucleic acids encoding the peptides, vectors comprising the nucleic acids and host cells transformed with the vectors. The peptides may be used as medicaments. Also... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090011001 - Manufacturing process for liposomal preparations: The present invention provides a manufacturing process for liposomal preparations comprising water-insoluble or hydrophobic active principals. In accordance with one aspect of the inventive method, at least one active principal and lipid fraction are dissolved in an organic solvent. This solution is then subjected to reduced pressure (vacuum) in a... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090011002 - Nano - and mesosized particles comprising an inorganic core, process and applications thereof: Method for the preparation of nano- and mesosized particles consisting of a lipid layer comprising at least one amphiphile and a core of an inorganic compound and/or a metal, comprising: (i) dissolving in a common solvent at least one self-aggregating amphiphile with at least one inorganic, organometallic or metallorganic precursor... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090011005 - Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions: Pharmaceutical compositions containing nanomaterials useful for treating restenotic lesions, which comprise nanomaterials containing one or more antiproliferative agents for treatment of intra-stent restenotic lesions by means of a local infusion, providing the increase in adhesion, penetration, and diffusion of the nanomaterials that contain the antiproliferative active agent in the tissue... Agent: Patent Law Agency, LLC

20090011008 - Nanoparticles for protein drug delivery: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery.... Agent: Hosheng Tu

20090011006 - Once daily formulations of tetracyclines: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.... Agent: Foley And Lardner LLP Suite 500

20090011007 - Pharmaceutical compositions containing mixtures of polymers and active agents poorly soluble in water: The invention relates to a pharmaceutical composition comprising a mixture of at least one cationic, water-soluble (meth)acrylate copolymer, at least one water-insoluble polymer and at least one active ingredient having a solubility in demineralized water of 3.3 g/l or less, characterized in that the water-insoluble polymer and the active ingredient... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090011009 - Microspheres comprising nanocapsules containing a lipophilic drug: The present invention provides microspheres comprising a plurality of nanocapsules accommodated in a gel forming polymer, the plurality of nanocapsules comprising an oil core carrying a non hydrophilic active agent and a shell of polymeric coating. The invention also provides a method for preparing the microspheres of the invention, pharmaceutical... Agent: The Nath Law Group

20090011010 - Controlled release and taste masking oral pharmaceutical composition: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution... Agent: Young & Thompson

20090011011 - Stable dosage formulations of imidazolylalkyl-pyridines: Stable formulations of imidazolylalkyl-pyridines, including controlled-release formulations.... Agent: Hoffman Warnick LLC

20090011012 - Fatty acid compositions and methods of use: The invention relates to highly concentrated DHA and EPA formulations in a soft gel capsule. A capsule may contain at least 80% omega-3 fatty acids, salts or derivatives thereof, where EPA and DHA are present in relative amounts of greater than or equal to 3:1 or less than or equal... Agent: Morriss Obryant Compagni, P.C.

20090011013 - Tacrolimus combination products: The present invention relates to a pharmaceutical composition comprising tacrolimus or an analogue thereof and a substance being a substrate for CYP3A4 and/or P-glycoprotein, oral solid dosage forms comprising the pharmaceutical composition such as tablets, methods for preparing the pharmaceutical composition and oral dosage forms and use of the pharmaceutical... Agent: Darby & Darby P.C.

20090011016 - Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion: Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa.... Agent: Foley And Lardner LLP Suite 500

20090011015 - Method for promoting sleep: Supplemental compositions, and methods for administering same to a user, are provided for promoting a restful night's sleep by speedily inducing a person to fall asleep and to maintain sleep, as well as alleviating minor aches and pains so as to further improve the quality of a person sleep. The... Agent: Fitzpatrick Cella Harper & Scinto

20090011014 - Tablet formulation for sustained drug-release: Disclosed is a pharmaceutical sustained release tablet for oral administration of a drug which is made of a compressed blend of at least three dry powders including a powder of a drug, a powder of a sustained release matrix for the drug, and a powder of at least one electrolyte.... Agent: Dickinson Wright PLLC

20090011017 - Polymers based on water-soluble monoolefinic comprising colloidal silica and their use as matrix polymers for solid dosage forms: s

20090011019 - Pharmaceutical compositions for gastrointestinal drug delivery: A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition... Agent: Merchant & Gould PC

20090011018 - Sustained release formulation for tacrolimus: A sustained release pharmaceutical composition for tacrolimus, comprising a solid dispersion containing tacrolimus or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of tacrolimus after 4 hours from the beginning of a dissolution test is less than 35%, is disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090011020 - Gastroresistant pharmaceutical formulations containing rifaximin: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090011023 - Chemotherapeutic compositions: The present invention relates to the treatment of gastrointestinal and/or cancer, and a method of weight gain, via the ingestion of polymeric compositions in humans, animals or birds in need of said treatment. The invention provides methods for the treatment of cancer, the treatment and/or prevention of gastrointestinal disease and/or... Agent: Birch Stewart Kolasch & Birch

20090011021 - Engineered extracellular matrices: The invention relates to engineered matrices comprising collagen fibrils with specific characteristics, including, but not limited to, a specific fibril area fraction (i.e., density) and/or a specific elastic or linear modulus (i.e., stiffness). The invention also relates to methods of preparation and use of the matrices.... Agent: Barnes & Thornburg LLP

20090011022 - Use of deuterium oxide for treatment of virus-based diseases of the skin: The present invention relates to the use of deuterium dioxide (D2O) for prevention and/or treatment of virus-based diseases of the skin, in particular herpes virus-based and verrucal virus-based diseases of the skin.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090011024 - Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers: A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use... Agent: Chernoff, Vilhauer, Mcclung & Stenzel

20090011025 - Biotin-amino acid conjugate useful as a hydrogelator and hydrogel prepared therefrom: A biotin-amino acid conjugate, wherein the carboxylic group of biotin and the α-amino group of an amino acid is linked by an amide bond, is biocompatible and has an excellent gelation capability in an aqueous medium. Accordingly, a hydrogel prepared therefrom is useful as a drug delivery system.... Agent: Sughrue Mion, PLLC

20090011027 - Modifying drug release in suspensions of ionic resin systems: The present invention includes compositions and methods for delivering one or more unit dosage units by modifying the release profile of an optionally coated drug-resin complex suspended in an ionic salt solution, wherein the optionally coated drug-resin complex includes one or more active agents loaded on to one or more... Agent: Chalker Flores, LLP

20090011028 - Self-precipitating pharmaceutical formulations for the moified release of an active principle: e

20090011026 - Transcorneal system for delivery of a pharmaceutical agent: The invention relates to a transcorneal system for delivery of a pharmaceutical agent, made from a matrix material forming a baseplate (1), said baseplate (1) being connected to a number of projections (4) for penetration of the Stratum corneum of the skin, said projections (4) being made from the matrix... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090011030 - Breakthrough pain management: The present invention is directed to a powdered formulation comprising an analgesic, preferably fentanyl, for use in pulmonary inhalation administration for the rapid analgesic titration of pain, in particular breakthrough pain. Upon administration, the powdered formulation is able to provide a narrower titration range in patients suffering from pain, as... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20090011029 - Colorless and transparent antibiotic material including silver, and a method for the preparation of it: Disclosed herein is a colorless and transparent antibiotic material including silver and a method of preparing the same. Specifically, the current invention pertains to a method of preparing a colorless and transparent antibiotic material including silver (Ag), which includes a) reacting a salt including a silver ion (Ag+) with a... Agent: LexyoumeIPGroup, LLC

20090011031 - Delivery of oral drugs: Disclosed is a system for delivery of a drug comprising a multiple unit dosing device comprising a chousing and an actuator, said device containing multiple doses of multiparticulates comprising drug particles, said device upon actuation delivering a unit dose of said multiparticulates, said drug particles having a mean diameter of... Agent: Davidson, Davidson & Kappel, LLC

20090011032 - Methods for improved cryo-chemotherapy tissue ablation: The current invention relates to a process for increasing the efficacy of cancerous disease inhibiting therapeutic agents delivered to a treatment region of a tissue structure, such as a tumor. The multi-step procedure takes advantage of the resulting thermal stress response occurring as a result of exposure to the cold.... Agent: Mchale & Slavin, P.A.

20090011033 - Process for the manufacture of cellulose sulfate with improved characteristics: The invention refers to a method for the production of cellulose sulfate which is completely water-soluble and has an adjustable solution viscosity in aqueous solution, which qualifies the produced sodium cellulose sulfate (SCS) as auxiliary material with ideal biological compatibility for biological and medical applications, in particular it is suitable... Agent: Hiscock & Barclay, LLP

20090011034 - Sustained release micropellets and process for producing the same: Sustained release micropellets showing a stable controlled-release of a drug without being affected by the changes in pH value etc., characterized by being produced by coating core particles with a layer containing a water-soluble drug and further forming a film layer containing a water-insoluble polymer compound and a plasticizer on... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090011035 - Personal care composition: Stable personal care composition comprising from about 0.1% to about 15% of a non-emulsifying crosslinked siloxane elastomer; from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; from about 1% to about 40% of an elastomer solvent; less than 0.1% of a solidifying agent; an aqueous phase comprising... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090011036 - Drug containing hollow protein nanoparticles of particle-forming protein, fused with disease-treating target-cell-substance: The subject invention provides a disease-treating drug that uses hollow protein nanoparticles to specifically act on a target cell or tissue. The present invention allows a protein drug to be effectively capsulated in the particles. The invention also provides a therapeutic method using such a drug. The drug according to... Agent: Harness, Dickey & Pierce, P.L.C

20090011037 - Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of... Agent: Innovar, LLC

20090011038 - Drug-delivery systems: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090011039 - Modified-release particles of polyelectrolytes and pharmaceutical formulations thereof: e

20090011040 - Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases: The present invention is a method of using compacted nucleic acid (such as DNA) nanoparticles for non-viral gene transfer to various tissues of the human eye or eyes of other mammals. These nanoparticles comprise, in one embodiment, a neutrally-charged complex containing a single molecule of plasmid DNA compacted with polyethylene... Agent: Dunlap Codding, P.C.

20090011041 - Compositions for correcting age related changes of a human endocrine system and methods for producing a pharmaceutical form bases on said compositions: The present invention relates to anti-aging pharmacology and is intended for correction of age-related changes in human endocrine system. The essence of the invention is the compositions for correction of certain age-related endocrine changes and method for production of pharmaceutical form based thereon. Each composition contains a mixture of substances... Agent: Ladas & Parry LLP

20090011042 - Antimicrobial and antiviral composition: An antimicrobial and antiviral barrier composition for topical application to the proximal anterior nares includes an antiseptic solution in combination with cocos nucifera (coconut oil) and one or more citrus oils such as, for example, citrus sinensis (orange oil). Various embodiments may also include one or more of the following... Agent: Robert M. Downey, P.A.

20090011043 - Tissue sealant made from whole blood: Disclosed are tissue sealants that include whole blood and an effective amount of an exogenous protein cross-linker to cross-link the whole blood. Also disclosed are methods for forming a tissue sealant. Such methods include, providing whole blood and mixing the whole blood with an effective amount of an exogenous protein... Agent: Klarquist Sparkman, LLP

20090011044 - Ozone containing product package: A product package is provided for containing a product or object. The package contains a first agent that is energizably convertible by an energy source to a sanitizing agent including ozone in the package. The sanitizing agent including ozone in the package is transferred to the product or object while... Agent: Fleit Gibbons Gutman Bongini & Bianco P.l.

20090011046 - Composition comprising silver nanoparticles and the use thereof: The present invention relates to a pharmaceutical composition comprising an effective amount of silver nanoparticles, a method for increasing hair growth by administering the said pharmaceutical composition locally to a host and use thereof.... Agent: Beyer Weaver LLP

20090011045 - Pharmaceutical for hygienic administration in the ear: The invention relates to a system for hygienically administering, particularly in animals, an ear medicament which can be dosed reproducibly even in the case of low volumes and which is not flung out once again even when the head is shaken.... Agent: Bayer Healthcare LLC

20090011047 - Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment or urogenital cancer and its metastasis: The present application relates to pharmaceutical compositions and methods for treatment of urogenital diseases and bone metastasis in a human, which pharmaceutical composition contains an effective amount of arsenous acid alkaline or earth alkaline metal salt and/or a pharmaceutically acceptable adjuvant. According to the present invention, the alkaline arsenous acid... Agent: Mcdermott Will & Emery LLP

20090011048 - Dietary supplement for promoting removal of heavy metals from the body: A dietary supplement for removing or preventing the bio-accumulation of heavy metals in the body includes one or more chelators, precursors therefore, with at least one chelator capable of crossing the blood brain barrier to promote capture of a heavy metal ion from a site in the central nervous system,... Agent: William J. Sapone Coleman Sudol Sapone P.C.

20090011049 - Methylation markers for prognosis and treatment of cancers: Genes for thirteen DNA damage repair or DNA damage response enzymes can be epigenetically silenced in cancers. The silencing of nucleic acids encoding a DNA repair or DNA damage response enzyme can be used prognostically and for selecting treatments that are well tailored for an individual patient. Combinations of these... Agent: Banner & Witcoff, Ltd.

20090011050 - Skin treatment composition and method: Disclosed is a composition which is provided as a cream. One use for the product is for removing urushiol oil from the dermal layer of the skin using a combination of other oils. The composition may include all or some of Apricot oil (kernel oil), Avocado oil, Dead Sea Salts,... Agent: Lathrop & Gage Lc

20090011051 - Methods, compositions and articles of manufacture for hif modulating compounds: The present invention generally relates to the modulation of hypoxia-inducible factor (HIF) using the compounds and methods disclosed herein. These compounds and methods can be applied to the prevention, pretreatment, and/or treatment of conditions or states associated with HIF, such as hypoxia- and ischemia-related conditions and the induction of stasis.... Agent: Fulbright & Jaworski L.L.P.

20090011052 - Anti-hiv medicinal herbs composition, preparation thereof and use of the same: A medicinal herbs composition includes the extract powders of Scutellaria baicalensis Georgi and Rubia cordifolia L, and powders of ginsenoside and Cordyceps sinensis (Berk.) Sacc. The present invention further concerns the preparation method of the said medicinal herbs composition and the use of the same for treating AIDS.... Agent: Sofer & Haroun LLP.

20090011053 - Method of deleting nef gene in hiv-1 using red ginseng: A method for inducing defective nef genes in HIV-1 using red ginseng is provided. More particularly, the present invention provides a method for inducing defective nef genes in HIV-1, which comprises administering an effective amount of red ginseng to a subject in need thereof. This method can derive gross deletion... Agent: Thelen LLP

20090011054 - Plant-based formulations for improving liver health: The present invention is directed to plant based formulations for improving liver health by protecting the liver from alcohol and chemical insults and/or by inducing phase II enzymes. Formulations according to the present invention include wasabi root fiber powder, artichoke leaf extract, asparagus dehydrate, kudzu root extract, oregano extract, schisandra... Agent: Alticor Inc.

20090011055 - Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism: The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or... Agent: Marshall, Gerstein & Borun LLP

20090011057 - Formulations and methods for inhibiting anaerobes, gram negative bacteria, protozoa and other microbial growth with morinda citrifolia l. enhanced formulations: The invention relates to the administration of products enhanced with Morinda citrifolia L. in order to inhibit anaerobes, gram negative bacteria, protozoa and other microbial growth related to various maladies and illnesses which result in detrimental physiological effects.... Agent: Kirton And Mcconkie

20090011056 - Lingonberry extract, methods of preparing, and uses thereof: A first extract of lingonberry (Vaccinium vitis-idaea L.) comprising 5-35 wt % of anthocyanin, 20-95 wt % of proanthocyanin, less than 5 wt % of resveratrol, and the balance of other components, a second extract containing 60-98 wt % of resveratrol, and a third extract composed any ratio of comprising... Agent: Fish & Richardson, PC

20090011058 - Standardized extract of the peppercorns from the plant zanthoxylum pipertium(hua jiao or sansho) used to manage, treat and/or reverse autism, autism, spectrum disorders, autistic-like symptoms, fragile-x, and/or fragile-x symptoms (fxs) by seleltively blo: This invention provides a standardized extract of the peppercorns from the plant Zanthoxylum pipertium (Hua Jiao or Sansho). The extract provides an all natural, side effect free method to manage, treat and/or reverse autism, autism spectrum disorders, autistic-like symptoms, Fragile-X, and/or Fragile-X symptoms (FXS) by selectively blocking and halting the... Agent: Scott Carlson

20090011059 - Ginger extract for inhibiting human drug transporters: The present invention relates to the use of a ginger extract on its own or in combination with pharmaceutical compositions for inhibiting human drug transporters for positively influencing the oral bioavailability and pharmacokinetics of active substances.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090011060 - Campsiandra angustifolia extract and methods of extracting and using such extract: A method of inhibiting COX-2, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Campsiandra angustifolia to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Campsiandra angustifolia suspended in... Agent: Cox Smith Matthews Incorporated

20090004102 - Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a heat shock cognate (HSC70) protein 70 on the surface of such a multidrug resistant neoplastic or damaged cells as compared... Agent: Wilmerhale/boston

20090004101 - Method and means for enhanced pulmonary drug delivery: The present invention provides a method of enhancing the absorption of molecules across the airway epithelium, thereby enhancing the delivery of desired therapeutic or diagnostic agents across the airway epithelium via the systemic circulation to the target site of action. The method comprises administration of a formulation comprising a pharmaceutical... Agent: Buchanan, Ingersoll & Rooney PC

20090004103 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.A.

20090004104 - Methods and compositions for delivering active agents with enhanced pharmacological properties: Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when... Agent: Myers Bigel Sibley & Sajovec

20090004105 - Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin: Embodiments of the present disclosure provide for: methods for imaging MMP-2 positive tissue; methods of diagnosing the presence of one or more of MMP-2 positive precancerous cells, MMP-2 positive cancerous cells, MMP-2 positive tumor cells, and MMP-2 positive diseases in a tissue; method of monitoring the progress of one or... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090004106 - Radioligands for the 5 -ht1b receptor: The present invention provides novel radioligands for the 5-HT1B receptor of the formula I.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090004107 - Beta-amyloid and neurofibrillary tangle imaging agents: Compounds, compositions and methods are contemplated in which senile plaques and/or neurofibrillary tangles are labeled using compounds with improved permeability across the blood brain barrier and improved selective binding to senile plaques and/or neurofibrillary tangles. Contemplated compounds are derivatives of FDDNP or curcumin, which most preferably have improved solubility in... Agent: Fish & Associates, PC Robert D. Fish

20090004109 - Antibodies and molecules derived therefrom that bind to steap-1 proteins: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Aya Jakobovits

20090004110 - Multi-functional gelatin particle and its use: We modified particle preparation steps and then, we can add extra functions in inside and outside of gelatin particles. Such multi-modified and functioned gelatin particles worked for the encapsulation of cells and serve subcutaneous injection too. Such Multi-functional gelatin particles can work as molecular indicator, target molecule isolator, and local... Agent: Thomas Spinelli Scully Scott, Murph & Presser, PC.

20090004108 - Smmr (small molecule metabolite reporters) for use as in vivo glucose biosensors: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.... Agent: Knobbe Martens Olson & Bear LLP

20090004113 - Macrophage-enhanced mri (memri): Methods for assessing stage of cancer in a subject are provided, comprising administering a macrophage imaging agent to the subject, making a magnetic resonance image of regions of the subject's body at cancer risk, and using the image to assess macrophage density and displacement associated with any primary cancer or... Agent: Bromberg & Sunstein LLP

20090004112 - Methods for the treatment of neurodegenerative diseases using nmda receptor glycine site antagonists: The disclosure provides methods for treating a neurodegenerative disease by administering a NMDA receptor glycine site antagonist. Compounds that can be used in the methods are also provided. Methods are also provided for determining whether a compound inhibits activity of a Parkinson's Disease-associated mutant of leucine-rich repeat kinase-2 (LRRK2). The... Agent: Wilmerhale/columbia University

20090004111 - Structure of the hepatitis c ns5a protein: The present invention provides a crystallized N-terminal domain of an NS5A protein of hepatitis C virus, methods of producing the same and methods of use thereof. The present invention also relates to structural elements of the N-terminal domain of hepatitis C virus NS5A protein, and methods of inhibiting hepatitis C... Agent: Thompson Coburn, LLP

20090004114 - System and method for monitoring in vivo drug release using overhauser-enhanced nmr: Systems and methods for monitoring in vivo release of therapeutic and/or diagnostic agents, e.g., drugs, are provided. The disclosed systems and methods use a contrast agent and Overhauser-enhanced nuclear magnetic resonance (NMR) to monitor and/or measure the concentration and distribution of the contrast agent. Provided the contrast agent and the... Agent: Philips Intellectual Property & Standards

20090004118 - Multifunctional nanoparticle conjugates and their use: Disclosed herein are conjugates comprising a nanocarrier, a therapeutic agent or imaging agent and a targeting agent. Also disclosed herein are compositions comprising such conjugates and methods for using the conjugates to deliver therapeutic and/or imaging agents to cells. Also disclosed are methods for using the conjugates to treat particular... Agent: Klarquist Sparkman, LLP

20090004119 - Polymers: The present invention relates to novel linear polymers, compositions comprising said polymers and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and magnetic resonance spectroscopy (MRS).... Agent: Ge Healthcare, Inc.

20090004115 - In vivo cell trafficking: Provided herein are methods of monitoring inflammatory cell migration in a mammal. The methods include the steps of: providing a donor mammalian subject; introducing an inflammatory agent into the donor mammal to create a granuloma; isolating granuloma-derived nucleated cells from the granuloma of the donor mammalian subject; labeling the granuloma-derived... Agent: General Electric Company Global Research

20090004116 - In vivo optical imaging: Provided herein are methods for imaging an optically labeled target cell implanted in vivo using a reporter construct that encodes an enzyme that is not endogenous to the target cell. The disclosed methods include the steps of: (a) introducing target cell transformed with non-endogenous enzyme into a mammalian subject; (b)... Agent: General Electric Company Global Research

20090004117 - Self-illiminating dot systems and methods of use thereof: Generally, aspects of the present disclosure are directed to conjugate systems, self-illuminating quantum dot conjugates, methods of detecting a target in a host, methods of treating a disease in a host, and the like.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090004120 - Antimicrobial compositions: Provided are personal care products and compositions that comprise at least one preservative compound selected from the group consisting of phenoxyethanol, 2-phenyl ethanol, phenoxypropanol, 3-phenylpropanol and benzylalcohol, in a total concentration of 0.1 to 1% (w/w); and at least one preservative enhancer compound selected from the group consisting of 4-methylbenzaldehyde,... Agent: Norris, Mclaughlin & Marcus

20090004121 - Combination of picotamide with nafronyl: The invention relates to a combination of picotamide(N,N′-bis-(3-picolyl)-4-methoxy-isophthalamide) and nafronyl(2-diethylaminoethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate), pharmaceutical compositions, and use of this combination in the treatment of intermittent claudication.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090004122 - Skin and surface disinfectant compositions containing botanicals: The present invention relates to a skin or surface disinfectant composition with broad spectrum antimicrobial activity comprising one or more essential oil (and/or one or more component thereof) and one or more fruit acid. The compositions of the invention may be used as non-toxic alternatives to conventional disinfectants or may... Agent: Baker Botts L.L.P.

20090004124 - Cosmetic composition comprising fluidized particles: Cosmetic compositions for caring for and/or making up the human body comprising fluidized-particles are disclosed. Fluidized-particles have a solid core that is modified to exhibit liquid-like properties in the absence of solvent. In particular, the disclosure relates to the use of fluidized-particles in lipsticks, eyeliners, face and body creams, eye... Agent: Connolly Bove Lodge & Hutz LLP

20090004123 - Cosmetic composition comprising polyorganosiloxane and uses thereof: The invention relates to a cosmetic composition comprising a cosmetically acceptable vector and polyorganosiloxane. The polyorganosiloxane comprises a group that includes a sterically hindered amine, and a polyalkoxyl group.... Agent: Hunton & Williams LLP Intellectual Property Department

20090004125 - Dispersions of polymers in organic medium, and compositions comprising them: The invention relates to self-stabilized dispersions of polymer particles in a non-aqueous non-silicone medium, and to a process for preparing the said polymers. The invention also relates to cosmetic or pharmaceutical compositions comprising the said polymer particle dispersions.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090004126 - Colour compensating system: A method for coating a skin blemish (10) such that the coated blemish visually blends into the surrounding skin (12) comprises measuring at least one colour property of the skin blemish (10) and measuring at least one colour property of the surrounding skin (12), suitably by using a spectrophotometer. From... Agent: Cantor Colburn, LLP

20090004127 - Guar gum containing compounds: where R10 through R11 are each independently —H or an alkyl group; and n and o are independently integers from 2 to 100, where at least one of R1 through R9 is an alkoxy group, acyloxy group, amino group, amido group, sulfate group, sulfonate group, phosphate group, phosphonate group, or... Agent: Fulbright & Jaworski L.L.P.

20090004128 - Non-irritant rapid-action dipilatory composition: The invention relates to a rapid-action depilatory composition, comprising at least one bisulphic and/or sulphite compound and an organic reducing agent in a cosmetically acceptable medium.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090004131 - Wax-free cosmetic composition in foam form: A composition in the foam form having a continuous oily phase and at least one structuring agent for the oily phase, the composition being devoid of wax. Method of use. Kit.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090004129 - Composition for the permanent shaping of human hair: The present invention concerns a composition for the permanent shaping of human hair comprising a copolymer of vinylpyrrolidone and quaternized vinylimidazole at a concentration in the range of 0.1 to 2.5% by weight calculated to total composition and process for permanent shaping human hair with the said compositions.... Agent: Norris, Mclaughlin & Marcus, P.A.

20090004130 - Composition for the permanent shaping of human hair: The present innovation concerns a composition for the permanent shaping of human hair comprising at least one reducing agent at a concentration of above 2% by weight an aminated silicone compound at a concentration in the range of 0.1 to 2.5% by weight calculated to total composition and a copolymer... Agent: Norris, Mclaughlin & Marcus, P.A.

20090004132 - Transfer resistant cosmetic composition with improved feel: e

20090004133 - Methods and compositions for phosphate binding: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a... Agent: Quarles & Brady LLP

20090004134 - Kit for treating a health condition by inducing translocation of an erp57 protein to a cellular membrane: A kit for treating a health condition in a mammal, comprises a ERP57 protein and/or compound for inducing a translocation of an ERP57 protein to a cellular membrane in order to provoke an immunogenic apoptosis. The ERP57 protein may include any one or more of: endogenous ERP57, recombinant ERP57, and... Agent: Samuel A. Kassatly

20090004136 - Compounds to promote regeneration of bone marrow: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds to promote regeneration of bone marrow from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts.... Agent: Faegre & Benson LLP Patent Docketing

20090004135 - Modified fluorinated nucleoside analogues: The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.... Agent: Duane Morris LLP - AtlantaIPDepartment

20090004138 - Bicyclic nucleosides and nucleotides as therapeutic agents: The invention relates to the use of bicyclic nucleosides and nucleotides based on formula (II) for the treatment of infectious diseases, and in particular, viral infections.... Agent: Seed Intellectual Property Law Group PLLC

20090004137 - Uridine derivatives as antiviral drugs against a flaviviridae, especially hcv: The invention relates to the use of an uridine derivative of formula (I); wherein —R1 represents monohalogenated alkynyl or dihalogenated alkenyl; —R2 is chosen from among hydrogen, hydroxyl, O-alkyl, O—CO alkyl and halogen; —R3 is chosen from among hydrogen, hydroxyl, O-alkyl, O—CO alkyl, halogen, SH, S-alkyl and N3; and —R4... Agent: Davidson, Davidson & Kappel, LLC

20090004140 - 4-substituted pyrrolidine as anti-infectives: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Elmore Patent Law Group, PC

20090004139 - Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly: Use of interferon-beta (IFN-β) and/or IFN-λ for treating rhinovirus (RV) infection in elderly people, particularly elderly people who are, or have been long-term smokers, especially those who have a clinical history of recurrent RV infections, and may have other medical conditions, such as cardiac or circulation problems, and who are... Agent: Morrison & Foerster LLP

20090004142 - A cell therapy method for the treatment of tumors: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting... Agent: Philip S. Johnson Johnson & Johnson

20090004141 - Broad spectrum immune and antiviral gene modulation by oral interferon: An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human α-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.... Agent: Nixon & Vanderhye, PC

20090004143 - Treatment of diseases caused by viral infection: A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden infant... Agent: Kohn & Associates, PLLC

20090004145 - Compositions and methods involving gene therapy and proteasome modulation: The present invention concerns the methods and compositions involving a therapeutic polypeptide, such as a tumor suppressor or a nucleic acid encoding such in combination with a proteasome inhibitor, for the treatment of cancer. In certain examples, a treatment for ovarian cancer is provided.... Agent: Fulbright & Jaworski L.L.P.

20090004146 - Humanised baculovirus: A genetically engineered baculovirus which is engineered to target therapeutic agents to cells, typically cancer cells, for example prostate cancer cells.... Agent: Crowell & Moring LLP Intellectual Property Group

20090004144 - Recombinant adeno-associated virus vector for treatment of alzheimer disease: Disclosed is an adeno-associated virus vector capable of expressing a peptide fragment containing a humoral immunity induction site of the β-amyloid peptide, comprising DNA encoding the peptide fragment in an operative form.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090004162 - Hecgf-1 related polymorphisms and applications thereof: The invention identifies tumor-associated antigens that may be used for immunotherapy of malignancies in patients having undergone an allogeneic stem cell transplantation, whereby the therapy is mediated by induction of a graft versus tumor immune response. The invention discloses minor histocompatibility antigens encoded by polymorphisms in reading frames present in... Agent: Morgan Lewis & Bockius LLP

20090004163 - Method of enhancing proliferation and/or hematopoietic differentiation of stem cells: The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic... Agent: David S. Resnick

20090004147 - Composition for a healthy gastrointestinal tract: The composition combines Zinc Carnosine; Beta Carotene; Vitamin A; Copper; Calcium Ascorbate; White Tea; Fructo-oligosaccharides; and Probiotic (Acidophilus & Bifidus) to treat, and prevent peptic ulcers and promote a healthy gastrointestinal tract. Each component has an effect on its own combined with a synergistic effect with other components.... Agent: Hoffman, Wasson & Gitler, P.C.

20090004148 - Novel probiotic: The present invention relates to a novel Gram positive species that has been isolated from the porcine intestine. The Gram positive bacterium of the invention has unprecedented properties that relate to its capacity to grow on a wide range of industrial feeds including oligosaccharide carbohydrates both in vitro and in... Agent: Foley And Lardner LLP Suite 500

20090004165 - Feline probiotic lactobacilli: According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090004164 - Nutritional composition with probiotics: A composition comprising Bifidobacterium breve, a non-digestible saccharide A and a non-digestible saccharide B, optionally combined with Lactobacillus paracasei and the use of said composition for the treatment and/or prevention of gastrointestinal disorder, immune disorder and/or endocrine disorder.... Agent: Foley And Lardner LLP Suite 500

20090004149 - Method for limiting the growth of cancer cells using an attenuated measles virus: A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 103 pfus to about 1012 pfus and is delivered by direct injection into a group of cancer cells... Agent: Fish & Richardson P.C.

20090004160 - Mass producing method of growth factor using adipose derived adult stem cells: The present invention relates to a method for producing large amounts of human growth factors from human adipose-derived stem cells. More specifically, the invention provides a method capable of synthesizing human growth factors in significantly large amounts by culturing adipose-derived stem cells extracted from human adipose cells in suitable media... Agent: Edwards Angell Palmer & Dodge LLP

20090004157 - Mature type-1 polarized dendritic cells with enhanced il-12 production and methods of serum-free production and use: The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγ receptor, in combination... Agent: Klarquist Sparkman, LLP

20090004150 - Method for expanding postembryonic stem and progenitor cells from umbilical cord blood and immunotherapeutic agent: Method for obtaining and expanding postembryonic hematopoietic stem cells from umbilical cord blood while avoiding unwanted differentiation. Initial cells from umbilical cord blood are proliferated and multiplied ex vivo in a stroma-free medium and in the presence of a regio-modified glycan or glycosaminoglycan. The regio-modified glycan or glycosaminoglycan, e.g. a... Agent: Hoffmann & Baron, LLP

20090004155 - Method for treating a mammal having damaged myocardium tissue: A method for treating a mammal having damaged myocardium tissue includes harvesting a tissue sample from the mammal, growing myocardium cells from the tissue sample, and transplanting the myocardium cells into the damaged tissue. Growing the myocardium cells from the tissue sample can be accomplished by breaking the tissue sample... Agent: Patrick R. Scanlon Preti Flaherty Beliveau & Pachios LLP

20090004154 - Method for treating a mammal having damaged pancreatic tissue: A method for treating a mammal having damaged pancreatic tissue includes harvesting a tissue sample from the mammal, growing pancreatic cells from the tissue sample, and transplanting the pancreatic cells into the damaged tissue. Growing the pancreatic cells from the tissue sample can be accomplished by breaking the tissue sample... Agent: Patrick R. Scanlon Preti Flaherty Beliveau & Pachios LLP

20090004151 - Method of three-dimesionally culturing chondrocytes: It is intended to provide a method of three-dimensionally culturing normal joint chondrocytes; the production and supply of chondrocytes; and a transplantation material to be used in an injured site in a joint tissue.... Agent: Sughrue Mion, PLLC

20090004161 - Methods for treating pustular conditions of the skin: The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP... Agent: Linda O. Palladino

20090004158 - Methods of controlling proliferation and differentiation of stem and progenitor cells: A method of ex-vivo expanding a population of stem cells, while at the same time inhibiting differentiation of the stem cells. The method comprises ex-vivo providing the stem cells with conditions for cell proliferation and with at least one copper chelator in an amount and for a time period for... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20090004152 - Methods of producing pancreatic hormones: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then,... Agent: Knobbe Martens Olson & Bear LLP

20090004153 - Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using same: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20090004159 - Polymerized hemoglobin media and its use in isolation and transplantation of islet cells: Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090004156 - Polynucleotides and polypeptides of the ifnalpha17 gene: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFNα-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFNα-17 protein comprising at least one mutation caused by at least one SNP of the invention, as well as their therapeutic uses.... Agent: Hunton & Williams LLP Intellectual Property Department

20090004166 - Carrier for enternal administration: There is provided a carrier for use in enteral administration of biologically active compounds, said carrier comprising an effective amount of one or more phosphate derivatives of one or more electron transfer agents.... Agent: Michael Best & Friedrich LLP

20090004170 - Composition comprising coenzyme q10: The present invention provides a composition superior in water-dispersibility/solubility, workability and tabletability, which contains coenzyme Q10, casein, and a saccharide other than polysaccharides, at a particular ratio. The composition can be utilized for food, food with nutrient function claims, food for specified health uses, nutritional supplement, nutritional product, animal drug,... Agent: Sughrue Mion, PLLC

20090004168 - Health enhancement system: A health enhancement system establishing a health enhancement program through which may be provided a group of natural products, vitamins and minerals, amino acids, herbs and essential oils that may be helpful in aiding the body in fighting the growth of cancers and the progression of other diseases and in... Agent: Santangelo Law Offices, P.C.

20090004169 - Nucleic acids for inhibiting hairless protein expression and methods of use thereof: The present invention provides DNAzymes and ribozymes that specifically cleave Hairless protein mRNA. The present invention also provides antisense oligonucleotides that specifically inhibit translation of Hairless Protein mRNA. The present invention also provides various methods of inhibiting the expression of Hairless Protein. Finally the invention provides pharmaceutical compositions containing the... Agent: Baker Botts L.L.P.

20090004167 - Use of inorganic peroxides for oxygenation of soil in order to prevent diseases caused by anaerobic agents in plants: A method for controlling diseases caused by anaerobic agents in plants by at least partially preventing, stopping or reversing the damage caused by the anaerobic agents, comprising treating the plant or the soil in which the plant is growing or will grow with at least one inorganic peroxide. A formulation... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090004171 - Compound profiling method: The present invention provides a method for deriving an upstream or downstream component of a component necessary for phenotypic alteration of a living organism, the method comprising the steps of: specifying a pathway of interest related to the phenotypic alteration and a reference pathway different from the pathway of interest,... Agent: Seed Intellectual Property Law Group PLLC

20090004172 - Service for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using erp57 translocation: Anthracyclines induce the rapid, pre-apoptotic translocation of ERP57 to the cell surface. Knock down of ERP57 inhibit the translocation of CRT, suppressed the phagocytosis of anthracyclines-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. In contrast, the blockade of ERP57 with blocking antibody had... Agent: Samuel A. Kassatly

20090004173 - Diagnosis and treatment of drug resistant leukemia: The present invention encompasses methods and compositions useful in the diagnosis and treatment of drug resistant leukemia. The invention provides a number of genes that are differentially expressed between drug resistant and drug sensitive acute lymphoblastic leukemia (ALL). These genes act as biomarkers for drug resistant leukemia, and further serve... Agent: Alston And Bird LLP St. Jude Children's Research Hospital

20090004174 - Fusion proteins: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on... Agent: Morris Manning Martin LLP

20090004177 - Combination treatment with t-pa variant and low molecular weight heparin: The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090004175 - Methods for optimizing forming vlla-based hemostatic treatment: The present invention relates to pharmacogenomic methods for optimizing prevention and treatment of bleeding episodes using therapeutic proteins such as, e.g., Vitamin K-dependent clotting factors.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090004176 - Non-neurotoxic plasminogen activating factors for treating of stroke: The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of Desmodus rotundus (DSPA) for the therapeutic treatment of stroke in humans in order to provide a new therapeutic concept for treating stroke in humans.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090004180 - Kifs as modifiers of the rho pathway and methods of use: Human KIF23 genes are identified as modulators of the RHO pathway, and thus are therapeutic targets for disorders associated with defective RHO function. Methods for identifying modulators of RHO, comprising screening for agents that modulate the activity of KIF23 are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090004178 - Pharmaceutical compound for blocking the crt or erp57 translocation: A pharmaceutical compound is used in the treatment of a health condition in a mammal. The compound comprises an antibody that interferes with an increased translocation of a protein, leading to an increased immunogenicity of cell death. The antibody may be, for example, anti-calreticulin and/or anti-ERP57. This antibody includes any... Agent: Samuel A. Kassatly

20090004179 - Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods: The invention provides methods of altering properties of Fc-containing molecule, comprising altering the sialylation of the oligosaccharides in the Fc region. Proteins having Fc regions having altered sialylation patterns are also provided.... Agent: Fox Rothschild, LLP Virdante Pharmaceuticals

20090004185 - Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents: The present invention relates to amino-substituted quinazoline derivatives as inhibitors of β-catenin/tcf-4 pathway, which can be useful in the treatment of cancer; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.... Agent: Wilmerhale/wyeth

20090004189 - Biological markers predictive of rheumatoid arthritis response to b-cell antagonists: Methods and assays examining expression of one or more biomarkers in a sample are provided for predicting or indicating the effectiveness of treatment of a rheumatoid arthritis patient with a B-cell antagonist. Methods are provided for identifying patients whose rheumatoid arthritis is likely to be responsive to B-cell-antagonist, anti-rheumatoid arthritis... Agent: Genentech, Inc.

20090004183 - Compositions and methods for regulating the alternative pathway of complement: The present invention provides compositions and methods for regulating the alternative complement pathway.... Agent: University Of Virginia Patent Foundation

20090004186 - Effector function enhanced recombinant antibody composition: The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic... Agent: Sughrue-265550

20090004181 - Method for modulating appetite: The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1 modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological... Agent: Nixon & Vanderhye, PC

20090004182 - Methods to treat or prevent viral-associated lymphoproliferative disorders: The disclosure relates to methods to prevent, treat, or slow the progression viral-associated lymphoproliferative disorders, EBV-associated lymphoproliferative disorders, and post-transplant lymphoproliferative disorders. In the methods, a TGF-β antagonist, e.g., an anti-TGF-β antibody is administered to a subject. Methods for treating viral-associated lymphoproliferative disorders and for enhancing T-cell responsiveness to a... Agent: Calfee Halter & Griswold, LLP

20090004187 - Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment